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Abstract 
Muscle wasting is an important complication of a wide range chronic diseases. Pulmonary arterial 
hypertension (PAH) is no different. Novel targets and treatments are required to help improve 
outcomes in patients with PAH complicated by muscle wasting. GDF-15 is prognostic marker in PAH 
and has been shown to cause muscle wasting in vitro and in vivo. The pathway through which GDF-15 
acts in muscle cells is not established.  
I used a human study, animal models of PAH; the monocrotaline (MCT) rat; and Sugen/hypoxia mouse, 
as well as C2C12 muscle cells to determine whether GDF-15 and its downstream signals may be 
important in the development of muscle wasting and low physical activity in PAH. 
Muscle wasting and low physical activity were associated with poor outcomes in a population of 
patients with PAH. Circulating GDF-15 levels were associated with markers of muscle strength and size 
in 2 animal models and in patients with PAH. In the MCT rat the pulmonary vasculature was an 
important site of production of GDF-15. GDF-15 acted by increasing the expression of ubiquitin ligases, 
which are involved in muscle wasting. GDF-15 decreased the activity of SMAD 1, 5 whilst increasing 
transforming growth factor β activated kinase 1 (TAK1) phosphorylation in muscle cells. Antagonising 
TAK1 with 5(Z)-7-oxozeaenol partially prevented muscle loss and rises in ubiquitin ligase expression in 
muscle cells and prevented weight loss in some MCT rats treated for 9 days with the drug.  
Muscle wasting and low physical activity are potentially modifiable risk factors for poor prognosis in 
PAH. GDF-15 may be a useful biomarker of muscle loss in PAH. Antagonising GDF-15 through its 
downstream mediator TAK1 requires further evaluation in animal models and patients with PAH to 
establish its usefulness in clinical practice. 
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Chapter 1. Introduction 
1.1 Pulmonary hypertension (PH) 
1.1.1 Clinical information 
PH describes a situation where there is raised pressure in the vessels taking blood from the heart to 
the lungs to pick up oxygen. The blood vessels are thicker and less elastic meaning the heart has to 
pump harder to meet the needs of the body, especially during exercise (1). ‘Pulmonary vascular 
sclerosis’, a pathological description of PH, was first noted in an autopsy specimen by Ernst von 
Romberg in 1891 (2, 3).  PH can only be confirmed by readings taken at right heart catheter (RHC) and 
is defined as a mean pulmonary artery pressure of greater than 25mmHg. PH is caused by a wide range 
of conditions (4). The current clinical classification of PH is based on the 5th World Symposium on PH, 
which was held in Nice in 2013 (5), which was the most recent update of the classification first outlined 
in Evian in 1998 (6).  This classification system split PH into 5 groups based on the cause, 
pathophysiology and response to treatment (6). The current classification system is outlined in Table 
1. There are 5 clinical groups: Group 1, pulmonary arterial hypertension (PAH); Group 2, PH due to left 
heart disease; Group 3, PH due to lung disease and / or hypoxia; Group 4, chronic thromboembolic 
PH; and Group 5 PH with unclear, multifactorial mechanisms (5). The only group of patients that 
responds to treatment targeted at the pulmonary vasculature are those with Group 1 disease (PAH). 
Current guidelines suggest that treatment of the other groups of PH should focus on optimisation of 
the underlying disease and identification of disproportionate PH that may respond to targeted therapy 
(7).  
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Group Description 
1 Pulmonary arterial hypertension 
1.1 Idiopathic 
1.2 Heritable 
1.2.1 BMPR2 
1.2.2 ALK-1, ENG, SMAD 9, CAV1, KCNK3 
1.2.3  Unknown 
1.3 Drug and toxin induced 
1.4 Associated with 
1.4.1 Connective tissue disease 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart disease 
1.4.5 Schistosomiasis 
1' Pulmonary veno-occlusive disease and /or pulmonary capillary haemangiomatosis 
1'' Persistent pulmonary hypertension of the new-born 
2 Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital / acquired left heart inflow / outflow tract obstruction and congenital cardiomyopathies 
3 Pulmonary hypertension due to lung disease and / or hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other lung diseases with mixed restrictive and obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorder 
3.6 Chronic exposure to high altitude 
3.7 Developmental lung diseases 
4 Chronic thromboembolic pulmonary hypertension (CTEPH) 
5 Pulmonary hypertension with unclear multifactorial mechanisms 
5.1 Haematologic disorders: chronic haemolytic anaemia, myeloproliferative disorders, splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary, histiocytosis, lymphangiolieiomyomatosis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
5.4 Others: tumoural obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH 
Table 1. Clinical Classification of Pulmonary hypertension. Updated clinical classification of Pulmonary 
Hypertension during the 5th World Symposium in NICE 2013. BMPR = bone morphogenetic protein receptor type 
II; CAV1 = caveolin-1; ENG = endoglin; HIV = human immunodeficiency virus (5). 
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1.1.2 PAH  
1.1.2.1 Definition 
As well as a mean pulmonary artery pressure of > 25 mmHg, PAH / Group 1 disease is further 
characterised by pre-capillary haemodynamics: (a wedge pressure of ≤ to 15 mmHg) and raised 
pulmonary vascular resistance (PVR), (> 3 Wood units), with no evidence of significant left heart 
disease, lung disease or chronic thromboembolic PH (5). PAH, and the associated increased PVR 
ultimately leads to right heart failure and death (8). The sub-categories of PAH are outlined in Table 1 
(5). Once again, they have been grouped together as they exhibit similar patho-physiological changes. 
These include typical vascular remodelling in the resistance arterioles of the pulmonary bed (<500 μm 
in diameter) and responses to disease targeted therapy (9).  
1.1.2.2 Epidemiology and prognosis of PAH 
PAH is a rare condition with a prevalence of 15 – 60 per million people (10-12). PAH in the modern era 
tends to be diagnosed in patients aged between 50 and 65 years old and has a female preponderance 
of between 60 and 83% in current registries (11). Historically 3 year survival was quoted at 50%, 
however with the emergence of novel therapies the prognosis of patients with PAH has improved, 
with current 3 year mortality being between 10 and 30% (13, 14), and 5 year mortality being 35 - 40% 
(15). The prognosis depends both on the cause of the PAH and the functional status of the patient. 
Patients with systemic sclerosis and portal hypertension associated PAH have the worse prognosis 
with 5 year survival of only approximately 40%, whilst those with congenital heart disease and toxin 
induced PAH had 5 year survival of 70-75%, with the other causes being somewhere in the middle 
(15).  
1.1.2.3 Pathophysiology of PAH 
On a biological level PAH is caused by endothelial cell dysfunction, vasoconstriction, endothelial and 
smooth muscle cell proliferation and in-situ thrombosis in the small and medium sized pulmonary 
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arteries. All of these factors contribute to narrowing of these vessels resulting in raised resistance, 
pressures and eventually lead to progressive heart failure (14). The pathogenesis underlying this 
vascular remodelling is incompletely understood. A number of factors have been shown to be 
important, including an increase in growth factors, inflammation, aberrations in calcium and bone 
morphogenetic protein (BMP) signalling cascades, a change in extra-cellular matrix structure and 
function and an imbalance between factors promoting vasoconstriction and vasodilation (16). 
Reversing the imbalance between vasoconstrictors and vasodilators is the basis for current targeted 
therapy in PAH (14). 
1.1.2.4 Clinical features of PAH 
The symptoms of PAH include dyspnoea, initially on exertion and then at rest, swelling of the ankles, 
palpitations and syncope (14). Prognostic indicators from the Reveal registry predicting poorer survival 
in PAH included: male gender; age over 60 years; portal hypertension; connective tissue disease; 
familial disease; functional WHO class III or IV; a PVR of greater than 32 Wood units; a right atrial 
pressure of more than 20mmHg; the presence of a pericardial effusion; a brain natriuretic peptide 
(BNP) of greater than 180 pg/ml; renal dysfunction; a transfer factor of carbon monoxide (DLCO) 
percent predicted of less than 32%; and a six minute walk distance (6MWD) of less than 165m. 
Predictors of good prognosis included: a BNP of less than 50 pg/ml; a 6MWD of greater than 440m; a 
DLCO percent predicted of more than 80%; and being in WHO functional class I (17). 
1.1.2.5 PAH treatment and its effects on outcomes 
PAH treatment has advanced significantly over the past 20 years. Current established treatments 
include anticoagulation, diuretics, management of anaemia, calcium channel blockers in those who 
have positive vaso-reactivity tests, phosphodiesterase inhibitors, endothelin antagonists and 
intravenous prostacyclin (7). As discussed earlier this modern combination of therapies has 
significantly improved outcomes in PAH (13-15). 
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Despite these treatments patients still suffer with excess morbidity and a reduction in quality of life 
(QOL), which is at least in part related to a poor exercise tolerance and an inability to engage in 
activities of daily living (18). The 6MWD has repeatedly been identified as predictor of prognosis and 
one of the primary outcomes by which interventions in PAH are evaluated (19). 6MWD is determined 
not only by a patients’ cardiorespiratory reserve but also by neuromuscular function (20). Loss of 
muscle function and size seems to be a ubiquitous outcome of chronic disease and PAH is no exception 
(21). Current guidelines have recognised this fact and now recommend increase in physical activity as 
well as supervised exercise programmes as general measures to improve both well-being and exercise 
tolerance in PAH (22). 
1.2 Skeletal muscle wasting in chronic cardio-respiratory disease 
1.2.1 Muscle loss in the vicious cycle of disease progression  
Muscle loss has been implicated as an important complication in individuals with a number of chronic 
diseases affecting both the heart and the lung. In these conditions muscle loss contributes to a 
downward spiral of breathlessness, fatigue, exercise intolerance, lack of physical activity, metabolic 
syndrome, and disease progression (Figure 1.1) (23).  
 
Figure 1.1. The vicious cycle disease progression. Muscle weakness and low physical as a focus of the spiral of 
breathless, fatigue, exercise intolerance, metabolic syndrome and disease progression in chronic cardio-
respiratory disease. 
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1.2.2 Clinical studies of muscle loss in chronic obstructive pulmonary disease (COPD) and heart 
failure  
Unlike in PAH, muscle loss in COPD and heart failure have been widely studied. In COPD up to 36% of 
patients experience a reduction in quadriceps strength (24) which may be present in early disease and 
is only weakly associated with lung function (25-27). Studies using both ultrasound (28) and 
computerised tomography (29) have shown that this loss of strength is accompanied by a 
proportionate loss in quadriceps size (30). In COPD loss of quadriceps muscle function has been shown 
to be associated with a reduction in exercise tolerance (31), QOL (32) and an increase in healthcare 
utilisation (33) and mortality (34).  
In heart failure, in one study, approximately 20% of patients were found to have skeletal muscle 
wasting (35). Quadriceps cross sectional area was lower in patients than controls as was strength, 
however unlike in COPD, researchers have reported that even when muscle size was corrected for, 
strength remained impaired (36). Again, as opposed to COPD, where little relationship existed 
between muscle function and lung function (37), muscle loss was more strongly linked to left 
ventricular ejection fraction and  with maximal oxygen uptake (VO2 max), independent of other 
variables, in heart failure (35).  A reduction in quadriceps strength in heart failure has been associated 
with both a reduction in QOL (38) and an increase in mortality (39). One author has even implicated 
skeletal muscle wasting as the predominant cause of exercise intolerance in patients with heart failure 
(40). 
1.2.3 Muscle fibres in health, COPD and heart failure 
In normal human skeletal muscle there are 3 different types of muscle fibre, which depend on which 
type of myosin heavy chain the fibre produces. Type 1 fibres are oxidative and fatigue resistant. Type 
2x fibres are glycolytic and type 2a fibres have a mixed phenotype.  Because of the disparate metabolic 
pathways that these fibres rely on to function the proportion of each fibre within a given muscle can 
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help define its metabolic efficiency, with type 1 fibres conferring greater endurance to a muscle. Fibre 
shift is a change in proportion of these fibres within a muscle (41, 42).  
In the quadriceps of patients with COPD, there is a reduction in type 1 fibres and an increase in type 
2x fibres (43), which is associated with exercise intolerance, lower DLCO but interestingly not with 
forced expiratory volume in 1 second (FEV1) or physical activity (44). Concurrently there is a type 2x 
fibre specific atrophy (45), with a predictable reduction in oxidative enzymes, without any change in 
glycolytic enzymes (46). The quadriceps of patients with heart failure exhibit similar changes to those 
seen in COPD, with a shift towards a type 2 fibre predominance (47) and a reduction in oxidative 
enzymes (48). In the diaphragm of these patients the fibre shift is reversed with an increase in type 1 
fibres and a decrease in type 2 fibres, suggesting an increase in fatigue resistance and improved 
performance (49, 50). 
1.2.4 Molecular pathways leading to muscle loss in chronic disease 
Loss and gain of muscle depends on the interplay between protein synthesis and breakdown (51). In 
chronic diseases loss of muscle function and size is thought to be due to a relative up-regulation of 
atrophic and down-regulation of hypertrophic pathways, loss of muscle satellite stem cell function, 
upregulation of autophagy and apoptosis, and shift in fibre type (51-53). The signalling pathways 
involved in muscle wasting are vast and complex but some of the major pathways that are retained 
across the spectrum of chronic diseases are shown in figure 1.2.  
In muscle it has been suggested that the ubiquitin-proteasomal system is important in stimulating the 
breakdown of protein, a cause of muscle atrophy. The most well studied ubiquitin ligases that have 
been shown to be involved in this pathway are atrogin-1 and muscle ring finger 1 (MuRF1) (51, 53, 
54). A number of studies have shown that the ubiquitin ligases atrogin-1 and MuRF-1 are variably up-
regulated in the quadriceps of patients with COPD (52, 55-58), heart failure (59) and in an animal 
model of cardio-respiratory disease (60). This increase in ubiquitin ligase expression is, however, not 
a universal finding. Members of my group found no difference in MuRF-1 and a decrease in atrogin-1 
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expression in the quadriceps of patients with COPD when compared to controls. The authors argued 
that this lack of association between muscle mass and ubiquitin ligase expression did not exclude a 
role for these proteins in the muscle wasting process, as their levels may vary with time (61). This 
conclusion is supported by data from animal studies of denervation muscle injury, which shows that 
ubiquitin ligase levels peak at day 4 and return to baseline by 2 weeks (54).    
 Hypertrophy in muscle is driven by a number of factors. One of the most important mediators of 
muscle hypertrophy is insulin like growth factor 1 (IGF-1).  IGF-1 binds to its receptor and stimulates 
protein kinase B (AKT) phosphorylation which in turn activates mechanistic target of rapamycin 
(mTOR), leading to upregulation of pro-hypertrophic transcription factors. IGF-1 also inhibits forkhead 
box protein O1 (FOX-O1) activity, which is a major stimulus for muscle breakdown (51, 53). IGF-1 has 
been shown to be both up and downregulated in the quadriceps of patients with chronic disease. For 
example, in 2 studies, in patients with COPD quadriceps mRNA levels of IGF-1 were upregulated, (62, 
63), whilst in another study in a study in early heart failure they were downregulated (64).   
Another important mediator of muscle loss and gain is myostatin (Growth and Differentiation Factor 
8 (GDF-8)). GDF-8 is a transforming growth factor beta (TGFβ) super-family member which acts as a 
potent negative regulator of muscle growth (65). It acts through SMADs (66) and non-SMAD pathways 
(67) to alter transcription of a number of mediators of muscle strength and size. It interacts with both 
ubiquitin proteasome and IGF-1 pathways (51, 53). GDF-8 has been shown to be upregulated in the 
muscle of both COPD (68) and heart failure (69) patients.  
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Figure 1.2. Pathways of muscle loss in chronic disease. Some of the major pathways involved in the 
development of muscle hypertrophy and atrophy. Blue boxes contain stimuli of hypertrophic responses whilst 
red boxes represent atrophic signalling molecules. Insulin like growth factor 1 (IGF-1), phosphoinositide 3-kinase 
(PI3K), protein kinase B (AKT), mammalian target of rapamycin (mTOR), calcium (Ca2+), sarcoplasmic neuronal 
nitric oxide synthase (sarco-n NOS), P70S6 kinase (P70S6K), eukaryotic translation initiation factor 4E binding 
protein 1 (4EBP1), glycogen synthase kinase 3 beta (GSK3B), eukaryotic initiation factor 2B (ELF2B), reactive 
oxygen species (ROS), cytoplasmic neuronal nitric oxide synthase (cyto-nNOS), myostatin (GDF-8), follistatin 
(FSTN), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α4), tumour necrosis 
factor α (TNFα), forkhead box protein (FOXO), TGFβ activated kinase 1 (TAK1), mitogen-activated protein kinase 
6 (MKK6), p38-mitogen-activated protein kinase (p38-MPAK), inhibitor of nuclear factor kappa-B kinase subunit 
β (IKKβ), nuclear factor kappa B (NFKB), Muscle RING finger protein 1 (MuRF-1), Interleukin 1/6 (IL1/6), janus 
kinase (JAK), signal transducer and activator of transcription (STAT)(based on references(51-53, 70-73)). 
 
 
  
32 
  
The molecular pathways activated by chronic disease leading to muscle loss are thought to be driven 
by a number of factors including disuse, malnutrition, inflammation, hypoxia, oxidative stress, acidosis 
and medication, some of which will be outlined below (51-53). 
1.2.5 The drivers of muscle loss in chronic disease  
1.2.5.1 Physical inactivity 
As well as being implicated in the development of both heart failure (74) and COPD (75) physical 
inactivity is also a common consequence of chronic cardio-respiratory disease which may interact with 
inflammation, metabolic abnormalities and oxidative stress to increase transcription of various genes 
involved in the muscle wasting process (76). Disuse has been shown to promote atrophy through 
increases in oxidative stress and inflammation, particularly through the upregulation of nuclear factor 
kappa B (NFκB), as well as by reducing pro-hypertrophic neuronal nitric oxide synthase. This process 
may be further enhanced by physical inactivity effects on insulin resistance, apoptosis and a reduction 
in antioxidants (77, 78). Taken together this data suggests a central role for physical inactivity in 
propagating muscle loss in patients suffering with chronic diseases of the heart and lung. 
1.2.5.2 Malnutrition 
Malnutrition makes a significant contribution to skeletal muscle wasting in COPD (79) and heart failure 
(80). Increased amino acid availability has been shown to activate a number of pathways involved in 
protein synthesis including the mTOR pathway (51). In an elderly population sensitivity to essential 
amino acids particularly leucine is significantly reduced, meaning supra-normal supplementation in 
these individuals may be required to stimulate muscle growth (81); this may be similar in COPD and 
heart failure where some authors argue that the disease process causes an accelerated ageing 
phenotype (82, 83).   
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1.2.5.3 Inflammation 
Systemic Inflammation is found in some patients suffering with both COPD and heart failure (84, 85). 
Inflammatory cytokines, particularly NFκB and tumour necrosis factor alpha (TNFα), have been shown 
ex-vivo to be important mediators of muscle atrophy through up-regulation of ubiquitin ligases. Other 
inflammatory mediators including interleukin 6 and 1, signal transducer and activator of transcription 
3, Janus kinase and TNF receptor associated factor 6 (TRAF6) have also all been shown to mediate 
muscle loss. As well as up-regulating ubiquitin ligases and promoting atrophy these pro-inflammatory 
ligands inhibit hypertrophy through down-regulation of IGF-1 / AKT signals (51). It is not clear however 
whether systemic inflammation plays a significant role in the development of muscle wasting in all 
chronic disease. In COPD there is some evidence that systemic but not local inflammation may be 
associated with loss of muscle (86).  
1.2.5.4 Hypoxia 
Tissue hypoxia is an important consequence of COPD (86) and heart failure (87), which has been 
associated with a decrease in overall muscle mass (88) and muscle fibre cross sectional area (89). 
Hypoxia causes an increase in hypoxia inducible factor (HIF) which in turn inhibits mTOR activity and 
increases mitogen activated protein kinase (MAPK) activity resulting in decreased protein synthesis 
and increased protein atrophy. Other proteins implicated in hypoxia induced muscle wasting include 
peroxisome proliferator-activated receptor (PPAR), peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC1α), NFκB, and GDF-8 (90). Reactive oxygen species (ROS) are 
generated in mitochondria exposed to hypoxic conditions. Excess ROS, which are found in both COPD 
(91) and heart failure (92), lead to muscle tissue damage, apoptosis, a decrease in mTOR activity and 
a reduction in protein synthesis (93) resulting in wasting. 
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1.2.6 Treatments aimed at improving muscle function in chronic disease 
1.2.6.1 Rehabilitation 
In patients with COPD, pulmonary rehabilitation has been shown to increase exercise capacity and 
QOL (94), whilst reducing anxiety and depression (95). Although a survival benefit has not been 
demonstrated (96), rehabilitation has also been shown to and reduce exacerbation and admission 
rates in COPD patients  (30, 37, 97, 98).   
Cardiac rehabilitation programs have been shown to have similar effects in ischaemic heart disease 
and heart failure to those seen with pulmonary rehabilitation in COPD. Rehabilitation results in a 
reduction in hospital admissions and an improvement in QOL (99) and exercise tolerance (100) in 
cardiac patients. There is also a demonstrable mortality benefit in cardiac patients undergoing 
rehabilitation, that was not seen in patients with COPD, possibly due to the smaller numbers of 
patients enrolled in these studies (101).    
Rehabilitation, which includes resistance training, has been shown to increase muscle strength in both 
patients with COPD and heart disease (102-106). A study in COPD has examined the effects of strength 
training on the expression of various proteins known to be involved in the balance between muscle 
hypertrophy and atrophy. They showed that there was no change in ubiquitin ligase or GDF-8 
expression, but there was a significant upregulation of MyoD, a transcription factor involved in 
myogenesis (107). 
1.2.6.2 Nutritional Supplementation  
COPD patients, who were treated with nutritional supplements gained weight, improved their QOL, 
increased their exercise tolerance and, overall, improved their muscle strength in some studies (108-
110), although the latter finding was not universal (111). In patients with heart failure nutritional 
supplementation, in some studies also caused patients to gain weight and improve their exercise 
tolerance without altering muscle size, strength or QOL (112). The exact nature of the ideal 
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supplement to the diet in COPD and heart failure is yet to be established with some advocating a high 
fat, low carbohydrate diet (113) whilst others have recommended the supplementation of essential 
amino acids (114). The biological basis for supplementing amino acids such as leucine in patients with 
cardio-respiratory disease has been investigated. Leucine can activate the IGF-1 pathway including 
AKT and mTOR in skeletal muscle, potentially stimulating hypertrophy signalling (115). 
 1.2.6.3 Anabolic agents 
Anabolic agents have been shown to cause an increase in weight and muscle size in COPD and heart 
failure. The clinical use of these supplements has been limited by off target adverse side effects, which 
limit their potential clinical benefits (116, 117).  
Growth hormone has been used effectively in patients with human immunodeficiency virus (HIV) 
related cachexia (118).  In those with COPD growth hormone caused a gain in lean weight but failed 
to increase peripheral muscle strength (119, 120). In an unselected group of heart failure patients 
growth hormone had no positive effects on functional outcomes (121), whereas in those patients 
identified as growth hormone deficient replacement did improve exercise duration, QOL and ejection 
fraction, suggesting that its primary effect in these patients was in cardiac rather than skeletal muscle 
(122). 
Testosterone, as an anabolic agent, has been trialled alone and alongside resistance training in COPD. 
In one trial testosterone increased lean body mass and muscle strength in patients with COPD, an 
effect that was amplified by the combination of injection of testosterone with resistance exercise 
training (123). In a recent meta-analysis it was concluded that testosterone was able to increase 
muscle strength but had no effect on exercise performance or on QOL in COPD (124). 
Inhibition of angiotensin converting enzyme (ACE) with ACE inhibitors theoretically might be used to 
improve muscle strength in COPD and in heart disease, through actions on both the IGF-1 and ubiquitin 
proteasomal pathways (125). However in a trial of ACE inhibition versus placebo in a cohort of COPD 
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patients undergoing pulmonary rehabilitation the placebo group gained more muscle mass than the 
intervention arm suggesting that ACE inhibition is not effective in improving muscle strength in these 
patients and in fact may be detrimental (126).      
Alternative drugs under development include selective androgen modulators (SARMS) which 
theoretically have fewer off target effects than testosterone (127), GDF-8 antagonists (128), ghrelin 
analogues (129) and anti-catabolic / pro-anabolic agents like MT-102 (130). 
1.3 Muscle wasting in PH and PAH 
Muscle wasting has been studied much less frequently in PAH than in COPD or in heart failure. The 
monocrotaline (MCT) rat has, however, been widely used for many years as a model of cardiac 
cachexia and PH. The available literature on this model and other animal models of PH is therefore 
summarised below.  
1.3.1 Muscle wasting in animal models of PAH 
The most widely studied animal model of PAH related muscle loss is the MCT rat model.  MCT is a 
pyrrolizidine alkaloid which is the main toxic component of the Crotalaria spectabilis species of plants. 
It is known to induce pulmonary hypertension and either compensatory right ventricular hypertrophy 
or right heart failure (131). It is well established that after 4-6 weeks treatment with MCT, rats who 
develop heart failure also exhibit significant weight loss despite increases in water retention (132-
137).  
MCT treated rats have previously been shown to have lower hind-limb muscle dry weights and fibre 
cross sectional area when compared to control animals, although this is not a universal finding. Studies 
have shown loss of muscle mass in the soleus, tibialis anterior (TA) and extensor digitorum longus 
(EDL) muscles (132-141). In small animals, such as rodents there is an additional fibre type which, is 
not present in man, is faster than the type 2x fibres and has been termed 2b (142). It is in these type 
2b fibres that the fibre specific atrophy occurs in the EDL of MCT, much like the fibre specific atrophy 
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seen in the 2x fibres in humans (60).  The contractile properties of these same muscle in the MCT rat 
are also impaired, suggesting the decline in muscle mass observed is accompanied by a decline in the 
functional properties of that muscle (143). 
After MCT treatment, rats that developed heart failure showed a significant reduction in skeletal 
muscle oxidative enzymes, a reduction in antioxidants and an increase in lipid hydroperoxide, 
suggesting a significant decrease in potential for aerobic metabolism and an increase oxidative stress 
(132, 144). EDL (fast twitch) and TA (mixed fast and slow twitch) muscles also exhibited significant 
myosin heavy chain shift from 2a to 2b fibres, whilst the soleus (slow twitch) showed significant 
change from myosin heavy chain 1 to 2a fibres. This was associated with a significant decrease in 
skeletal muscle blood flow (134, 135, 138, 140, 145-147).   
The loss of muscle mass in the MCT rat is driven at least in part by increases in apoptosis.  In the EDL 
of the MCT rat there is an increase in proportion of apoptotic nuclei in both myofibres and interstitial 
cells, which has been associated with a decrease in the anti-apoptotic bcl-2 and an increase in the pro-
apoptotic caspase-3 (138, 145, 146, 148). The number of apoptotic nuclei in the muscle of these 
animals is significantly correlated with plasma BNP levels, right ventricular hypertrophy (138) and 
circulating levels of TNFα and its secondary messenger sphingosine (145), suggesting that both 
severity of heart failure and levels of systemic inflammation may be involved in propagating muscle 
loss in this model of PAH.  
Loss of muscle mass in the MCT rat is driven by a decrease in capacity for regeneration and an increase 
in atrophy. MCT rat EDL and soleus muscles exhibit a decrease in factors regulating muscle 
differentiation, development and regeneration including myoD, myogenic factor 6 (Mrf4) and 
myogenic (136, 141). It has also been shown that MCT treatment causes a significant reduction in 
soleus myoD+ and pax 7+ positive satellite cells (147), which have the potential to both differentiate 
and form new muscle. Taken together, this data suggests that there is a reduction in capacity for 
skeletal muscle regeneration in the MCT model of PAH.  As mentioned before, 2 key drivers of muscle 
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atrophy are the ubiquitin ligases atrogin-1 (60, 136) and MuRF-1 (60), both of which have been found 
to be over-expressed in the hind limb muscles of the MCT rat. In fact, higher atrogin-1 levels were 
associated with lower EDL muscle mass in this model (136).  
Mitochondrial dysfunction has been shown to be another factor involved in muscle loss in the MCT 
rat. Mitochondrial enzymes and markers of mitochondrial function PGC-1α, cytochrome c and 
calcineurin are all reduced in the muscle of the MCT rat (135). It has been demonstrated that there is 
a reduction in mRNA expression of mitochondrial proteins sirtuin 1 (SIRT1), PGC-1α and mitochondrial 
transcription factor A (TFAM) in the gastrocnemius of the MCT rat 2 weeks prior to these changes 
being seen in the right ventricle suggesting that mitochondrial dysfunction occurs in the skeletal 
muscle before the cardiac muscle in these animals (149).  
Other factors which may contribute to the muscle wasting process in the MCT rat include upregulation 
of expression and activity of the pro-inflammatory matrix metalloproteinase 9 (MMP9) (150) and a 
decrease phosphorylation of the pro-hypertrophic AKT and FOX0-3. There is also an increase in the E2 
activating ligases, e214k and ubiquitin-conjugating enzyme E2 (UBC7), which help ubiquitin ligases like 
atrogin-1 contribute to muscle wasting (136).  
Anorexia may also contribute to some of the changes in body weight, muscle weight and atrogene 
expression in the MCT rat (136). This anorexia was reversed by the soluble TNFα receptor but not by 
pentoxyfylline, a known inhibitor of TNFα function, and was associated with a reduction but not a 
normalisation of atrogene expression in the rodent’s EDLs (136). Interestingly in a MCT mouse model, 
where mice were injected weekly with 60 mg/kg of MCT for 6 - 8 weeks, there was no difference in 
the food intake between animals with PAH and controls (137).   
A number of interventions have been shown to be effective in reversing at least some of the changes 
seen in the skeletal muscle of rats with pulmonary hypertension and heart failure. This includes 
irbesartan, thalidomide, high dose growth hormone, L-carnitine and nebivolol which were able to 
partly restored normal MHC expression pattern (134, 140, 146, 151, 152). High dose growth hormone 
was able to partially reverse the atrophy seen in the TA (134) but not significantly in the soleus (135) 
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of treated animals as evidenced by a relative increase in fibre cross sectional area. This treatment was 
associated with decreased apoptosis, TNFα, and sphingosine blood levels (134) as well as 
normalization of PGC1α, cytochrome c and calcineurin expression (135). Carvedilol treatment of the 
MCT rat was shown to reduce the oxidation of muscle proteins and restored normal contractile 
properties to muscle (143). Nebivolol was also able to restore total animal and TA weight as well as 
fibre cross sectional area to normal.  It also reduced oxidation of proteins in the soleus, reduced 
apoptosis as measured by the presence of TUNEL positive nuclei and improved muscle twitch 
performance (140).   Both a soluble TNFα receptor and pentoxyfylline, a TNFα antagonist, were able 
to reverse changes seen in ubiquitin ligase expression in MCT rat muscle in a food intake dependant 
and independent mechanism respectively (136). The subcutaneous injection of human stem cells into 
the MCT rat was also associated with a significant increase in soleus weight and soleus fibre cross 
sectional area, as well as a reduction in apoptosis and an increase in pax-7+ and MyoD+ expressing 
satellite cell numbers back to near normal levels, as well as a significant shift in MHCs back to a normal 
distribution (147).   
Studies focussing on the role of TGFβ super-family ligands in the development of PAH associated 
muscle loss in animal models is limited to a single study examining circulating GDF-8 levels in the MCT 
rat (153). 
1.3.2 Muscle wasting and physical activity in PAH clinical observations 
Muscle dysfunction was first identified in the respiratory muscles of patients with PAH by Meyer et al. 
They showed that patients had reduced maximal inspiratory and expiratory pressures compared to 
controls indicating significant respiratory muscle weakness in this cohort (154). They also found that 
unlike patients with congestive cardiac failure (155, 156) and similar to patients with COPD (157), 
patients with IPAH suffered from an equal decrease in maximal inspiratory and expiratory pressures 
(154, 158).   These findings were confirmed by Kabitz et al. using non-volitional techniques to stimulate 
the respiratory muscles. His group was also able to demonstrate that maximum inspiratory pressures 
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and sniff nasal inspiratory trans-diaphragmatic pressures correlated significantly with exercise 
tolerance as measured by 6MWD in the group studied (159).  
Peripheral skeletal muscle dysfunction in PAH was first shown in 2007 when Bauer et al. demonstrated 
that maximal isometric forearm strength was significantly lower in patients with PAH than in healthy 
controls. They also demonstrated a significant correlation between 6MWD distance and hand grip, 
inspiratory and expiratory muscle strength. Interestingly there was no significant relationship between 
measured pulmonary artery pressure and handgrip strength (160).  Mainguy et al. demonstrated that 
quadriceps maximal volitional capacity and quadriceps twitch strength was significantly lower in 
patients with PAH than in age matched controls. They confirmed the close correlation between 
exercise capacity and muscle strength and again demonstrated that there was no significant 
relationship between muscle strength and pulmonary haemodynamics. They also showed that 
strength correlated with maximal oxygen uptake on CPET (161).  
Whilst not all researchers have found a change in peripheral skeletal muscle in PAH (162) Batt et al. 
have recently added significantly to the breadth of our knowledge in this area. They demonstrated 
that in 12 patients with IPAH computerized tomography assessed quadriceps cross sectional area was 
significantly reduced compared to controls (163). They also showed that muscle biopsies from patients 
with PAH showed a lower proportion of type 1 muscle fibres and increase in type 2 fibres (163) 
confirming earlier work by Mainguy et al.  (161). Type 1 fibres also had lower cross sectional area than 
controls (163) and there was an increase in phosphofructokinase: 3-hydroxyacyl–Co-A- 
dehydrogenase ratio suggesting an increase potential for anaerobic metabolic work (163, 164). 
Further elucidation of the metabolic pathways involved in the muscle wasting in PAH has shown that 
AKT, p70S6Kinase and FOX-O3 phosphorylation was decreased whilst both atrogin-1 and MuRF-1 were 
over-expressed in the quadriceps of patients (163).   
Some authors have understandably compared muscle weakness seen in PAH to that seen in congestive 
cardiac failure. It is thought that some of the exercise intolerance associated with heart failure is due 
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to a phenomenon known as the ergoreflex, where abnormalities in skeletal muscle metabolism in 
chronic heart failure results in a significant increase in ventilatory demand of exercise (165).The driver 
to this process is felt to be a reduction in skeletal muscle blood flow during exercise. Interestingly it 
has been noted that all 3 major classes of drugs prostaglandins (166), sildenafil (167) and endothelin 
receptor antagonists (168) used to treat PAH have the capability of vasodilating the skeletal muscle 
circulation as well as increasing patients’ exercise capacity, potentially through a reduction in this 
ergoreflex. Although this theory has not been formally tested in PAH, is it possible that the increases 
in exercise tolerance seen with these drugs may be in part due to a blunting of this ergoreflex (169) .  
Further data suggesting a link between right heart failure and muscle dysfunction come from an 
investigation into patients with congestive cardiac failure which suggested that maximal inspiratory 
pressure, which is an independent and important predictor of prognosis, is significantly and inversely 
correlated with mean pulmonary artery pressure, PVR, and pulmonary capillary wedge pressure 
suggesting a potential relationship between the pulmonary vasculature and muscle dysfunction in 
other cardio-respiratory conditions (170).  
Indirect evidence of the importance of a peripheral myopathy in PAH comes from studies looking at 
the effects of pulmonary rehabilitation on the condition. Mereles et al. showed that contrary to 
previous thinking, rehabilitation was safe and effective in patients with PAH. At 15 weeks, an exercise 
program was able to improve 6MWT distance by an average of 111m as well as improving QOL, WHO 
functional status, BORG score, peak oxygen consumption, oxygen consumption at the anaerobic 
threshold, and achieved workload, without altering haemodynamic parameters (171). De Man et al. 
showed that a 12 week supervised exercise training program involving cycling, muscle strength and 
endurance exercises was able to increase the patients anaerobic threshold, and exercise endurance 
time by 89% without changing distance achieved on 6MWD. Quadriceps strength increased by 13%, 
leg circumference remained unchanged and fibre type distribution was not altered.  There was 
however, a significant increase in the number of capillaries per myocyte and increase oxidative 
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capacity measured by succinate dehydrogenase levels in type I fibres (172). Mainguy et al. has 
demonstrated that a 12 week rehabilitation program involving 5 patients exposed to cycling, walking 
and weight training  resulted in a nearly 60m increase in 6MWD and significant decrease in the 
proportion of type 2x muscle fibres in quadriceps biopsy (164). 
As mentioned above physical activity is one unifying cause of muscle loss across a wide spectrum of 
diseases. Physical activity has been infrequently measured in PAH but is emerging as both a target for 
intervention and an outcome measure in this group of patients. The latest ESC/ERS guidelines have 
suggested that patients with PAH should be encouraged to remain as active as possible within 
symptom limits and that supervised rehabilitation is beneficial in terms of both exercise capacity and 
QOL (7, 22).  A small number of studies have shown that physical activity is reduced in patients with 
PAH when compared to healthy controls (173-176). Physical activity has been correlated with 6MWD 
(173), WHO functional class (174) and with QOL (175). Measuring and improving physical activity in 
PAH is a goal of treatment that requires further attention. The optimal method of assessing physical 
activity is not yet known with activity monitors and questionnaire having their own advantages and 
disadvantages (177). 
One molecular pathway that may play a critical role in muscle wasting but has, so far, not received 
much attention in muscle wasting in PAH is the TGFβ super-family of proteins. 
1.4 TGFβ signalling 
1.4.1 TGFβ signalling pathway  
The TGFβ super-family, is a group of proteins which are involved in developmental, physiological, 
homeostatic and pathological processes. They have a preserved structural homology with a 6-12 
residue cysteine knot and can be broadly divided into the TGFβ / activin group and the BMPs. GDFs 
are a divergent group with some members having more BMP- like properties, whilst others are more 
like TGFβ (178-180). 
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TGFβ super-family proteins act primarily in an autocrine and paracrine manner (178, 181), but recent 
evidence suggests that circulating levels can effect organs well away from their site of expression, 
suggesting they can also have endocrine actions (182). Generally TGFβ super-family proteins are 
secreted and stored in the extracellular matrix as inactive pro-peptides which are cleaved by proteases 
and activated to become dimeric proteins which then bind to their target receptors (183). The 
receptors are classed as type 1 and 2 (184). The ligand binds to its receptor which forms a 
heterotetrameric complex consisting of 2 type 1 and 2 type 2 receptors (185). The type 2 receptor is 
a constitutively active serine threonine kinase which is able to phosphorylate the type 1 receptor 
(184). This in turn phosphorylates intracellular SMAD molecules (186). The TGFβ / activin ligands tend 
to activate SMAD 2 and 3 whilst BMPs activate SMAD 1,5,8 but there is significant overlap within the 
system (187). These SMADs combine with the co-SMAD SMAD4 and the complex translocates to the 
nucleus to stimulate gene transcription (188). All SMADs recognise the binding site CAGAC whilst 
SMADs 1 and 5 have higher affinity for GC rich areas of DNA (179).  Meanwhile SMAD 6 and 7, known 
as the inhibitory SMADs, regulate the cellular signalling by enhancing degradation of receptors and 
inhibiting receptor/receptor-SMAD/co-SMAD interactions (189). The TGFβ super-family are also 
regulated by proteins which bind to them directly preventing them from interacting with their 
receptor, e.g. follistatin (187) (Figure 1.3). 
Despite nearly 40 TGFβ ligands being identified there are only 5 type 2 receptors and 7 type 1 
receptors meaning that most ligands can bind to different combinations of receptors with different 
affinities, altering the consequences for downstream signalling (178). The combination of receptors 
able bind different TGFβ ligands are outlined in Figure 1.4. 
As well as classical SMAD signalling it has been established that TGFβ superfamily members can 
interact directly and indirectly with a number of other pathways.  Particularly important pathways 
include the TGFβ activated kinase 1 (TAK1) pathway, inhibitor of nuclear factor kappa-B kinase subunit 
beta (Iκκβ), NFκB axis (190) p38 MAPK (191), extracellular signal regulated kinase 1 and 2 (ERK 1 / 2) 
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(192), c-Jun N terminal kinase (JNK) (193) and phosphoinositide 3 (PI3) kinase–AKT (194) pathways. 
These non-canonical pathways are often involved in antagonising or augmenting the effects of SMAD 
signalling. Taken together this data suggests that by activation of a number of competing and 
cooperating pathways the TGFβ super-family can fine tune its effects in a cell, time and environment 
dependent manner (178, 179) (Figure 1.3). 
 
 
Figure 1.3 Transforming growth factor β (TGFβ) super-family signalling. Blue boxes represent classical SMAD 
signalling, whilst red boxes represent non-canonical signalling. Blue arrows represent stimulatory signals, whilst 
red arrows represent inhibitory signals. Abbreviations used include receptor SMAD (R SMAD), inhibitory SMAD 
(I SMAD), phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), TGFβ activated kinase 1 (TAK1), p38-mitogen-
activated protein kinase (p38 MAPK), nuclear factor kappa B (NFκB), c-Jun N-terminal kinase (JNK) and 
extracellular signal-regulated kinase  (ERK) (179). 
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Figure 1.4 TGFβ super-family members and their potential receptors. TGFβ super-family members (blue) and 
their potential type 1 (red) type 2 (green) and non-specific (orange) receptors.  Bone morphogenetic proteins 
(BMPs), growth and differentiation factor (GDF), antimullerian hormone (AMH), inhibins (inh), activin receptor 
like kinase 3 / BMP receptor 1A (ALK3) activin receptor like kinase 6 / BMPreceptor 1B (ALK6) activin receptor 
like kinase 2 / activin receptor type 1 (ALK2), activin receptor like kinase 4 / activing receptor 1B  (ALK4), activin 
receptor like kinase 1 / TGFß-super-family receptor (ALK1), activin like kinase 5 / TGFβ receptor type 1 (ALK5), 
BMP receptor 2 (BMPR2), activin receptor 2A/B (ACVR2A/B), TGFβ receptor 2 (TGFBR2), Glial cell line-derived 
neurotrophic factor (GDNF) receptor a (GRFa), Other (GDNF, neurturin, artemin , persephin) (adapted from 
Mueller et al.)(178). 
 
The complex interplay between the relatively few constitutive components that make up the TGFβ 
system with an almost limitless potential for interaction thus allows the TGFβ signalling pathway to 
control the wide range of biological functions it contributes to. The outcome of the signal is dependent 
on: the amount of signal transduction apparatus present both inside and outside the cell, including 
the amount, ratio and type of TGFβ ligand; the receptor expression properties of the cell, the amount 
of downstream material available for activation; the other nuclear signals that are present at the time 
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of stimulation; the presence of co-factors required to propagate the signalling pathways; and the 
availability of the target genetic material which may be altered by processes such as methylation 
(195). 
1.4.2 TGFβ signalling in PAH  
Abnormalities in TGFβ signalling have been shown to be instrumental in the development of PAH. 
Eighty percent of those with familial and up to 25% of those with IPAH have a mutation in the bone 
morphogenetic proteins type 2 receptor (BMPR2) (196). BMPR2 dysfunction is not limited to those 
with genetic disorders as lower levels of expression of the receptor have been found in patients with 
IPAH without mutations (197). Furthermore mutations in the activin like kinase (ALK) 1 receptor 
account for the majority of cases of hereditary haemorrhagic telangiectasia (HHT) associated PAH with 
a smaller subset being caused by other mutations, for example those that code for endoglin, a TGFβ 
receptors (198) or SMAD 4 (199).   
In pulmonary artery smooth muscle cells (PASMCs) BMPR2 mutations result in an absence or 
reduction in SMAD 1, 5 signalling in response to BMPs whilst SMAD 2, 3 responses are up-regulated 
due to compensatory effects of the activin type 2 receptors (200). BMPs 2, 4 and 7 activate both anti-
proliferative SMAD and pro-proliferative p38 MAPK signalling in PASMCs. Normally these ligands have 
predominant anti-proliferative effects in proximal vessels and pro-proliferative effects in the distal 
vasculature. In cells lacking BMPR2 the anti-proliferative actions of the BMPs are lost resulting in 
unchecked smooth muscle hyperplasia (201). In endothelial cells BMP 4 and 6 cause cell proliferation 
and migration as well as protecting from apoptosis. Lack of BMP signalling in these cells results in loss 
of the endothelial cell layer exposing the PASMCs, and contributing to a lack in their ability to respond 
normally to hypertrophic signalling by growth factors. This causes uncontrolled PASMC proliferation, 
whilst an apoptotic resistant pool of endothelial cells is selected out allowing them to proliferate 
forming plexiform lesions (202).  
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Abnormalities in the BMPR2 and ALK1 pathways are not the only aberrations in TGFβ signalling seen 
in PAH. In MCT rats pulmonary vascular TGFβ1 and SMAD 2 were up-regulated and were associated 
with disease progression and increased apoptosis. Furthermore pulmonary haemodynamics and 
vascular remodelling were improved by an ALK-5 inhibitor (203). TGFβ1 which is normally anti-
proliferative in PASMCs has been shown to cause proliferation in PASMCs from patients with IPAH 
(204). This has led some to suggest that aberration in BMPR2 function is able to switch the effect of 
TGFB1 from anti to pro-proliferative in smooth muscle cells. However this is not a universally accepted 
hypothesis as other groups have shown a reduction in TGFβ1 and SMAD signalling in response to 
treatment with MCT (205).  
Other TGFβ super-family members have been found in increased levels in patients with PAH. Activin 
A and its natural antagonist follistatin have been linked to prognosis in PAH and activin A has been 
shown to cause PASMC proliferation in vitro, suggesting it may be an important mediator in the 
development of PAH (206).   
GDF-15 is a molecule of interest that has been associated with prognosis in PAH (207) and will be 
discussed later in the introduction.   
1.4.3 TGFβ signalling in skeletal muscle atrophy 
As mentioned GDF-8, is a TGFβ super-family member and potent negative regulator of muscle mass. 
GDF-8 has been shown to be elevated in the muscle of the elderly, the inactive and those with chronic 
diseases including COPD, HIV, heart failure, renal failure and cancer (70). GDF-8 null mice exhibit an 
increase in muscle mass compared to controls (208). Transgenic expression of follistatin, GDF-8’s 
trapping protein, resulted in a further increase in mass above GDF-8 inhibition alone, suggesting other 
TGFβ super family proteins that are bound by follistatin protein can also influence muscle mass. 
Candidate proteins include the activins (209). GDF-8 acts via the activin receptor 2B (ACVR2B) and ALK 
4/5 and SMAD 2/3 (51). It has multiple effects inhibiting both hypertrophic and hyperplastic signalling 
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pathways (53). GDF-8 also down-regulates phosphorylation of the AKT pathway (210) whilst follistatin 
is able to induce a significant increase in AKT phosphorylation and is associated with hypertrophy 
(211). GDF-8 can cause muscle atrophy through an increase in the ubiquitin ligase atrogin-1, but not 
MuRF1. Interestingly this is dependent on FOX-O activation but independent of SMADs and AKT (71). 
GDF-8 can also act via TAK1 to stimulate NFκB, P38 MAPK, ERK1/2 and JNK all of which are involved in 
inhibiting hypertrophy and promoting atrophy (72). In muscle cells GDF-8 has been shown to cause a 
reduction in levels of the regenerative transcription factors MyoD, MRF5 and myogenin (73). This 
process may keep satellite cells in a quiescent state (71). It has recently been shown that in an animal 
model of heart failure systemic levels of GDF-8, influenced primarily by up-regulation of GDF-8 
expression from the heart,  can have a significant impact on peripheral muscle mass suggesting that 
this and other TGFβ super-family proteins can function in an endocrine manner (212). This observation 
is supported by evidence suggesting that over-expression of GDF-8 in one leg muscle of a mouse cause 
leak of the protein into the circulation resulting in a generalised wasting of other hind limb muscles.  
It therefore seems possible that circulating levels of TGFβ super-family members may make an 
important contribution to muscle mass in chronic disease by influencing the availability of active local 
stores of the ligand (182). 
Other TGFβ super-family members have been implicated in the development of muscle atrophy and 
hypertrophy. TGFβ1 has been associated with fibrosis, inflammation, SMAD 2, 3 activation and muscle 
dysfunction through impairing hypertrophy and stimulating atrophy (213, 214). BMPs, particularly 
BMP 7, 13 and 14 have been associated with hypertrophy in adult skeletal muscle probably dependent 
on SMAD 1, 5 phosphorylation, and may be related to up-regulation of mTOR, inhibition of FOXO, 
down-regulation of ubiquitin ligases and maintenance of a pool of replicating satellite cells (215, 216).    
TGFβ super-family members, such as the activins and BMPs can bind to the ACVR2B and influence 
downstream signalling (73). Antagonising the ACVR2B has proved more successful than blocking the 
effects of GDF-8 alone, with soluble ACVR2B treatments resulting in a 60% increase in muscle size 
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(209) and causing an improvement in cardiac function, metabolic handling of glucose and an increase 
in longevity in a mouse cancer cachexia model (217). Further evidence that we should be looking 
beyond GDF-8 in muscle comes from my group. Bloch et al. showed that in patients on intensive care 
(ICU) blood GDF-8 levels were not different in those who did and did not develop quadriceps atrophy 
following aortic surgery. GDF-8 levels actually declined in patients immediately after surgery.  
Conversely, another TGFβ super-family member, GDF-15 was elevated in the blood of patients 
following surgery and remained significantly elevated in the patients who lost more than 10% of the 
area of their rectus femoris muscle but not in those that lost less than 10% (218). 
1.5 GDF-15  
1.5.1 GDF-15 in health and disease 
One TGFβ super-family protein of interest that has a potential role in the development of both muscle 
wasting and PAH and is a potential target for future drug development is GDF-15. 
Initially called macrophage inhibitory cytokine 1 (219), placental bone morphogenetic protein (220), 
prostate derived factor (221), placental TGFβ (222), non-steroidal anti-inflammatory associated gene 
(223), GDF-15 was discovered almost simultaneously in a number of tissues including macrophages 
(219), the placenta (220, 222), the prostate (221) and in colorectal cancer cells (223). It was also found 
in low levels in other tissues (220) particularly the epithelial tissue of the intestine, lung, 
submandibular gland, kidney, liver, spleen, lactating mammary glands (224, 225), skin and cartilage 
(221) the choroid plexus in the brain (224) and the CSF (226).   
GDF-15 is a 62-kDa intra-cellular protein which is secreted as a 25kDa protein after cleavage by a furin 
like protease (219). It was noted to be similar in structure to other members of the TGFβ super-family 
of cytokines (219-221), which have 7 cysteine residues arranged in a knot (219-221) but, due to its lack 
of structural homology to pre-existing subgroups, it has been hypothesised that GDF-15 was the first 
member of a new sub-family (178, 219, 220).  
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GDF-15 has generally low expression levels during periods without cellular stress, but on stimulation 
by hypoxia, inflammation, short wavelength light exposure, tissue injury and cancer progression, 
levels can substantially increase. Some of the stimulants to GDF-15 expression include TNF α, 
interleukin-1B (IL-1B), IL6, granulocyte monocyte colony stimulating factor, androgens, non-steroidal 
anti-inflammatory drugs, PPAR γ ligands, retinoids, resevratol, etopiside, doxorubicin, 
cyclophosphamide and epirubicin, tissue plasminogen activator, early growth response protein 1, 
NFκB, hypoxia inducible factor 1α, hydrogen peroxide, TGFβ1, AKT, α dihydrotestosterone, MAPK, 
microphtlamia-associated transcription, p53 tumour suppressor and p21WAF1 (227). 
The physiological role of GDF-15 remains to be fully elucidated. GDF-15 levels are raised in pregnancy 
(228). GDF-15 is produced in large quantities by the placenta (220) and low levels in pregnancy are 
associated with increased risk of pre-eclampsia and miscarriage (229, 230). GDF-15 also seems to be 
anti-inflammatory, as it prevents activation of macrophages (219). One of the physiological roles of 
GDF-15 may be in preventing maternal inflammatory proteins from affecting the developing foetus 
and modulating the immune system allowing the mother to develop immune-tolerance to the foetus 
(220, 229, 230). Further evidence of the importance of GDF-15 in human reproduction comes from 
data showing that GDF-15 has anti-inflammatory effects in seminal fluid, where it is found at high 
levels (231).  
Even though GDF-15 null mice are viable and female mice are fertile (232) there is some evidence that 
GDF-15 plays an important role in health and disease.  GDF-15 may have a physiological role in the 
regeneration of neurones (233). For example, GDF-15 knockout mice lose sensory and motor neurones 
at a faster rate than wild type mice (234).  There is also some evidence that GDF-15 is a cardio-
protective TGFβ super-family member. GDF-15, both locally produced and exogenously administered, 
may have role in limiting the cardiac hypertrophic response to pressure overload (235). GDF-15 
knockout mice exhibit increased extent of ischaemia reperfusion injury after coronary artery ligation 
(236) and due to an increase in inflammatory cell infiltrate suffered with fatal myocardial rupture more 
often than wild type mice (237). GDF-15 also has also been reported to have some negative effects on 
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the heart. In one study GDF-15 increased protein synthesis and caused hypertrophy of cardiomyocytes 
as well as protecting against apoptosis (238), in contrast to findings discussed above. Others have 
shown that GDF-15 deficient mice or mice with GDF-15 deficient macrophages are resistant to the 
formation of unstable, occlusive atherosclerotic plaques, resulting in a reduction in ischaemic heart 
disease (239, 240). Overall it seems that GDF-15 may be involved in disease progression but is also 
intrinsic in limiting the damage done by the disease process. 
Like in cardiovascular disease, GDF-15 has been shown to have a number of opposing effects in cancer. 
It is generally felt that early on in the disease that GDF-15 is pro-apoptotic and anti-proliferative (227). 
This anti-tumorigenic effect was first seen in vitro in breast cancer cells and in vivo in athymic mice 
xenografted with colorectal cancer cells (223, 241). GDF-15 seems to have the opposite role in later 
stages of cancer progression, where in general it has been shown to enhance invasiveness and be pro-
metastatic. GDF-15 has been shown to enhance malignant behaviour in melanoma (242), gastric (243, 
244), breast (244, 245), oral squamous cell (246) and prostate cancer (247). GDF-15 has also been 
shown to confer chemotherapeutic resistance to cancer cells. This was first shown in breast cancer 
where excess GDF-15 conferred tamoxifem resistance (248) and may be particularly relevant in 
prostate cancer resistant to docetaxel and mitoxantrone (249, 250).   
Perhaps most importantly high circulating GDF-15 levels are a strong independent predictor of 
outcomes in a wide range of conditions (207, 251-255) and in the general population higher levels 
have been linked to all-cause mortality (256-258). Muscle loss another ubiquitous outcome of chronic 
disease and a marker of poor prognosis in almost every condition that it has been measured (21) has 
consistently been associated with raised circulating GDF-15 levels.  
1.5.2. GDF-15 in muscle wasting 
GDF-15 deficient mice weigh more (234, 259) whilst GDF-15 over-expressing mice weight less than 
their normal counterparts, interestingly this is independent of whether GDF-15 had a tumour 
enhancing or inhibiting effect in the animal model studied (259, 260).  
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GDF-15 levels have been associated with the development of weight loss and muscle wasting in a 
number of cancers. In mice injected with GDF-15 secreting prostate cancer cells those who developed 
raised circulating GDF-15 levels had lower body weight than those with normal levels. The weight loss 
involved a decrease in muscle mass of between 25 and 30% and was reversed by a GDF-15 antibody. 
The authors noted significant hypophagia in these animals which they felt completely explained the 
weight loss. The associations of circulating GDF-15 with weight loss was confirmed in patients with 
prostate cancer and those with renal failure (260).  
Members of my group have shown that, as well as an effect on appetite, GDF-15 has a direct effect on 
muscle. Circulating GDF-15 levels are associated with muscle atrophy in patients with ICU acquired 
weakness, with patients who exhibited quadriceps wasting after cardiopulmonary bypass having 
persistently raised serum levels of GDF-15. In vitro they also showed for the first time that adding GDF-
15 to myotubes was able to cause atrophy (218). Other groups have shown that GDF-15 has a role in 
the development of mitochondrial skeletal myopathies (261), that circulating GDF-15 levels are 
associated with muscle loss in both patients with cancer (262) and in healthy elderly women (263). 
Furthermore, one group commented that GDF-15 was one of the only proteins that could potentially 
cause cancer cachexia, where circulating levels were also correlated with BMI (264). More recently my 
group has shown that GDF-15 can up-regulate atrogin-1 and MuRF-1 ubiquitin ligase mRNA expression 
in vitro. GDF-15 was raised in the serum and in the muscle of patients with ICUAW and was associated 
with markers of muscle wasting. They also showed that systemic GDF-15 levels were negatively 
associated with a number of pro-hypertrophic microRNAs (265). Other results from my group confirm 
the association of circulating GDF-15 with muscle mass in a stable cohort of COPD patients. We also 
showed that when GDF-15 was over-expressed in mouse muscle their fibre diameter was lower than 
in muscle over-expressing control vectors (266).  
One exception to this association is the case of obese patients with diabetes where GDF-15 levels were 
associated positively with BMI (267). Another study in gastric cancer showed no correlation between 
GDF-15 with weight loss nor with BMI (268). 
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Finally in cancer cachexia GDF-15 was shown to be an important mediator of both fat and muscle loss. 
In this study treatment with a GDF-15 antibody was able to prevent weight loss in a number of models 
of cancer cachexia, and when given in conjunction with tumour suppressing chemotherapy it was able 
to prolong survival (269). 
1.5.3 GDF-15 and food intake 
GDF-15’s effect on muscle mass has been shown to be at least partially dependant on reduced food 
intake. Johnen et al. suggested that this was the predominant reason for muscle loss in GDF-15 over-
expressing states. Xenografted GDF-15 over-expressing tumours resulted in a significant reduction in 
food intake, which was prevented by administration of a GDF-15 antibody. GDF-15 was also able to 
induce weight loss through appetite suppression in obese mice, whilst GDF-15’s effects on weight loss 
was completely obviated by pair feeding animals. Furthermore direct injection of GDF-15 into the 
hypothalamus upregulated the anorexigen pro-opiomelanocortin and downregulated the appetite 
stimulus neuro-peptide Y (260). Macia et al. also suggested that GDF-15 transgenic mice lost more fat 
mass than lean mass, primarily as a result of decrease food intake (270). Further evidence for an 
anorexigenic effect of GDF-15 comes from data showing knockout mice ate less than wild type 
counterparts, a process that was rescued by GDF-15 infusion (271). The same group showed that 
injection of GDF-15 into the CNS resulted in reduced weight and a reduction of food intake that was 
dependent on an intact brainstem axis (272). 
GDF-15 levels have not universally been associated with poor oral intake.  Although GDF-15 levels 
were associated with prognosis in patients with gastric cancer they were only weakly correlated with 
nutritional intake in these patients (268). A GDF-15 over-expressing mouse model lost weight but ate 
more than control animals (273). Finally although GDF-15 levels changed diurnally and were inversely 
related to BMI in a twin cohort, they did not change post-prandially making the authors of one study 
suggest that it was unlikely to be a satiety factor (274). These findings suggest that GDF-15 may not 
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just act via appetite suppression and that alternative mechanisms by which GDF-15 can cause muscle 
loss are worth investigating. 
1.5.4 GDF-15 and physical activity 
Muscle loss is both a cause and effect of physical inactivity (75). GDF-15 has been infrequently 
measured at the same time as physical activity and energy expenditure. GDF-15 over-expressing mice 
have been shown to have both a reduction (260, 270) and an increase in energy expenditure and 
metabolic rate (273).  Furthermore, female but not male GDF-15 knockout mice had a lower physical 
activity level than wild type counterparts (271). Taken together this suggests that GDF-15’s effects on 
physical activity and energy expenditure are dependent on a complex interplay of factors in individual 
experiments and animals, or a result of type 1 errors. 
In health, in ultra-marathon athletes, circulating GDF-15 levels transiently increased to an average of 
above twice the upper limit of normal, falling back to baseline at days 2 post race. This rise was 
postulated to be due to the endothelial dysfunction associated with endurance sport (275) and is 
supported by data showing similar findings in professional footballers and rugby players (276, 277). 
In cardiac disease where GDF-15 levels were compared pre- and post- coronary intervention and then 
pre and post 6 months rehabilitation there was a transient rise in GDF-15 levels around the time of 
stent insertion which fell back to baseline. Furthermore there was no change in GDF-15 level after the 
exercise program, suggesting GDF-15 levels are not responsive to the amount of exercise performed 
during the rehabilitation program (257).  
1.5.5 GDF-15 and PH 
In patients with IPAH, GDF-15 is an independent marker of prognosis. GDF-15 levels above 2097pg/ml 
predicted those with an increase in mortality. Patients with higher GDF-15 levels were older, were 
more likely to be male, were in a higher functional class and had higher creatinine levels. GDF-15 levels 
correlated significantly with 6MWD, BNP and right atrial pressure. Interestingly there was no 
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association with cardiac output, pulmonary vascular resistance or pulmonary arterial pressure. 
Furthermore, in follow up, GDF-15 levels responded to changes in PAH treatment in line with changes 
in BNP levels (207). In adult congenital heart disease GDF-15 has been shown to be associated with 
BNP, elevated pulmonary artery pressure, exercise tolerance and NYHA functional class (278). In 
systemic sclerosis GDF-15 could be used to define those with and without evidence of PAH. In this 
cohort GDF-15 levels correlated with right ventricular systolic pressure and BNP and inversely with 
DLCO percent predicted (279). GDF-15 levels have also been shown to be raised in the serum of 
patients with CTEPH (280), sickle cell disease (281) and β-thalassaemia (282) when associated with 
pulmonary hypertension.  
In the lung tissue of patients with IPAH and Eisenmenger’s syndrome, GDF-15 messenger ribonucleic 
acid (mRNA) expression was shown to be significantly increased compared to controls. GDF-15 was 
localised in endothelial cells and plexiform lesions confirmed by immunohistochemistry and laser 
capture micro-dissection (283). GDF-15 has also been shown to be up-regulated in the lungs of 
patients with systemic sclerosis with PAH and IPAH but not in those with systemic sclerosis without 
PAH. The source of this GDF-15 in this study was felt to be macrophages (279). Mechanistic studies on 
the role GDF-15 might play in the development of PAH has been limited to one study investigating its 
effect on human microvascular endothelial cells. In these cells exposure to hypoxia and sheer stress 
increased GDF-15 expression. In endothelial cells, GDF-15 at low levels (5ng/ml) was shown to be pro-
proliferative, whilst at high levels (50ng/ml) it was anti-proliferative. However both high and low 
concentrations were able to prevent hypoxia associated apoptosis and induce AKT phosphorylation 
(283).  
In human vascular endothelial cells (HUVECs) GDF-15 treatment of hypoxic cells stimulated 
angiogenesis through an increase in VEGF, an increase in HIF 1 α and a reduction in p53 (284). 
Circulating GDF-15 has been associated with a number of vascular endothelial markers, including 
tissue inhibitor of metalloproteinases metallopeptidase inhibitor 1, D-dimer and von Willebrand 
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factor, suggesting that GDF-15 is involved in cellular inflammation in the endothelium promoting 
endothelial dysfunction (285). 
Few investigations into the physiological role of GDF-15 in vascular tissue have been performed. GDF-
15 knockout mice exhibit an increase in platelet aggregation after induction of pulmonary embolism 
which was associated with an increased risk of early death. Furthermore GDF-15 treatment of wild 
type mice improved outcomes after PE suggesting that GDF-15 has an antithrombotic role in acute 
pulmonary embolism.(286). A further role for GDF-15 in vascular tissue is suggested by a study which 
showed that GDF-15 interferes with nitric oxide mediated changes in vascular tone in mice aortic 
tissue (287).   
1.5.6 GDF-15 and downstream signalling  
The signalling cascades activated by GDF-15 are wide, varied and cell, environment and dose 
dependant. The pathways that GDF-15 activates have not been examined in detail in skeletal muscle 
cells, but have been characterised in other cells lines.  
The receptor through which GDF-15 acts is unclear (227). In cells expressing mutant TGFBR2, mutant 
ALK-5 or those cells lacking SMAD 4, GDF-15 had no growth inhibitory effect on cancer cells, indicating 
that GDF-15 requires an intact TGFβ receptor complex and canonical pathway in order to function in 
some cells (288).  Johnen et al. added support to the argument that GDF-15 acts via the TGFBR2 by 
injecting a cohort of mice directly into to one half of their hypothalamus, a known site of action of 
GDF-15, with a TGFBR2 blocking antibody. They then injected the mice with GDF-15 and showed that 
these blocking antibodies prevented GDF-15 mediated c-fos activation only in the side with the 
blocking antibody. (260). In vascular cells GDF-15 has been shown to interact with TGFBR2, ALK-5 and 
SMAD 3 but that blockade of the type 1 receptor had the opposite effect to blockade of the type 2 
receptor suggesting a complicated receptor ligand interaction (239).  Other studies have shown that 
the TGFBR2 but not ALK-5 is necessary for GDF-15 to have its clinical effect on potassium channels in 
rat granular cerebellar neurones (289). In fact in colorectal cells, GDF-15 induced phosphorylation of 
  
57 
  
SMAD 2 and 3, which was dependant on the intact ALK-4, 6 or 7 (290), whilst in airway epithelial cells 
GDF-15 was able to inhibit cigarette smoke induced senescence through ALK1 receptor and SMAD1 
activation, suggesting that GDF-15 can act via a number of type 1 receptors (291). The requirement 
for an intact TGFβ1 receptor complex has not been a universal finding, with GDF-15’s effects on 
urokinase receptor upregulation being TGFβ1 receptor independent (243).  
More recently 3 groups have identified with some certainty the receptor through which GDF-15 acts 
in the hindbrain to control appetite (292-294). The glial cell line-derived neurotrophic factor 
family receptor-alpha-like (GFRAL) was first described in 2005 and is located solely in the membrane 
of cells in the area prostrema of the brain (295). GDF-15 has been shown to bind directly to the GFRAL 
(292-294) to activate ERK, and AKT (294). Knockout of the GFRAL has been shown to prevent GDF-15 
mediated weight loss in obese (294) and normal weight animals (296). This process is mediated 
through prevention of the anorexigenic effects of GDF-15 on neural pathways (292-294).  Interestingly 
the GFRAL has not been found in skeletal muscle (295) and its knockout seems to have a greater 
relative effect on fat compared to lean body mass (293). 
A number of groups have investigated the effects of GDF-15 on SMADs. GDF-15 has been shown to 
activate (235, 297), inhibit (298) and have no effect (238, 260, 299, 300) on SMAD 2, 3. It has also been 
shown to activate (235, 238, 300) and have no effect (260, 299) on SMAD 1, 5. This is dependent on 
the dose used and the cell type investigated. 
With an increase in constituent parts the effects of GDF-15 on the non-canonical pathway is even more 
complicated and varied. Some of the most widely studied pathways are AKT and ERK 1 and 2. In cardiac 
myocytes GDF-15 activated AKT (235, 236, 238) and ERK (235, 238). This was also true in breast, 
gastric, epithelial oesophageal and colon cancer cells, all of which showed that GDF-15 can activate 
ERK and AKT concurrently with some of the cancer progression seen in these models dependant on 
PI3Kinase and mTOR activity (243-245, 301-305). GDF-15 has also been shown to induce AKT 
phosphorylation in HUVEC cells (283), Huh7.5.1 cells (306), in human epithelial lung NCI-H292 cells 
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(307, 308), in glioblastoma (297) and in tracheobronchial epithelial cells (308), whilst in fibroblasts and 
in the hypothalamus of mice, GDF-15 resulted in ERK phosphorylation (260, 309).  The up-regulation 
of both AKT and ERK activity in the presence of GDF-15 is not a universal finding. In cerebellar granular 
neurones GDF-15 caused an increase in phosphorylation of AKT and was shown to act through 
upregulating PI3 kinase but down-regulated ERK activity (310). Furthermore, in gastric cancer HCT116 
cells inhibiting GDF-15 expression, through siRNA, increased phosphorylation of both AKT and ERK1/2, 
suggesting that GDF-15 might actually inhibit their activity in this cell line (311). In vivo in GDF-15 over-
expressing mice there was no increase in lung AKT or JNK phosphorylation (312). This finding was 
mimicked in RAW 267.4 cells, where GDF-15 had no effect on AKT or JNK (300). Finally in neonatal rat 
cardiomyocytes GDF-15 inhibited activation of AKT and ERK (313), suggesting that there is a significant 
difference in the pathways activated by GDF-15 in mature and developing cells. 
Another potential downstream target of GDF-15 examined in the literature is p38 MAPK. GDF-15 has 
been shown to upregulate p38 MAPK activity in RAW267.4 cells (300), in SK-BR-3 and HER2 breast 
cancer cells (303, 314), in HUVECs (315) and in ovarian cancer cells (304). In contrast, in both normal 
lung tissue and in lung tumours in GDF-15 over-expressing mice there was a reduction in phospho-p38 
MAPK. Furthermore in A549 cells, GDF-15 was able to inhibit increases in p38 MAPK induced by 
cigarette smoke (312), suggesting a potential role for GDF-15 and p38 MAPK inhibition in the 
propagation of lung cancer progression. In cardiac myocytes GDF-15 did not seem to have any effect 
on p38 MAPK activity (235) 
GDF-15’s effect on the NFκB pathway have also been examined in a number of cell lines with varying 
results. In HUVECs GDF-15 knockout seemed to have an enhancing effect on glucose mediated NFκB 
activation (316), whilst in RAW 267.4 cells GDF-15 delayed the induction of IKKB and thereby inhibited 
activation of NFκB, measured by luciferase (300). In contrast Hinoi et al. showed that GDF-15 induced 
phosphorylation of NFκB p65 in these same cells in the presence of receptor activator of nuclear NFκB 
ligand (317). Some of the most convincing evidence of GDF-15’s downstream pathway comes from E-
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Coli infected intestinal cancer cells, where GDF-15 siRNA prevented TAK1 and NFκB p65 activation. 
Furthermore, GDF-15 induced TAK1 phosphorylation peaking at 240 minutes and TAK1 inhibition with 
5(Z)-7-oxozeaenol prevented enteropathic E-Coli mediated increases in phosphorylation of NFκB p65 
(318). The same pathway was shown to be involved in Ras homolog gene family, member A guanosine 
triphosphatase (RhoA GTPase) cell survival pathway in the same cell line (319). This suggests that GDF-
15 may propagate its signal, in at least some cells, through actions on TAK1.   
1.6 TAK1 
1.6.1 TAK1 signalling  
TAK1 was discovered in 1995. It is a mitogen activated protein kinase kinase kinase that was stimulated 
by both TGFβ and BMPs (320). It is found bound to accessory proteins TAB1 (321), and TAB2 (322) or 
3 (323). The potential mechanism through which TGFβ1 activates TAK1 has been investigated. In one 
study TGFβ 1 was shown to bind to TGFBR2 which combines with the type 1 receptor ALK-5 resulting 
in its phosphorylation. The TGFBR2 was found bound directly to TAK1. As well as stimulating SMAD 
signalling ALK-5 was shown to be able to bind to X-linked inhibitor of apoptosis. This, in turn, bound 
to TAB1, combining TAK1 with both the type 1 and type 2 receptor, allowing it to phosphorylate 
downstream kinases (324) (Figure 1.5 A). Another group has shown that under unstimulated 
conditions TAK1 is bound via TAB2 and TRAF 6 to the ALK-5 receptor. Stimulation of the TGFBR2 by 
TGFβ1 resulted in the recruitment of ALK-5 causing a polyubiquination of TRAF6 and TAK1 at Lysine 
158, allowing the release of TAK1 from the receptor complex, leaving it free to combine with TAB1 
stimulating auto-phosphorylation (325, 326) (Figure 1.5 B). TGFβ1 is not the only TGFβ superfamily 
member that can activate TAK1. Studies have shown that GDF-8 which acts through the ACVR2B 
receptor can also stimulate TAK1 activity (327). 
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Figure 1.5 A and B. The interaction of TGFβ and TAK1 signalling. Schematic representations of potential 
mechanisms by which TGFβ1 might stimulate TAK1 activity. X-linked inhibitor of apoptosis protein (XIAP), 
phosphorylation (P), ubiquination (U) (324-326).   
 
As well as TGF β there are a number of other factors that have been shown to stimulate TAK1 including 
interleukin-1 (328), interleukin 18 (329), TNFα (330) and lipopolysaccharide (331).   
TAK1 activation has been shown dependant on phosphorylation at a number of sites including Serine 
192 (332) Threonine 184 and 187 (333, 334) and Serine 412 (335). Recent data has suggested that 
Serine 412 phosphorylation is required for full activation of TAK1 (335). Downstream TAK1 activates 
NFκB (336), p38 MAPK (337) and JNK (338). TAK1 also interacts with a number of other important 
pathways including  (339), PPAR (340) and the canonical TGFβ SMADs (341). Importantly SMAD 6 and 
7 can inhibit TAK1 mediated p38 MAPK activation (341) and SMAD 7 can inhibit TNFα mediated TAK1 
activation (342). Furthermore TAK1 can interact with the linker region of SMAD 2 and is essential for 
its phosphorylation (343). 
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1.6.2 TAK1 as a target for therapeutic intervention 
TAK1 is essential for embryonic development, innate and adaptive immunity and homeostasis of 
essential organ function (344-346). TAK1 is also involved in a number of disease processes. TAK1 
activity has been associated with inflammatory conditions, cancers (347), cardiovascular disease 
(348), and fibrosis (349, 350). TAK1 has become an exciting potential therapeutic target in a wide 
range of conditions and a number of compounds, aimed at antagonising its actions, are in 
development. These include: covalent cysteine binders such as 5(Z)-7-oxozeaenol and hypothemycin, 
which act on the cysteine residue in the Asp-Phe-Gly / DFG region; type I molecules which interact 
with the hinge region of the kinase, e.g. AZ-TAK1; and type II DFG out-binders, like PF-04358168, which 
change the confirmation of the active region of the protein rendering it inactive (351). All the 
mechanisms by which it might be possible to inhibit TAK1 have advantages and disadvantages with 
some compounds being potent but having off-target effects whilst others may be more specific but 
less effective (351).  
5(Z)-7-oxozeaenol was the first TAK1 inhibitor characterised (352) and has been the most widely used 
to inhibit TAK1 in vitro and in vivo. It is a resorcyclic lactone naturally produced by a fungus (352). It 
acts as an irreversible kinase inhibitor by forming a covalent bond between the cis-enone group of 
5(Z)-7-oxozeaenol and the functional thiol group of the cysteine residue of TAK1 resulting in alkylation 
of the protein and preventing the binding of TAK1 and ATP at its DFG site (353).  In vivo 5(Z)-7-
oxozeaenol has been shown to: enhance the chemotherapeutic effect of doxorubicin on 
neuroblastoma tumours in mice (354); prevent diabetes in a mouse model of the disease (355); reduce 
the severity of nephropathy in diabetic mice (356); increase neuronal survival and decrease seizure 
duration in epileptic rats  (357); reduce the size of infarct after stroke (358); and prevent neo-intimal 
formation in wire induced vascular injury (359). Its effects on muscle wasting have not been 
investigated. 5(Z)-7-oxozeaenol has been used intra-peritoneally at doses of between 0.5 – 5 
mg/kg/day (356, 358, 359). 
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1.6.3 TAK1 in PH 
Only one paper has examined the role of TAK1 in pulmonary hypertension. In mutant BMPR2 knockout 
mouse primary pulmonary artery smooth muscle cells TAK1 inhibition with 5(Z)-7-oxozeaenol 
prevented proliferation both at baseline and in response to TGFβ1 stimulation. 5(Z)-7-oxozeaenol also 
increased apoptosis in both wild type and BMPR2 knockout cells. The researchers found increased 
activity of TAK1 in the lung tissue of both MCT and hypoxic rats. It was also established that TAK1 
inhibited BMP induced SMAD1 signalling which was rescued by 5(Z)-7-oxozeaenol. Taken together the 
authors argued that TAK1 could be a target for therapeutic intervention in PH (360).  
1.6.4 TAK1 in muscle wasting 
A detailed study of TAK1 in skeletal muscle showed that phsopho-TAK1 and TAK1 levels are high in 
cells at day 1 and in young mice and fall as cells differentiate and mice grow. This group also found 
that regenerating muscle had higher mRNA expression of TAK1 and that TAK1 was required for 
proliferation but not survival of myoblasts. They confirmed that TAK1 was involved in differentiation 
through a number of normally competing pathways including p38 MAPK, AKT, IGF-1 and myoD (361). 
The p38 MAPK and AKT pathways were also activated in vitro and in vivo in response to TAK1 
phosphorylation by TRAF 6, which is stimulated in differentiating and regenerating cells (362). In 
keeping with these results TAK1 seems to be a vital component of satellite stem cell function in 
regenerating muscle or in muscle development in immature animals (363, 364). 
In contrast to its role in regeneration and development TAK1 activity can be stimulated by nutrient 
withdrawal as well as inflammation. As we have discussed above, both of these may be propagated 
by an increase in GDF-15 (365). The direct effects and influence of TAK1 activation in skeletal muscle 
has been rarely studied.  GDF-8, a known TGFβ super-family member, and negative regulator of muscle 
mass, requires TAK1 to propagate its growth inhibitory signal in muscle cells (67, 366). TAK1 has also 
been shown to be vital in the over-expression of matrix metalloproteinase 9 in C2C12 muscle cells 
treated with TNFα, suggesting a role for TAK1 in the development of muscle wasting (367). 
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Adiponectin is a negative mediator of muscle mass in chronic heart failure (368), APPL1 is an adaptor 
protein for adiponectin and is vital for its signalling. TAK1 seems to be integral in allowing APPL1 to 
stimulate p38 MAPK phosphorylation and thereby allow adiponectin to propagate its downstream 
signal. These researchers also found no interactions between p38 MAPK activated by TNFα and that 
activated by APPL1 /adiponectin, suggesting that the TAK1 axis has a complicated role in determining 
skeletal muscle mass (369). The effect of inhibition of TAK1 with a small molecule inhibitor has not as 
yet been studied in vivo. 
1.7 Summary, aims and hypotheses 
1.7.1 Summary 
Muscle wasting is a ubiquitous outcome of chronic disease. Rehabilitation is now a mainstay of 
treatment for many conditions. There are currently no established pharmacological interventions or 
biomarkers for muscle wasting in chronic cardio-respiratory disease. Novel targets for intervention 
and biomarkers are needed to improve outcomes in diseases complicated by muscle loss including 
PAH.   
From the data presented above I described the reasons that muscle wasting is likely to be important 
in influencing outcomes in PAH, but unlike in COPD and heart failure, there is very little established 
evidence that physical activity or muscle wasting in these patients directly affects mortality, 
admissions to hospital or QOL.  
I have described the animal models used to study muscle wasting in PAH. I have presented the 
evidence that GDF-15, a member of the TGFβ super-family, is raised in the circulation of patients with 
PAH. I have also shown that GDF-15 can influence muscle mass in vitro and in vivo, both directly and 
through actions on appetite suppression. The role of GDF-15 in the development of muscle wasting in 
PAH is unclear. It is also not established whether local or systemic levels of GDF-15 are important in 
the development of muscle wasting in vivo and in man.  
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Previous work has shown that GDF-15 may act through the TGFBR2 and ALK-5 to stimulate both SMAD 
and non-SMAD pathways, including TAK1 and NFκB. The specific pathway through which GDF-15 acts 
in muscle has not been determined, although there is some evidence that it can cause muscle wasting 
through up-regulation of ubiquitin ligases atrogin-1 and MuRF-1.  
Targeting GDF-15 and its downstream signalling may be a viable method to prevent and treat muscle 
wasting in PAH.  
1.7.3 Hypotheses 
Circulating GDF-15 levels released from the pulmonary vasculature and not locally are associated with 
muscle loss in patients and in animal models of PH. GDF-15 causes muscle loss directly, through a non-
canonical pathway and up-regulation of atrophic signalling, a process that may be reversed by blocking 
GDF-15 signalling via its receptor or downstream mediators. This may have clinical value as muscle 
loss and low physical activity in PAH is associated with poor outcomes.  
1.7.2 Aims 
To measure the associations of muscle strength and size and physical activity in a well characterised 
group of patients with PAH.  
To determine the effects of muscle strength and size and physical activity on outcomes such as    
hospitalisation and mortality in patients with PAH 
To investigate the association of physical activity outcome measures from QOL questionnaires with 
objectively measured physical activity in patients with PAH to determine the best way of measuring 
physical activity in PAH. 
To define the association of GDF-15 with muscle function and size in animal models and in patients 
with PAH. 
To identify the source of GDF-15 in animal models of PAH 
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To define the pathway through which GDF-15 might cause muscle wasting in vitro with a view to 
antagonising its effects. 
To determine whether inhibition of the pathway identified as being downstream of GDF-15 prevented 
muscle loss in the MCT rat model of PAH 
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Chapter 2 Methods  
2.1 Clinical methods  
2.1.1 Ethical approval  
The clinical study performed as part of this thesis was undertaken with ethical approval given by the 
National Research Ethics Committee under study number 13/LO/0481. The study was approved by 
the Royal Brompton Hospital (RBH) research and development team and was undertaken with the 
support of the RBH National Institute for Health Research (NIHR) Respiratory Biomedical Research 
Unit. Two control muscle biopsy samples were kindly donated by Professor Polkey and Ghulam Haji 
under REC approval 12/LO/0088. All patients gave written informed consent. 
2.1.2 Inclusion and exclusion criteria 
Patients aged 16 and over with PAH with World Health Organisation (WHO) stage I - III disease were 
eligible for recruitment. Interested healthy age-matched volunteers were also enrolled. Exclusion 
criteria included: those patients with co-morbidities including other significant cardio-respiratory 
disease, metabolic abnormalities including diabetes, eating disorders or untreated thyroid disease. 
Potential participants were excluded if they could not safely exercise or if they were wheelchair bound. 
Patients with other, pre-existing, known causes of muscle weakness or wasting, including, but not 
limited to, debilitating stroke, neuromuscular disease or active malignancy were also excluded. 
Patients with platelet counts of less than 80 were excluded from the muscle biopsy portion of the 
study. Finally those unable to give informed consent and those who were pregnant were also 
excluded.   
2.1.3 Demographics 
Age, sex, and date of birth were documented along with diagnosis, date of diagnosis, co-morbidities 
and treatment. WHO functional status for pulmonary hypertension was also defined. The different 
functional classes are listed in Table 2.1. 
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Functional Class Symptomatic Profile  
I No limitation on physical activity. Ordinary activity does  
  not cause symptoms 
II Slight limitation of physical activity. Comfortable at rest.  
  Ordinary activity can cause symptoms  
III Marked limitation of physical activity. Comfortable at rest. 
   Less than ordinary activity can cause symptoms 
IV Inability to carry out physical activity without symptoms.  
  Signs of right heart failure. Discomfort increased by physical activity.  
Table 2.1 WHO / NYHA functional class in pulmonary hypertension (22). 
2.1.4 Measurement of muscle mass, size and strength. 
2.1.4.1 Fat free mass index  
Fat free mass is a measure of lean body weight and can define those patients with sarcopaenia (370). 
In our study fat free mass index (FFMI) was measured by bioelectrical impedance using the Bodystat 
1500 (Bodystat, Isle of Man, UK). Electrodes were placed over the right foot (one behind the second 
toe and one between the malleoli) and on the right hand (one on the knuckle of the middle finger and 
one on the wrist adjacent to the ulnar head). Alligator clips were attached to the electrodes. The red 
clips were attached distally and the black clips were attached proximally. The machine was then 
turned on and individual patient data entered. The machine went through a number of prompts after 
which measurements were taken and the results were displayed and documented. Cut offs for FFMI 
of low, normal and high FFMI were < 14, 14-19 and > 19 kg/m2 respectively.  
2.1.4.2 Rectus femoris cross sectional area  
Cross sectional area of the rectus femoris muscle was assessed using ultrasound (US RFcsa). This was 
undertaken with an 8MHz 5.cm linear transducer array in B-mode (PLM805, Toshiba Medical Systems, 
Crawley, UK) or a 10MHz 12L-RS probe (Logiq E, GE Healthcare, UK). The subject was asked to lie down 
with the dominant leg held straight and relaxed. A point 3/5 of the way between the anterior superior 
iliac spine (ASIS) and the upper border of the patella was marked. The cross sectional ultrasound image 
was taken at this point. Contact gel and minimal pressure was used to reduce image distortion. The 
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smallest cross sectional area of the rectus femoris was identified by small movements of the probe to 
avoid oblique sampling. The femur was visualised in all images as a reference point. The septa which 
defined the edges of the muscle were identified. This process was aided by asking the patients to 
perform voluntary contractions of the leg. Three images of the rectus femoris were frozen and the 
inner echogenic line of the muscle was delineated. The area of the rectus femoris was measured using 
a planimetric technique (Nemio, Toshiba Medical Systems). The average of the 3 
USRFCSA measurements that were within 10% of each other was taken and documented. The 
technique is that described by Seymour et al (28) and used in a number of other studies (371-373). An 
example image of the US RFCSA is shown in Figure 2.1. 
 
Figure 2.1 Ultrasound image of rectus femoris cross sectional area (USRFCSA). Representative cross sectional 
ultrasound image of the thigh used to measured rectus femoris cross sectional area. 
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2.1.4.3 Quadriceps maximal volitional capacity (QMVC) 
Quadriceps maximal voluntary contraction (QMVC) is the gold standard for assessment of quadriceps 
strength. This is best assessed using the method first described by Edwards et al. (374). A specially 
designed chair (figure 2.2) was calibrated daily with a 29kg weight. Measurements were made using 
Labchart version 7 (ADI instruments, Oxford, UK). The patient was placed in a sitting position. A strap 
attached to a strain gauge was looped around the participants’ dominant leg. The participant was 
asked to make an isometric voluntary contraction of the quadriceps muscles. The procedure was 
repeated until the maximum contraction was determined. This was normally the 3rd or 4th attempt. 
There were no adverse events in the patients with PAH performing this task (374). For analysis 
quadriceps QMVC was normalised to body mass index to allow comparison across different 
individuals, with variable height and weight. This method has been used in studies by Swallow et al. 
(34) and Canavan et al. (375). Cut off values of a QMVC/BMI of > 1.5 were chosen to represent those 
patients with preserved muscle strength.  
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Figure 2.2 Chair used to measure quadriceps maximal volitional capacity (QMVC). Picture of specially designed 
chair for measurement of QMVC. 
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2.1.5 Physical activity measurements 
The Sensewear armband (SWA) (SenseWear Pro armband; BodyMedia Inc., Pittsburgh, PA, USA) is a 
physical activity monitor that is worn over the triceps in the position shown in Figure 2.3. It is a biaxial 
accelerometer, with other sensors including those for galvanic skin response, heat flux, skin 
temperature, and near-body ambient temperature. It has been validated in healthy individuals (376) 
and in some patients with chronic disease such as COPD (377). It has also been used to evaluate activity 
in patents with PAH (173). Participants were given the monitor to wear for seven days at all times 
except when bathing or swimming to avoid the armband getting wet. The SWA data output includes 
steps per day, total energy expenditure and time spent in moderate physical activity (above 3.0 
metabolic equivalents) (378).  The physical activity level (PAL: total energy expenditure per day divided 
by basal metabolic rate) was calculated using minute to minute data generated by the SWA Pro 
software version 6.1.0 (BodyMedia Inc., Pittsburgh, PA, USA) (379). PAL, total energy expenditure and 
time spent in moderate physical activity data was excluded from analysis if the SWA was worn for less 
than an average of 22.5 hours per day for 5 days including at least one weekend day as described by 
Watz et al. (378). Steps per day were excluded if the patient wore the armband for fewer than 8 hours 
for 4 days as described by Demeyer et al. (380). In analysis of the data basal, and therefore very low 
activity, was defined as: <2500 steps per day based on recommendations by Tudor-Locke et al. (381) 
or  a PAL < 1.4 which has previously used to define extremely inactive individuals (382, 383). Highly 
active individuals were defined as those achieving 30 minutes of at least moderate activity (> 3.0 
metabolic equivalents (METs)) as per current recommendations  (384).   
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Figure 2.3 Sensewear armband (SWA) position. Picture showing the positioning of the SWA over the triceps of 
a control subject. 
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2.1.6 Quality of life questionnaires 
2.1.6.1 The St. George’s respiratory questionnaire (SGRQ) 
The SGRQ is a QOL questionnaire, which consists of 7 sections and 50 questions, which are weighted 
to allow the user to define the participants QOL (385). A copy of the SGRQ is available in appendix 2.1. 
Permission to use the questionnaire for this study was granted by the copyright holder and is also 
contained in appendix 2.1. All participants were asked to fill in the questionnaire and answer all the 
questions according to instructions in the SGRQ manual (386). Completed questionnaires were scored 
by entering data generated into a specifically designed excel spreadsheet which weights answers and 
produces scores in a number of domains (386). The questionnaire was developed for use specifically 
in obstructive lung diseases asthma and COPD in which it has been validated (385). However, it has 
also been used to measure QOL in a number of other diseases including PAH (387). The outputs of the 
SGRQ include scores related to symptoms, activity, impact and total or overall QOL. All of these have 
a minimum score of 0 and a maximum score of 100, with lower scores representing better outcomes 
(388).  
2.1.6.2 The Cambridge pulmonary hypertension outcome review (CAMPHOR) 
The CAMPHOR QOL questionnaire was specifically designed for use in pulmonary hypertension (389). 
It has been related to outcomes in the condition(390). It consists of 3 sections: symptoms, which has 
25 questions; activities, which has 15 questions; and QOL, which has 25 questions. It is scored 
according to the manual with each section generating its own maximum score of 25, 30 and 25 points 
respectively. A total overall score with a maximum of 80 is also generated as a sum of all the sub-
sections (389). The CAMPHOR was used with permission of the copyright holder Galen research after 
signing a material transfer agreement and paying a nominal fee. A copy of the license for the 
questionnaire is included in appendix 2.2. 
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2.1.6.3 The emPHasis 10 questionnaire 
As part of normal clinical practice, patients in PH clinic at the Royal Brompton Hospital have their QOL 
measured and followed up with the emPHasis 10 questionnaire. This questionnaire is specifically 
developed for use in PH and uses only 10 questions. The maximum score is 50 with higher scores 
indicating worse QOL. Higher scores are associated with worsening functional status and exercise 
tolerance (391). The emPHasis 10 questionnaire provides only one outcome unlike the other 
questionnaires employed in the study. It was therefore used primarily to track changes in QOL over 
time in the population studied, and the relation of baseline characteristics to this change. 
2.1.7 Echocardiogram  
Echocardiography was carried out according to European association of echocardiography guidelines 
by a trained echocardiographer as part of the patient’s routine clinical assessment in clinic. Right 
ventricular function was assessed with tricuspid annular plane systolic excursion (TAPSE). The 
difference in distance between the position of the tricuspid lateral annulus in systole and diastole is 
measured. A TAPSE of ≥ 16mm is considered normal. Although it officially only measures longitudinal 
function, it is closely correlated with overall right ventricular function in a number of studies. 
Measurement of tricuspid regurgitant velocity (TR vel) and right atrial pressure (RAP) allows 
estimation of right ventricular systolic pressure (RVSP), where RVSP is (peak TR vel) 4 + RAP. RAP can 
be accurately estimated by IVC collapse during respiration. Normal values of TRvel are < 2.8 -2.9 m/s, 
which corresponds to a RVSP of 35 or 36 mmHg if the RAP is 3-5. (392, 393) Pulmonary artery 
acceleration time (PAcT) is the time between the onset of systolic pulmonary artery flow and the peak 
velocity of this flow. It has been shown to correlate with invasively measured mean pulmonary artery 
pressure and can be measured in those without tricuspid regurgitation. It also correlated closely with 
pulmonary vascular resistance (394).  
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2.1.8 The six minute walk test distance (6MWD) 
The 6MWD is one of the best markers of prognosis in patients with PAH (395). It is an accepted end 
point in the testing of novel therapies in clinical trials (396). Six minute walk tests were carried out 
according to ATS guidelines (397) adapted to suit the environment in the clinic. Briefly patients walked 
as far as they could on a 20 m track over 6 minutes. The instructions were given as per the guidelines 
(397).  
2.1.9 Blood tests 
Participants had blood drawn at the time of enrolment into the study. Blood was taken in 
ethylenediamineteracetic acid (EDTA) and serum separator tubes (SST) tubes. Within 30 minutes EDTA 
tubes were spun down in a cold centrifuge at 4oC at 14000 revolutions per minute (rpm) for 10 
minutes. Plasma was extracted with a Pasteur pipette and stored for later use at -80 0C. BNP is a 
prognostic marker in PAH (398). It was measured in the patients by ELISA by the hospital laboratory 
as part of the routine assessment of patients in clinic. A cut off of BNP of 100 pmol/L was used to 
define high and low values.  Growth and differentiation factor 15 plasma levels were measured by 
ELISA (R&D systems, Abingdon, UK) according to manufacturer’s instructions.  
Samples in the SST tubes were left for at least 30 minutes to allow for coagulation. Samples were then 
spun in a cold centrifuge at 10000 rpm at 18oC. Serum was removed and an assay was carried out for 
C-reactive protein (CRP) in the hospital laboratory according to local protocols and as part of the 
patients’ standard care. A CRP of > 10 mg/L was used as a cut off of high and low values. 
2.1.10 Muscle biopsies and protein extraction 
In this study 3 patients and 1 healthy volunteer consented and underwent muscle biopsy as described 
by Bergstrom et al. (399). Other biopsies from healthy adults were kindly donated by Dr. Ghulam Haji; 
those patients’ biopsies were covered by a separate REC permission (12/LO/0088) which included 
sharing of material to further the understanding of muscle disease in patients with cardiorespiratory 
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disease. Patients had anticoagulation stopped for an appropriate length of time (depending on the 
medicine used to achieve anticoagulation) prior to the biopsy taking place. Bergstrom needles (Stille, 
Stockholm, Sweden) were used with a modified suction port as described by Tarnopolsky et al. (400). 
The patient’s right vastus lateralis muscle was biopsied, just anterior to the lateral fascia and at 
approximately 50% of the distance from the greater trochanter to the knee. The area was cleaned 
with chlorhexidine and then infiltrated with up to 10 mls of 1% lidocaine first with a 26 gauge needle 
and then a 22 gauge needle ensuring the fascia is not affected. Next an incision was made in the skin 
just into the fascia with a scalpel and the needle was advanced into the incision. The biopsy needle 
was advanced into the muscle with a twisting motion to at least 1 cm beyond the fascia. The trochar 
was removed by at least a centimetre to expose the muscle to the cutting surface of the needle. An 
assistant attached a sterile 60 ml syringe to the end of the needle and suction was applied. The needle 
was rotated and the trochar advanced up and down to take the sample. The needle was removed and 
the sample was placed on saline soaked filter paper prior to processing. Pressure was applied to the 
area for 10-15 minutes to avoid bleeding. The wound was closed with steri-strips and patients were 
provided with paracetamol pain relief. The biopsy sample was frozen in liquid nitrogen for analysis or 
mounted on cork using TissueTech optimal cutting temperature compound (OCT) (VWR, Leicester, UK) 
and frozen in isopentane (Fisher Scientific, Loughborough, UK) cooled in liquid nitrogen. Samples were 
then stored at -80OC for later analysis. 
2.2 Animal models 
All animal model experiments were performed in conjunction with Dr. Alexi Crosby, Mr. Pieran Yang, 
Mr. Stephen Moore, Mr. Cai Reed, Dr. Stephen Sawiak, Mr. Martin Rice, Dr. Mark Ormiston and 
Professor Nicholas Morrel at the University of Cambridge under Home office license number 80/2460. 
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2.2.1 The Monocrotaline rat model  
2.2.1.1 Observational study 
Male Sprague-Dawley rats (Charles River Laboratories, Harlow, UK), (6 to 7 weeks old) received a 
single subcutaneous injection of MCT (Sigma-Aldrich, St-Louis, MO, USA) (40 mg/kg) or Phosphate 
buffered saline (PBS) control (Sigma-Aldrich, St-Louis, MO, USA) (401). 120mg of MCT was 
dissolved in 1.2ml of 0.5N hydrochloric acid (ThermoFisher Scientific, MA, USA) to which 0.72ml 
of 0.5N sodium hydroxide was added. The pH was adjusted to between 7 and 7.5 and the solution 
was made up to 4mls with water for injection to give a working concentration of 30mg/ml. Food 
intake was monitored throughout the experiment on a per cage basis with 2-4 similarly treated 
rats per cage. To characterise the muscle loss associated with PAH animals were humanely killed, 
by exsanguination, after 4 weeks, after weighing and haemodynamic assessment (402).  
2.2.1.2 Transforming growth factor β activated kinase 1 (TAK1) inhibitor study 
In the TAK1 inhibitor (TAK1i) study rats were treated with MCT or with control injections as above. 
After 2 weeks half the animals in the MCT group were treated with 5(Z)-7-oxozeaenol (Merck 
Millipore, MA, USA) 0.5mg/kg/day (dissolved in 10% Dimethyl sulfoxide(DMSO) (Sigma-Aldrich, 
St-Louis, MO, USA) / 90% PBS (Sigma-Aldrich, St-Louis, MO, USA) ) intra-peritoneally for 9 days as 
previously described (358). 1 mg of 5(Z)-7-oxozeaenol was dissolved in 800μl of DMSO and made 
up to 8ml with PBS to give a working concentration of 0.125mg/ml. Control treated and the other 
MCT animals were treated with 10% DMSO/90% PBS for the same length of time. One animal in 
the MCT TAK1i group failed to reach the endpoint of the experiment and was therefore excluded 
from further analysis. Rats were humanely killed, by exsanguination, after assessment as above. 
Rats were weighed regularly throughout the experiment.  
2.2.2 The Sugen/hypoxia mouse 
Male C57BL/6J mice (Charles River Laboratories, Harlow, UK), (11 weeks old) were injected 
subcutaneously with SU5416 (Sugen) (Sigma-Aldrich, St-Louis, MO) (20 mg/kg) or vehicle control 
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on a weekly basis by Stephen Moore. Mice were exposed to either room air or chronic normobaric 
hypoxia inside a ventilated plexiglass chamber as previously described (403). To characterise the 
muscle loss associated with PAH animals were humanely killed, by exsanguination, after 3 weeks, 
immediately after haemodynamic assessment. 
2.2.3 MRI Imaging  
Hind limb MRI was carried out by Stephen Sawiak at Cambridge University, who used the following 
methodology, which he described below. ‘Three rats in each group were anaesthetised with 
isoflurane (2-3% in 1l/min O2).  MRI was performed at 4.7T using a Bruker BioSpec 47/40 system 
with an 86mm transmit/receive coil provided by the manufacturer (Bruker Inc., Germany). To 
separate signals from water and fat contributions, a three-point Dixon method based on IDEAL 
(404) was used with echo times of 5.44ms, 5.70ms and 6.21ms and a repetition of time of 12ms. 
The flip angle was 20° and the receiver bandwidth was 50kHz. Images were reconstructed using 
Matlab (Mathworks, Cambridge, UK) using iterative estimation of local field deviations to produce 
images showing water and fat’. A similar technique was used to perform cardiac MRI which has 
been described by Yang et al. (405). 
2.2.4 Right heart catheter 
Under isofluorane anaesthesia rats the right internal jugular vein was blunt dissected out and 
stretched in an anterior posterior orientation. A suture was placed around the proximal end of 
the vessel. A small hole was made in the vessel and a pressure catheter (Millar Mikrotip, Millar, 
Texas, USA) was introduced through this and advanced into the right ventricle. Pressure-volume 
curves and pressure-time traces were monitored throughout the procedure using Labchart 8 (ADI 
systems, Oxford, UK). A right ventricle trace was generated and right ventricular systolic pressure 
was recorded (406). 
2.2.5 Dissection and tissue removal 
Rats and mice were exsanguinated and blood was collected in SST or EDTA coated tubes and later 
spun down for removal of serum or plasma which was stored at -800C. Half of the lungs were 
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rendered in a distended state by infusion of low melting point agarose into the trachea for 1 
minute and then were placed in 4% paraformaldehyde (Cellstore, Powys, UK) before being 
embedded in paraffin. The remaining lungs were immediately frozen in liquid nitrogen for protein 
and RNA isolation. The heart was dissected out for assessment of right ventricular and left 
ventricular weights. The TA and soleus muscles were identified (Figure 2.4) and dissected out 
bilaterally and weighed. One was immediately frozen in liquid nitrogen the other was cut 
longitudinally, placed in OCT (VWR, Leicester, UK) on a cork and then frozen in isopentane 
(ThermoFisher Scientific, MA, USA) dipped in liquid nitrogen (MCT) or placed in 4% 
paraformaldehyde (Cellstore, Powys, UK) (Sugen/hypoxia) for future analysis. 
 
Figure 2.4 Sketch of the rat / mouse hind limb. This diagram shows the tibialis anterior muscle and the 
position of the soleus muscle deep to the gastrocnemius (407).  
 
2.2.7 Right ventricular / Left ventricular plus septal weight (RV/LV+S) 
To assess the extent of right ventricular hypertrophy (RVH), a marker of severity of pulmonary 
hypertension, the heart was removed, and the RV free wall was dissected from the left ventricle 
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and septum (LV+S) and weighed separately; the degree of RVH was determined from the ratio 
RV/LV+S. 
2.2.8 Assessment of muscle mass 
To assess muscle mass both right and left TA and soleus were weighed, prior to processing, and the 
average of the 2 weights was documented. 
2.2.9 Tissue processing 
Muscle and lung samples were homogenised using the Precellys 24 tissue homogeniser (Stretton 
Scientific, Derbyshire, UK) with 1.4mm ceramic beads (CDK‐14, Stretton Scientific, Derbyshire, UK) 
in 2ml tubes. The machine was run twice for 15 seconds after which samples were assessed to 
see if they were homogenised. If the samples were not homogenised the process was repeated 
up to 3 times in total.  RNA was extracted using trizol (Life Technologies, Carlsbad, CA, USA). The 
homogenised tissue in the trizol was mixed with chloroform (ThermoFisher Scientific, MA, USA) 
at a ratio of 5:1. To separate RNA from protein and DNA. The sample was centrifuged at 13000 
rpm for 15 minutes at 4oC. The top aqueous phase, which contains the RNA was removed and 
placed in a separate microcentrifuge tube.  The RNA was precipitated with isopropyl alcohol 
(ThermoFisher Scientific, MA, USA), using 250μl of isopropyl alcohol per 500μl of trizol initially 
used. This mixture was vortexed and left at -80oC overnight. The next day a RNA pellet was 
precipitated by centrifugation at 13000 rpm in a bench-top microcentrifuge for 10 minutes at 4oC. 
The supernatant was removed and the pellet was washed twice in 75% ethanol (VWR, Leicester, 
UK) before being re-suspended in 30μl of RNAse free water. The RNA content of the extraction 
was quantified using a spectrophotometer (Nanodrop ND1000, Thermofisher, Waltham, MA, 
USA). RNA content was determined by measuring absorbance at 260nm and RNA purity estimated 
by quantifying the absorbance ratios 260nm:230nm and 260nm:280nm ratios.  
Protein was extracted using cell lysis buffer (CLB) and phenylmethylsulfonyl fluoride (PMSF) (Cell 
signalling technologies, Danvers, MA, USA). Samples were homogenised in 497.5μl CLB with 2.5μl 
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PMSF. Protein content was analysed using Bio-rad protein assay reagent (Biorad, CA, USA) with 
absorbance at 595nm quantified on a plate reader (Biotek, Swindon, UK) and compared to known 
protein contents of bovine serum albumin standards (Sigma Aldrich, St Louis, MA, USA). Protein 
for ELISA was stored at -20oC. The rest of the protein extracted was mixed with 3x loading buffer 
(Cell signalling technology, Danvers, MA, USA) and 10% 2-mercaptoethanol (Sigma Aldrich, St 
Louis, MA, USA), which was heated to 95oC for 5 minutes, before being stored at -20oC.  
TA muscle from each animal was cut into 10μm sections (from OCT blocks in the MCT rat done by 
myself and from wax embedded blocks in the Sugen/hypoxia mouse done by Lorraine Lawrence 
in the histopathology department at Imperial College) and mounted by hand onto slides. The 
muscle was stained with haematoxylin and eosin (H&E) by Lorraine Lawrence in the histology 
department at Imperial College. Agarose inflated lung tissue samples that had been fixed in 4% 
paraformaldehyde (Cellstore, Powys, UK) were embedded in wax and sectioned at 6 microns prior 
to being mounted on slides by Lorraine Lawrence in the histology department at Imperial College. 
2.3 Cell culture 
2.3.1 C2C12 mouse myoblast cells 
C2C12 myoblast cells were cultured in Dulbecco’s modified eagle medium (DMEM) containing 4500 
mg/L glucose, L-glutamine, and sodium bicarbonate, without sodium pyruvate (Sigma Aldrich, St Louis, 
MA, USA) supplemented with 10% (v/v) foetal calf serum (Sigma Aldrich, St Louis, MA, USA ) and 1% 
penicillin/streptomycin (GIBCO, ThermoFisher Scientific, MA, USA)   to a confluence of 70%. At this 
point cells were removed from the cell culture plastic with trypsin-EDTA 0.05% (GIBCO, ThermoFisher 
Scientific, MA, USA), counted with a haemocytometer and seeded in dishes or plates. The number of 
cells seeded per well in various plates and dishes and the experiments they were used in is outlined 
in Table 2.2. Some myoblasts were transfected for use in luciferase studies after which they were 
treated with agents as described in the appropriate section. Some myoblasts were transfected for 
myotube diameter experiments after which they were allowed to grow to 70% confluence and treated 
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with DMEM containing 4500 mg/L glucose, L-glutamine, and sodium bicarbonate, without sodium 
pyruvate (Sigma Aldrich, St Louis, MA, USA) supplemented with 2% (v/v) horse serum (Sigma Aldrich, 
St Louis, MA, USA) and 1% pencillin/streptomycin (GIBCO, ThermoFisher Scientific, MA, USA) to allow 
them to differentiate into myotubes. The media was changed every 2 days for a total of 10 days after 
which they were treated with agents as described in the appropriate section. Some untransfected 
myoblasts were also allowed to differentiate for 10 days in differentiation media prior to treatment 
as described above. 
Plate size Cells Experiment 
10cm 1000000 Western blot 
6 well 100000 Myotube diameter / qPCR 
12 well 50000 qPCR 
24 well 25000 Luciferase / Nuclear localisation / Immunofluorescence 
96 well 6250 Luciferase 
Table 2.2 Number of C2C12 cells seeded per well in different plates. 
2.3.2 C2C12 treatment 
Cells for western blot and those for nuclear localisation of nuclear factor kappa B p65 (NFκB p65) were 
serum starved overnight prior to treatment. Myoblasts for luciferase, western blot and nuclear 
localisation of NFκB p65 were treated with the compounds listed below in serum free DMEM. For 
myotube diameter and quantitative PCR experiments, due to the longer time course employed, cells 
were treated with the compounds in DMEM supplemented with 1% penicillin/streptomycin with 10% 
(v/v) foetal calf serum or 2% (v/v) horse serum depending on their stage of differentiation. GDF-15 
(R&D systems, Abingdon, UK) was dissolved in sterile 4 mM hydrochloric acid containing 0.1% bovine 
serum albumin (BSA) (Sigma Aldrich, St Louis, MA, USA) to a working concentration of 100 μg/mL. Cells 
were then treated at various concentrations from 0.5 to 50ng/ml by diluting GDF-15 in DMEM. Low 
dose was defined as 5ng/ml, whereas high dose was defined as 50 ng/ml (283). For some experiments 
cells were co-treated with GDF-15 and TGFβ1 or pre-treated with GDF-15 for 48 hours and then co-
treated with GDF-15 and TGFβ1 and / or BMP-4. In some experiments cells were treated with the TGFβ 
activated kinase 1 inhibitor (TAK1i) (5Z)-7-oxozeaenol (Tocris bioscience, Bristol, UK), which was 
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dissolved in DMSO (Sigma Aldrich, St Louis, MA, USA) to a concentration of 25 mM and then further 
diluted in medium to give doses between 100 and 1000 nM. In some experiments cells were treated 
with the activin like kinase 5 (ALK-5) inhibitor SB431542 (Sigma Aldrich, St Louis, MA, USA), which was 
dissolved in DMSO (Sigma Aldrich, St Louis, MA, USA) to a concentration of 10 mM and then further 
diluted in DMEM (Sigma Aldrich, St Louis, MA, USA) to give doses of 10 μM, a dose used in other 
publications (408). As a positive control TGFβ1 (R&D systems, Abingdon, UK) dissolved in sterile 4 mM 
hydrochloric acid containing 0.1% BSA was used at various concentrations from 0.01 to 50 ng/ml. In 
experiments not requiring a dose response a dose of 2.5 ng/ml was used. Other positive controls used 
in the myoblast experiments include Myostatin (GDF-8) (R&D systems, Abingdon, UK) dissolved in 
sterile 4 mM hydrochloric acid containing 0.1% BSA, and used at 50 and 100 ng/ml, BMP-4 (R&D 
systems, Abingdon, UK) dissolved in sterile 4 mM hydrochloric acid containing 0.1% BSA, and used at 
10 ng/ml and Tumour Necrosis Factor α (TNFα) dissolved in PBS and used at 10ng/ml. For negative 
control the appropriate diluent without active ingredients at the same volume used in the 
experimental condition was added to DMEM with or without serum. 
2.3.3 Harvesting mRNA and protein from cell culture 
At various time points after treatment cells were washed with cold Phosphate Buffered Saline (PBS) 
on ice. For RNA extraction between 250 and 500 μL of trizol (Life Technologies, Carlsbad, CA, USA) was 
added to the well after which the cells were scraped and trizol cell mix was placed in a microcentrifuge 
tube. From then on the RNA extraction process was undertaken as described previously. For protein 
extraction cells were scraped in ice cold PBS after which they were placed in a 15ml falcon tube and 
centrifuged at 1000 rpm for 5 minutes to form a pellet. The PBS was removed and the pellet was re-
suspended in between 250 to 500 μL of CLB and PMSF (Cell signalling technologies, Danvers, MA, USA). 
The protein content was then analysed and stored as described above. 
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2.4 Plasmids, restriction digests, cloning and transfection 
2.4.1 Plasmids, restriction digests and transformation of super-competent bacteria 
Plasmids used throughout this thesis were cut with restriction enzymes to confirm their identity. 
NEB 5 alpha competent E-Coli bacteria (New England biolabs, MA, USA) were transformed with 
plasmids. 5 μl of plasmid was added to 40 μl of supercompetent cells and the samples were 
incubated on ice for 15 minutes. The sample was heat shocked for 90 seconds in a water bath at 
42oC after which it was returned to ice for 2 minutes. Thereafter 500μl of LB broth was added to 
the mixture and incubated for 45 minutes at 37oC. After this 200μl of the plasmid bacteria mix 
was plated onto plates with ampicillin (100 μg/ml) (Sigma-Aldrich, St. Louis, MO, USA) and allowed 
to grow into colonies overnight at 37oC. These colonies were picked and the plate was placed 
stored at 4oC for future use. Picked colonies for future mini-prepping were added to LB broth with 
ampicillin 100 μg/ml and incubated at 37oC overnight. The next day plasmids were mini-prepped 
using a QIAprep spin mini-prep kit (Qiagen, Hilden, Germany). Bacteria were pelleted by 
centrifugation at 8000 rpms for 3 minutes at room temperature. The pellet was re-suspended in 
250 μl of P1 buffer (Qiagen, Hilden, Germany) and transferred to a microcentrifuge tube. Next 
250 μl of P2 buffer (Qiagen, Hilden, Germany) was mixed in by inverting the tube 6 times, after 
which 350 μl of N3 buffer (Qiagen, Hilden, Germany) was added to the sample. The sample was 
before centrifuged the tube for 10 minutes at 13000 rpms. The supernatant was added to the 
QIAprep spin column and spun for 60 seconds at 13000 rpms. The flow-through was discarded 
and the process was repeated with 500 μl of PB buffer (Qiagen, Hilden, Germany) and then with 
750 μl of PE buffer (Qiagen, Hilden, Germany) with ethanol. Residual wash buffer was removed 
with another spin and the column was placed in a fresh microcentrifuge tube after which 50 μL of 
EB buffer was added and spun for 1 minute. The resulting DNA was checked for concentration and 
purity using a spectrophotometer (Nanodrop ND1000, Thermofisher, Waltham, MA, USA). DNA 
content was determined by measuring absorbance at 260nm and purity was determined by 
  
85 
  
measuring the absorbance ratios 260nm:230nm and 260nm:280nm. The plasmids were then 
checked by restriction digest. In a PCR tube 4 μl of plasmid DNA was incubated with 12.5 μl of 
water, 2 μl of 10x buffer (dependant on the enzymes used), 0.5 μl of restriction enzyme one, 0.5 
μl of restriction enzyme 2 and 0.5 μl of BSA (New England biolabs, MA, USA) for 1 hour at room 
temperature. A 1.5% agarose gel was prepared by adding 2.25 g of agarose (Bioline, London, UK) 
to TBE buffer, a 10 x stock of which is made from 108 g tris base (Sigma-Aldrich, St. Louis, MO, 
USA), 55 g of boric acid (Sigma-Aldrich, St. Louis, MO, USA) and 7.5 g of EDTA (Sigma-Aldrich, St. 
Louis, MO, USA) in 1 L of distilled water. This was heated in the microwave to allow the agarose 
to dissolve after which the mixture was cooled. At this point either 5 μl of ethidium bromide 
(ThermoFisher Scientific, MA, USA) or SYBR safe (ThermoFisher, MA, USA) was added to the 
mixture prior to it being made into a gel with lanes. The gel was placed in a gel electrophoresis 
tank (ThermoFisher Scientific, MA, USA) filled with 1x TBE and the wells were loaded with 10 μl of 
DNA with 5x loading buffer (Bioline, London, UK) or DNA ladders Hyperladder I or II (Bioline, 
London, UK). The gel was run in the tank at 120 volts for 40 minutes to allow band separation. The 
gel was then viewed on a Biorad chemidoc XRS+ running imagelab software (Biorad, CA, USA) and 
images saved and analysed for the size of DNA fragments. The plasmids, restriction enzymes and 
band sizes are listed in Table 2.3.      
Plasmids Restriction Band sizes 
pCDNA3 Pst1 4072, 1356 
pRL-TK EcoR1, BamH1 2582, 1463 
pRL-TK no BRE EcoR1, BglII 3680, 365 
pCAGA12 luciferase HindIII,  BamH1 2471, 1574 
pBRE luciferase Nhe1 4370, 45 
pCDNA3 hum TGFBR2 EcoR1, Pst1 4500, 4100 
pCMV Sport 6.1 TGFBR2 EcoR1, Xho 1 3863, 1013 
pCMV Sport 6.1 ACVR2B EcoR1, Xho1 3863, 1762 
pCMV Sport 6.1 BMPR2 EcoR1 4302, 3461, 74 
pCDNA3 hum TTGBFR2 Pst1 3682, 1385, 379 
pCAGGs-EGFP BamH1 3734, 1471, 337 
Table 2 .3 Plasmids. Plasmids used throughout my thesis, restriction enzymes and sizes of bands expected 
when run on a gel. All pCMV Sport 6.1 vectors coded for receptors of mouse origin.   
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2.4.2 Cloning the truncated TGFBR2 
The plasmid map for plasmids coding for human and mouse TGFBR2 was examined and the sequence 
coding for the extracellular, transmembrane and intracellular portion of the receptor was identified 
using Uniprot (http://www.uniprot.org/). Primers were designed to encompass the extracellular area 
and transmembrane portion. For the human TGFBR2 these were forward 
GCGCTGGGGCTCGGTCTATGAC and reverse GCCGGTTTCCCAGGTTGAACTC and for the mouse TGFBR2 
these were forward GCAGGCTGGTACCGGTCCGGAATTC and reverse 
CCTCCAGGATGATGGCACAATTGTC. The human TTGFBR2 was used in subsequent experiments and is 
therefore described below. PCR of the appropriate portion was carried out using HotStart HiFidelity 
polymerase kit (Qiagen, Hilden, Germany) and Taq DNA Polymerase HiFidelity kit (ThermoFisher, MA, 
USA).  For the Qiagen kit 1 μl of TGFBR2 DNA was added to 5 μl of 10x buffer, 2 μl of 5 μM DNTPs, 2 
μl Q buffer, 2.5 μl forward and 2.5 μl reverse primers, 1 μl Taq polymerase, and 36.5 μl of water 
(Qaigen, Hilden, Germany). For the ThermoFisher kit 1 μl of DNA was added to 5 μl of 10x buffer, 2 μl 
of DNTPs, 2 μl DMSO, 2.5 μl of forward and 2.5 μl or reverse primer, 1 μl of Taq polymerase and 37.0 
μl of water (ThermoFisher, MA, USA). The mixes were placed on ice and the thermal cycler 
(ThermoFisher Scientific, MA, USA) was heated to 80oC for a hot start. The machine was cycled to 95oC 
for 1 minute, and then through 40 cycles of 95oC for 30 seconds, 65oC for 30 seconds and 72oC for 1 
minute. The resulting product was run on an agarose gel and imaged as above. An image showing a 
product of just over 800 bp that corresponds to the extracellular and transmembrane portion of the 
receptor is shown in Figure 2.5. 
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Figure 2.5 PCR product of the truncated TGFBR2 receptor. Image of agarose gel showing the PCR product of the 
truncated TGFBR2 primers (2 bright bands on the left) 
 
The gel was imaged under ultra-violet light and the bands were cut out and placed in a microcentrifuge 
tube. The DNA was then gel extracted using a Qiagen gel extraction kit (Qiagen, Hilden, Germany). The 
agarose gel was suspended in QG buffer heated to 50oC for 10 minutes after which isopropanol was 
added and solution was centrifuged in a QIAquick spin column for 1 minute at 13000 rpms. The flow 
through was discarded and the column was washed with PE buffer with ethanol and centrifuged again. 
The column was spun again and then 50 μl of EB buffer was added to elute the DNA into a new 
microcentrifuge tube (Qiagen, Hilden, Germany). The resulting DNA product was ligated into a pGEM-
T Easy vector using the pGEM-T Easy vector kit (Promega, Wisconsin, USA). 3.5 μl of DNA insert, control 
or water negative control was added to 5 μl of 2x ligation buffer, 1 μl of pGEM-T vector and 0.5 μl of 
DNA ligase (Promega, Wisconsin, USA) and left overnight on the bench. The DNA was transformed 
into super-competent bacteria as described above. These were plated with 30 μl isopropyl β-D-1 
thiogalactopyranoside (IPTG) (Sigma-Aldrich, St Louis, MO, USA) and 30 μl 5-Bromo-4-chloro-3-inodyl 
β-D-galactopyranoside (X-gal) (Sigma-Aldrich, St Louis, MO, USA) for blue white screening. Colonies 
were screened and white colonies, which contain recombinant DNA and not just vector, were picked. 
These were cultured overnight in LB-broth and mini-prepped using the technique described above. To 
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create an insert of truncated TGFBR2 with sticky ends the pGEM-T TTGFBR2 was cut with EcoR1 
restriction enzyme. 16 μl of DNA was added to 5 μl of 10x EcoR1 buffer, 2 μl of EcoR1 restriction 
enzyme, and 0.5 μl of BSA, with water up to 50 μl (ThermoFisher Scientific, MA, USA).   For the vector 
into which the TTGFBR2 was to be inserted pCDNA3 was also cut with EcoR1 and dephosphorylated 
to prevent self-ligation of the linearized vector. 10 μl of DNA was cut with 1 μl EcoR1, 3 μl of 10x EcoR1 
buffer, 1.5 μl of BSA, 1 μl of alkaline phosphatase and 13.5 μl of water (ThermoFisher Scientific, MA, 
USA). The products were run on a gel, cut out, and the gel extracted using the technique described 
above (Qiagen, Hilden, Germany). The products were the ligated. 9 μl of DNA (7.2 μl insert and 1.8 μl 
of vector) were added to 4 μl of quickstick ligase buffer (Bioline, London, UK), 1 μl quickstick ligase 
enzyme (Bioline, London, UK) and 5 μl of water on the bench overnight as per protocol. The resulting 
DNA was transformed, plated with IPTG/X-gal and incubated overnight as above. Colonies were 
blue/white screened, picked and PCR screened. 5 μl of PCR buffer, 2.5 μl of forward and 2.5 μl of 
reverse primers (see earlier), 2 μl of DNTPs, 0.25 μl Taq polymerase and 5 μl of 10x buffer (Qiagen , 
Hilden, Germany) had a single colony re-suspended in TE buffer (ThermoFisher Scientific, MA, USA) 
dropped into it. PCR was performed on a thermal cycler (ThermoFisher Scientific, MA, USA) using the 
protocol, 94oC for 3 minutes, and then 40 cycles of 94oC for 30 seconds, 60oC for 30 seconds and 72oC 
for 2 minutes after which the solution was held at 72oC for  further 10 minutes before the end of the 
experiment. The resultant product was run on a gel which is shown in Figure 2.6. 
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Figure 2.6 PCR screening for TTGFBR2 insert in pCDNA3. Gel showing PCR screen for TTGFBFR2 insert in pCDNA3 
in colonies picked by blue / white screening. Lanes 1, 3, 7, 8, 9 and 10 were positive for the mutant vector.  
 
The colonies that contained the product identified by PCR screening were transformed and resulting 
DNA from the mini-prep was cut with the restriction enzyme Pst1 to show directionality that the insert 
had been incorporated into the plasmid. If the insert had gone in forward the lowest band would be 
379 base pairs, backwards the lowest band would be 246. The gel of pCDNA3 TTGFBR2 cut with Pst1 
is shown in Figure 2.7. The DNA was sent for sequencing (Source Bioscience, Nottingham, UK) and the 
results showed 100% homology with the sequence of the TTGFBR2 (Appendix 2.3). This was used in 
subsequent experiments. 
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Figure 2.7.  pCDNA3 hum TTGFBR2 plasmids cut with PST1 showing directionality.  Highlighted samples 3 and 
9 have a lowest band of 379 bp showing that the insert was in the appropriate orientation 
 
2.4.3 Cloning a BMP responsive element (BRE) luciferase and removing a BRE from pRL-TK 
The BMP responsive element luciferase vector was cloned using methods described by Korchynskyi 
and Dijke (409). Oligonucleotides (Sigma-Alrich, St Louis, MO, USA) CGCG GCGCCAGCCTGACAGCCCG, 
AGGACGGGCTGTCAGGCTGGCGC, TCCTGGCGTCTAACGGTCTGAG, CTAGCTCAGACCGTTAGACGCC 
were annealed by heating to 95oC and cooled by 1oC per minute to 50oC. This created an insert with 
a ‘NheI restriction site followed by 2 SMAD binding elements, 1 GGCG site, 2 CAGC sites, 2 GGCGCC 
palindromes, 2 CAGC sites, 1 GGCG site, 2 SBEs, and another NheI site’ (409). The resulting product 
was phosphorylated with T4 polynucleotide kinase (PNK) (New England Biolabs, MA). The pGL5 
luciferase reporter vector (Promega, CA, USA) was cut at the NheI site. 2 μl of DNA was added to 1 μl 
of 10x buffer, 1 μl of NheI restriction enzyme, 1μl of alkaline phosphatase and 1 μl of BSA (New 
England Biolabs, MA, USA). The linearised vector was run on an agarose gel, cut out and gel 
extracted as detailed above to remove the phosphatase.  The insert and vector were ligated as 
  
91 
  
described above with Quick-stick ligase (Bioline, London, UK). The resulting DNA was transformed 
into bacteria (New England Biolabs, MA, USA) plated and colonies picked. These were cut with NheI 
and run on a gel to check for the presence of the insert (Figure 2.8). Those with the insert were then 
used in subsequent experiments. 
 
Figure 2.8  BRE luciferase cut with Nhe 1 to show the presence of the insert. The 3rd column was discarded as 
the band was higher than expected. 
 
In the first experiments using the pGL5 BRE luc it was noted that BMP-4 treatment increased activity 
of the control pRL-TK luciferase (Figure 2.9). When the pRL-TK (Promega, CA, USA) sequence was 
examined a BMP responsive element in the HSV promoter of the vector was identified (Appendix 
2.4). pRL-TK vector was therefore cut with BglII and SmaI restriction enzymes (New England Biolabs, 
MA, USA) as described above to remove 284 base pairs including those which contained the BMP 
responsive element. The DNA was run on a gel and the higher band was cut out. The sticky end of 
the BglII restriction site was filled in with T4 DNA polymerase (New England Biolabs, MA, USA). 10 μl 
of pRL-TK DNA was added to 20 μl of 5x T4 buffer, 1 μl of DNTPs, 2 μl DNA polymerase, 10 μl BSA 
and 67 μl water for 5 minutes at room temperature after which the mixture was heated to 75oC for 
10 minutes to stop the reaction (New England Biolabs, MA, USA). The resulting linearised DNA with 
blunt ends was then ligated with Quick-stick ligase (Bioline, London, UK). It was then transformed, 
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cut with EcoR1 and BglII restriction enzymes run on an agarose gel and imaged to check for removal 
of the BRE from the pRL-TK. The resulting pRL-TK without the BRE was tested and showed no 
response to BMP-4 (Figure 2.9) 
 
Figure 2.9 Renilla activity in BMP-4 treated cells transfected with pRL-TK with and without BRE. Example of 
raw data from renilla activity in cells transfected with pRL-TK treated with Bone morphogenetic protein 4 (BMP-
4) at 10 ng/ml with A. the BMP responsive element included (Student’s t-test p = 0.017) and B. with the BMP 
responsive element removed (Student’s t-test p = 0.722). 
 
2.4.4 Transfection of DNA for luciferase, immunofluorescence and fibre diameter 
A total of 2 µg DNA was transfected per 4 wells of a 24 well plate and scaled up and down 
appropriately. For experiments involving SMAD 2, 3 dependant luciferase activity in the presence of 
various receptors 1 μg of p(CAGA)12-luc, 0.5 μg of pRL-TK and 0.25 μg of pCDNA3 with 0.25 µg of 
pCDNA3, pCDNA-TGFBR2 (Donated by P Kemp), pCDNA-TTGFBR2 (see cloning section) pCMV-
mACVR2B (Sinobiological, Ludong, Beijing, China) or pCMV-Myc-BMPR2 (Sinobiological, Ludong, 
Beijing, China) was incubated with 10 µl of Lipofectamine (Invitrogen, ThermoFisher, MA, USA) in 200 
μl of  Optimem (GIBCO, Life technologies, CA, USA) for 15 minutes at room temperature. The cells 
were washed twice in serum free media. 600 μl of serum free media was added to the transfection 
mix at this point to bring the total volume added to each well of a 24 well plate to 200 μl.  Cells were 
incubated in this transfection mix for 4.5 hours, after which the media was changed back to DMEM 
with 10% FCS. For experiments involving SMAD 1, 5 dependant luciferase activity in the presence of 
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various receptors cells were transfected in 24 well plates as above using pBRE-luc, and pRL-TK(no BRE) 
instead of p(CAGA)12-luc and pRL-TK and pCNDA3 or the receptors listed above at the same dose and 
using the same method described above. For experiments not requiring the addition of a plasmid 
coding for a receptor, cells were seeded in 96 well plates and transfected with 1.33μg of p(CAGA)12-
luc or pBRE-luc and 0.66μg of pRL-TK or pRL-TK(no BRE) per 16 wells using the method described 
above. 
Cells examining the effect of TTGFBR2 on myotube diameter were seeded in 6 well plates. The next 
day cells were transfected with 1μg of pCAGGs- enhanced green fluorescent protein (EGFP),  0.5μg of 
pCDNA3 and 0.5μg of pCDNA-TTGBR2 or 0.5 μg of pCDNA3 per well. Cells examining the effect of the 
TAK1 inhibitor, 5(Z)-7-oxozeaenol, on myotube diameter were transfected with 1 μg of pCAGGs-EGFP 
alone per well. These DNA mixes were combined with Optimem (GIBCO, Life technologies, CA, USA), 
Lipofectamine (Invitrogen, ThermoFisher, MA, USA) and DMEM in similar proportions to those used 
for other luciferase experiments scaled up appropriately. After transfection, cells were differentiated 
into myotubes until day 10, after which they were treated with control, GDF-15 and or 5(Z)-7-
oxozeaenol (Tocris bioscience, Bristol, UK).   
2.5 Molecular techniques 
2.5.1 Luciferase assay 
The Dual-Luciferase reporter assay system (Promega, Wisconsin, USA) was used as per manufacturer’s 
instructions to measure SMAD 2, 3 and SMAD 1, 5 dependent luciferase activity. Cells were transfected 
and treated as detailed above. Cells were removed from the incubator, placed on ice and the media 
was removed by washing twice with PBS. Cells were incubated with passive lysis buffer (Promega, 
Wisconsin, USA) (125 μl/well of a 24 well plate and 50 μl/well of a 96 well plate) for 15 minutes on an 
orbital plate shaker. 10 μl of the lysate was placed in a 96 well plate for further analysis. A white plate 
was used to enhance luminescence. As per manufacturer’s instructions 50μl of firefly assay substrate 
(Promega, Wisconsin, USA) was added to the lysate after which luminescence was read on a Luminark 
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spectrophotometer plate reader (BioRad, CA, USA) to define the SMAD 2, 3 or SMAD 1, 5 dependent 
luciferase activity. Next, 50μl of ‘Stop and Glow’ (Promega, Wisconsin, USA) substrate was added to 
the lysate and firefly assay substrate mix, after which luminescence was read again to define renilla 
activity. Firefly output was normalised to renilla output for each sample allowing adjustment of results 
for transfection efficiency.  
2.5.2 cDNA synthesis and quantative PCR (qPCR) for mRNA.  
150ng of mRNA was used for each reverse transcription reaction. The volume of sample containing 
150 ng was made up to 11 μl with water. The mRNA was heated to 65oC for 5 in a thermal cyler to 
denature it. Whilst cooling on ice a master mix of 2 μl water, 1 μl Omniscript (Qiagen, Hilden, 
Germany), 2 μl 5mM dNTPs (Qiagen, Hilden, Germany), 0.5 μl Ribolock (ThermoFisher Scientific, MA, 
USA), 0.5 μl random primers (Promega, Wisconsin, USA), 2 μl 10x buffer (Qiagen, Hilden, Germany) 
and 1 μl DTT (Qiagen, Hilden, Germany) was added to each sample.  The samples were placed back in 
the thermal cycler where they were heated to 42oC for 2 hours. The resulting cDNA was diluted with 
water up to a working volume of 200 μl before being frozen at -20OC.  
To test the relative expression of various genes involved in both TGFβ signalling and muscle wasting, 
appropriate primers were identified from the literature. These are listed in Table 2.4. Primer pairs 
were tested to ensure they were able to identify a single PCR product of appropriate size. A thermal 
cycler was used to undertake PCR. The resulting amplified DNA product was run on a 1.5% TBE agarose 
gel as described above to check for the presence of a single band. 
An ABI 7500 fast thermal cycler (ABI, Life technologies, CA, USA) was used throughout the qPCR 
experiments. A master mix of 10 μl of fast SYBR green (Qiagen, Hilden, Germany) 2 μl of a 2 μM 
forward and reverse primer mix (Table 2.4) and 5 μl of water were added to each well of a 96 well fast 
optical plate. 3μl of cDNA from each sample was added to each well containing the master mix. 
Samples were analysed in duplicate and water negative controls were included on each plate.  Plates 
were covered in a MicroAmp optical adhesive film (Life Technologies, CA, USA). Plates were then 
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centrifuged for 1 minute at 1000 rpms. The protocol for qPCR was to heat the samples to 95oC for 5 
minutes. This was followed by 40 cycles of 95oC for 10 seconds and 60oC for 30 seconds. A melt curve 
was included to pick up primer dimers, contamination and off target binding. The mean cycle 
threshold (CT) for each duplicated sample was recorded. Samples were excluded if the duplicates were 
not consistent or if the water in the plate had a measurable significant CT. Analysis was undertaken in 
valid samples using ΔCT method.   
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  Primers Sequence 
  Rat RPLPO F   ATGGGCAAGAACACCATGATG 
  Rat RPLPO R   CCTCCTTGGTGAACACAAAGC 
  Rat GAPDH F   ATGCCTTCCGTGTTCCTACCC 
  Rat GAPDH R   GCCTGCTTCACCACCTTCTTGAT 
  Rat GDF-15 F   AGC TGT CCG GAT ACT CAG TC 
  Rat GDF-15 R   GAG TCT CTT GGG TGC AAA TG 
  Rat TGFβ1 F GCGCCTGCAGAGATTCAAG 
  Rat TGFβ1 R GTATCAGTGGGGGTCAGCA 
  Rat GDF-8 F TGGGCATGATCTTGCTGTAA 
  Rat GDF-8 R TGTTACTTTGACCTTCTAAAAAGGGATT 
  Rat Atrogin-1 F   CCATCAGGAGAAGTGGATCTATGTT 
  Rat Atrogin-1 R   GCTTCCCCCAAAGTGCAGTA 
  Rat MuRF-1 F TGGAGATGAATTGCTCAGT 
  Rat MuRF-1 R GTGAAGTTGCCCCCTTACAA 
  Rat TAK1 F TGCGATTTTGGTACAGCTTG 
  Rat TAK1 R TGGTCGAGTGCCATTATGAA 
  Rat NFκB p65 F GGTGGAGTTTGGGAAGGAT 
  Rat NFκB p65 R TTTCTCCGAAGCTGAACA 
  Rat p38 MAPK F CGAAATGACCGGCTACGTGG 
  Rat p38 MAPK R CACTTCATCGTAGGTCAGGC 
  Mouse RPLPO F GGACCCGAGAAGACCTCCTT 
  Mouse RPLPO R TGCTGCCGTTGTCAAACACC 
  Mouse GAPDH F   ACTCCACTCCACGGCAAATTCA 
  Mouse GAPDH R   CGCTCCTGGAAGATGGTGAT 
  Mouse GDF-15 F   GGCTGCATGCCAACCAGAG 
  Mouse GDF-15 R   TCTCACCTCTGGACTGAGTATCC 
  Mouse TGFβ1 F TGGAGCAACATGTGGAACTC 
  Mouse TGFβ1 R GTCAGCAGCCGGTTACCA 
  Mouse GDF-8 F CGGACGGTACATGCACTAATATTTC 
  Mouse GDF-8 R GAGGGGAAGACCTTCCATGAC 
  Mouse atrogin-1 F   TCAGCCTCTGCATGATGTTC 
  Mouse atrogin-1 R   TGGGTGTATCGGATGGAGAC 
  Mouse MuRF-1 F CGGGCAACGACCGAGTGCAGACGATC 
  Mouse MuRF-1 R CCAGGATGGCGTAGAGGGTGTCAAAC 
  Mouse NFκB p65 F ATCTTCACCATGGCAGACGAT  
  Mouse NFκB p65 R TGAGTGAGTCAAAGCAGTGTTCAA  
Table 2.4 Primers. Primers used in qPCR experiments. Large ribosomal protein (RPLPO), glyceraldehyde-3 
phosphate dehydrogenase (GAPDH) are housekeeper genes  
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Figure 2.10 Example of melt curve generated by qPCR. Example of a melt curve of GAPDH and atrogin-1 genes 
from cells treated for 96 hours with GDF-15 at 5 ng/ml.  
 
 
  
98 
  
2.5.3 Western Blotting  
Protein samples were collected and heated as documented above. Pre-cast gels (gradient 4-15%) with 
10 wells each accommodating up to 50 μl (Biorad, CA, USA) were loaded with between 20 and 200 μg 
of protein, dependant on the protein of interest and the local expression level. The gel was run with 
at least one lane containing ‘Precision Plus protein Dual Colour Standard’ protein ladder (Biorad, CA, 
USA) to define the size of any product seen on the blot.  The gels were run in a BioRad gel tank at 120 
V until the samples could be seen to have run to the bottom of the gel in 1 x Tris glycine sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) buffer (National Diagnostics, GA, 
USA) normally taking between 60 and 90 minutes. A polyvinylidene difluoride (PVDF) membrane (GE 
healthcare, Little Chalfont, UK) was activated in 1 x Tris glycine SDS PAGE buffer (National Diagnostics, 
GA, USA) with 20% methanol (ThermoFisher, MA, USA). Transfer of the protein to this membrane was 
achieved using a wet transfer technique in 1 x Tris glycine SDS PAGE buffer (National Diagnostics, GA, 
USA) with 20% methanol (ThermoFisher, MA, USA) at 100 V (BioRad, CA, USA) for 75. Membranes 
were blocked in 5% milk (Marvel, UK) for non-phosho antibodies or 5% BSA (Sigma-Aldrich, St Louis, 
USA) for phospho antibodies in 1 x tris-buffered saline with 0.1% tween 20 (TBS-T) for 30 minutes on 
an orbital plate shaker. 10 x TBS was made with 24 g of Tris base (VWR, Leicester, UK) and 88 g of 
sodium chloride (VWR, Leicester, UK) dissolved in 900 ml of distilled water. The pH was brought down 
to 7.6 with hydrochloric acid (ThermoFisher Scientific, MA, USA) and the solution is made up to 1 L 
with water. The solution is diluted 1:10 and 1 ml of Tween 20 (Sigma-Aldrich, St. Louis, MO, USA) is 
added to 1 L of 1x solution to make TBS-T. After blocking, membranes were placed in sealed bags 
containing primary antibodies in 5% milk (non-phospho antibodies) or 5% BSA (phospho antibodies) 
in TBS-T overnight on an orbital plate shaker. The antibodies used are described in Table 2.5. The next 
day membranes were washed with TBS-T 3x for 5 minutes. Membranes were then placed in another 
plastic bag containing secondary horseradish peroxidise (HRP) conjugated antibodies in 5% milk in 
TBS-T for 1 hour. Membranes were washed again 3 x for 5 minutes in TBS-T. Membranes were then 
placed on cling film and Pierce enhanced chemoluminecence (ECL) reagent (Thermo Fisher Scientific, 
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MA, USA) was carefully pipetted on to ensure the entire blot was covered for 5 minutes. The 
membrane was then exposed to X-ray film (Life technologies, Carlsbad, CA, USA), for variable lengths 
of time, which was then developed on an automated film developing system in a dark room. 
Alternatively the membrane was exposed on an ettan dige imager (EDI) (GE Healthcare, Little Chalfont, 
UK). Proteins of interest probed with antibodies were identified by their molecular weight, which 
could be analysed by comparing band size to a known protein ladder. Protein and transfer efficiency 
can significantly alter band intensity across different lanes of a blot. In order to overcome this samples 
were probed for housekeeping proteins GAPDH, β-actin or the total non-phosphorylated protein of 
the protein of interest and or stained for Ponceau red (Biorad, CA, USA).  
Xray films exposed to the blots were scanned and both this and the files generated by the EDI were 
analysed by ImageJ. A rectangle was drawn around each band and the density of each lane was plotted 
as a curve. A line was drawn under the curve and the area under the curve was calculated giving a 
numerical representation of the density of the band. This allowed comparison of the density of the 
bands across the blot.  The target protein density level was then normalised to GAPDH, β-actin or the 
non-phosphorylated protein of the phosphorylated protein of interest.  
For the quantification of phosphorylated TAK1 in rat tissue samples, 5 were quantified. These samples 
were the first five MCT and control animals in the first MCT TAK1 inhibitor study.  
Antibody Accession Source Concentration Company 
anti-phosphoTAK1 (Ser 412) 9339 Rabbit 1:500 - 1:1000 Cell signalling 
anti-phospho NFκB p65 (Ser 536) 3031 Rabbit 1:500 - 1:1000 Cell signalling 
anti-phospho p38 MAPK (Thr 180/ Tyr 182) 9311 Rabbit 1:1000 Cell signalling 
anti-NFκB p65 sc 372 Rabbit 1:1000 Santa Cruz 
anti-p38 MAPK 9212 Rabbit 1:1000 Cell signalling 
anti-TGFBR2 sc 400 Rabbit 1:1000 Santa Cruz 
anti-ACVR2B sc 25453 Rabbit 1:1000 Santa Cruz 
anti-BMPR2 6979 Rabbit 1:1000 Cell signalling 
anti-β-actin 4967 Rabbit 1:1000 Cell signalling 
anti-GAPDH 2118 Rabbit 1:1000 Cell signalling 
anti-Rabbit IgG HRP linked secondary 7074 Goat 1:1000 Cell signalling 
Table 2.5 Antibodies for western blot. Antibodies used in western blots throughout my thesis. Higher 
concentrations of antibody for phospho-TAK1 and phospho-NFκB p65 were required for animal experiments. 
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2.5.4 Enzyme-linked immunosorbent assay (ELISA). 
GDF-15 protein levels in rat serum and lung and human plasma was analysed by commercially 
available rat/mouse and human ELISA kits (R&D systems, Abingdon, UK) as per manufacturer’s 
instructions. 50 μl of assay diluent was added to each well, along with 50 μl of standard control or 
sample to each well. The samples were covered with a plate sealer and incubated at room 
temperature for 2 hours on an orbital microplate shaker. Wells were aspirated and washed. 100 μl of 
conjugate was then added to each well and after covering was incubated for 2 hours on the shaker. 
The samples were aspirated and washed 4 times. 100 μl of substrate solution was added to each and 
protected from light for 30 minutes. 100 μl of stop solution was then added to each well. ELISA plates 
were then read on a microplate spectrometer (BioTek Powerwave XS, Winooski, USA) at 450 nm with 
a background wavelength correction of 540 nm. Sample results were compared to the standard curve 
generated by the kit to give the final concentration of GDF-15. For serum and plasma samples neat 
samples were used. For lung samples homogenates in CLB and PMSF were analysed and normalised 
to total protein content measured by Bradford assay which was assessed at the time of protein 
extraction. 
2.5.5 Muscle fibre and myotube diameter  
An Olympus CKX41 microscope and Cell^D software (Olympus, Essex, UK) at 10x magnification was 
used to image H+E stained sections of rat and mouse muscle tissue. Three different images were taken 
per animal. Image J was used to assess fibre diameter. The minimal Feret’s diameter, defined as ‘the 
smallest distance between 2 parallel edges of the fibre’, (265) was recorded for each fibre, after which 
the mean fibre diameter for each animal was calculated. The use of the Feret’s diameter removes the 
potential variability seen in measuring cross sectional fibre area where fibres are not cut in the same 
orientation. Between 67 and 486 fibres were counted per animal. This large variability was due in part 
to ice crystal formation and in part due to the size of the sample embedded and cut.  In the MCT TAK1i 
study the proportion of fibres below the 5 μm increments in diameter between 20 and 90 μm for each 
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animal was also calculated and analysed as previously described (410). In the MCT observational study 
2 control and 5 MCT animal samples had to be completely excluded due to ice crystal formation within 
the samples. In the MCT TAK1 inhibitor study and the Sugen/hypoxia mouse study all samples were 
included.  
After ten days myotubes transfected with pCAGGs-EGFP with or without pDNA3-TTGFBR2 were 
treated with GDF-15 (R&D systems, Abingdon, UK) with or without 5(Z)-7-oxozeaenol (Tocris 
bioscience, Bristol, UK) for 48 hours. Fluorescent images were taken on a Zeiss Axiovert 200 (Zeiss, 
Oberkochon, Germany) inverted microscope controlled by Improvision Volocity acquisition software 
(Perkin-Elmer, MA, USA) with a highly sensitive Hamamatsu Flash 4 (2048x2048 pixel) camera and a 
pE4000 CoolLed Led Illumination source. Using 10x magnification and a Green fluorescent protein 
(GFP) /Alexaflour 488 filter, 10 images were taken per well across 3 repeats, meaning for each 
condition studied there were between 154 and 367 myotubes for analysis. Myotube diameters were 
analysed using Image J. For each individual cell myotube diameter measurements were taken at 5 
evenly distributed points along the length of the cell and the mean diameter was calculated. Raw data 
and relative change in myotube diameter for each experiment is presented. In order to show that the 
myotubes imaged, were single cells containing multiple nuclei one of the pCAGGs-EGFP transfected 
plates was fixed and stained with DAPI and imaged as above to reveal multinucleated myotubes, which 
are shown in Figure 2.11.  
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Figure 2.11 Immunofluorescent image of p-CAGGs-EGFP over-expressing myotube co-stained with DAPI. This 
allows visualisation of the multiple nuclei within the cell. 
 
2.5.6 Immunohistochemistry 
Slides from lung tissue from 5 MCT and 5 control rats were prepared by the histology department at 
Imperial College were washed twice in Histo-clear (National Diagnostics, GA, USA), 100% ethanol 
(ThermoFisher Scientific, MA, USA) and 95% ethanol (ThermoFisher Scientific, MA, USA) to de-
parrafinise and rehydrate. Slides were then washed with water for 1 minute on a platform shaker. 
Next slides were placed in 10 mM sodium citrate pH 6 (Sigma-Aldrich, St. Louis, MO, USA) which was 
raised to boiling temperature for 40 minutes for heat induced epitope retrieval. The solution was 
topped up with water as needed and then left to cool for 2 minutes. The slides were then washed 
twice in distilled water for 3 minutes. Endogenous peroxidase activity was quenched in 3% hydrogen 
peroxidase (Sigma-Aldrich, St. Louis, MO, USA) for 20 minutes after which they were again washed in 
distilled water. Individual sections on each slide were then circled with a DAKO wax pen (DAKO, 
Glostrup, Denmark) and incubated in blocking solution, which contained 10ml of PBS (Sigma-Aldrich, 
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St. Louis, MO, USA) with 0.01% saponin (Sigma-Aldrich, MO, USA) and 3 drops of goat serum included 
in a Vectastain Elite kit ABC kit (Vectorlabs, CA, USA). This was removed and the sections were then 
incubated with primary antibody either rabbit anti-GDF-15 (orb2266633, Biorbyt, Cambridge, UK) at 
1:100 dilution or mouse anti-α smooth muscle actin (MO851, DAKO, Glostrup, Denmark) at 1:400 
dilution in PBS / 0.01% saponin with goat serum (2 drops per 10 ml of solution) as per manufacturer’s 
instructions, overnight at 4oC. After this the sections were washed twice for 5 minutes with PBS / 
0.01% saponin. This was removed and the sections were incubated for 30 minutes with goat anti-
rabbit or anti mouse biotinylated secondary provided in the Vectastain Elite kit (Vectorlabs, CA, USA). 
One drop of secondary antibody was added to 10mls of PBS / 0.01% saponin / goat serum (3 drops 
per 10mls) as per manufacturer’s instructions. This was washed off as before. Vectastain ABC reagent 
was reconstituted by adding 2 drops of reagent A (Vectorlabs, CA, USA) and 2 drops of reagent B 
(Vectorlabs, CA, USA) to 5 ml of PBS which is then left for 30 minutes prior to being added to the slide 
and incubated for 30 minutes. Slides were washed again and then incubated with 3’,3’-
diaminobenzidine tetrahydrochloride (Sigma-Aldrich, St. Louis, MO, USA) for 6 minutes for GDF-15 
sections and 4 minutes for smooth muscle actin sections after which the reaction was stopped by 
rinsing the slides in cold tap water. Slides were briefly counterstained with haematoxylin (VWR, 
Leicester, UK) for 15 seconds. After which they were washed in cold tap water. Sections were next 
dehydrated by placing them in 95% ethanol (ThermoFisher Scientific, MA, USA), 100% ethanol 
(ThermoFisher Scientific, MA, USA) and then Histo-clear (National Diagnostics, GA, USA) twice for 15 
seconds each in the reverse of the hydration steps. Slides were then covered carefully in histomount 
(National Diagnostics, GA, USA) and mounted with a coverslip (VWR, Leicester, UK) and allowed to dry 
overnight. These slides were imaged using an Olympus CKX41 microscope (Olympus, Essex, UK) at 20x 
magnification and representative sections are presented in the results section. Negative controls 
where the sections were incubated with primary or secondary antibody alone are presented in 
Appendix 4.1. 
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2.5.7 Immunofluorescent staining for nuclear localisation of NFκB and over-expression of TGFβ 
receptors. 
Cells were incubated overnight in serum free media and then treated for 1 hour with GDF-15, control 
or TNFα in serum free DMEM (Sigma-Aldrich, St. Louis, MO, USA) after which they were washed twice 
with ice cold PBS (Sigma-Aldrich, St. Louis, MO, USA) for 2 minutes. Cells were then fixed in 4% 
paraformaldehyde (Sigma-Aldrich, St Louis, MO, USA) in PBS for 10 minutes, after which they were 
washed three times with PBS with 0.05% Tween (PBS-T) (Sigma-Aldrich, St. Louis, MO, USA) for 5 
minutes. Fixed cells were then permeabilised with 1% Triton X100 (Sigma-Aldrich, St. Louis, MO, USA) 
in PBS-T for 15 minutes. After this, the wash step was repeated and the cells were blocked in 5% milk 
in PBS-T for 30 minutes. Cells were incubated overnight with primary antibody in 5% milk at 4oC. The 
next day cells were washed 3 times for 5 minutes with PBS-T, prior to incubation with Alexafluor-
conjugated secondary antibody for 1 hour at room temperature in the dark. Primary and secondary 
antibodies used are outlined in table 2.6. As a negative control cells were incubated in only primary or 
secondary antibody. Cells were then washed with PBS-T 3 times for 5 minutes. Cells were incubated 
for 1 minute with 1:10000 4,6-diamidino-2-phenylindole (DAPI) in PBS. After which they were again 
washed in PBS-T before being imaged on a Zeiss Axiovert 200 (Zeiss, Oberkochon, Germany) inverted 
microscope controlled by Improvision Volocity acquisition software (Perkin-Elmer, MA, USA) with a 
highly sensitive Hamamatsu Flash 4 (2048x2048 pixel) camera and a pE4000 CoolLed Led Illumination 
source using 10 or 20x magnification and GFP/FITC/Alexafluor 488 (green) or Texas red (red) and 
DAPI/Hoechst (blue) filters. For NFκB p65 nuclear localisation one representative image per well was 
taken over the course of 3 experiments, meaning between 120 and 134 cells were analysed in total 
per condition. The exposure, brightness and thresholds were set at the same level for all images in the 
same experiment. ImageJ was used to calculate nuclear signal and total signal intensity for each 
individual cell as well as background signal (411). The background signal was subtracted from the 2 
cell signal measurements and the nuclear signal was then normalised to the total signal to give a 
relative nuclear signal. For immunofluorescence showing over-expression of TGFβ receptors 
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representative images from each well were chosen and presented. Negative controls for the primary 
and secondary antibodies are shown in Appendix 5.2.  
Antibody Accession Source Concentration Company 
anti-TGFBR2 sc 400 Rabbit 1:100  Santa Cruz 
anti-ACVR2B sc 25453 Rabbit 1:100  Santa Cruz 
anti-NFκB p65 sc 372 Rabbit 1:200 Santa Cruz 
anti-Rabbit IgG (H+L) AlexaFluor488 A11008 Goat 1:500 Invitrogen 
anti-Rabbit IgG (H+L) AlexaFluor568 A11036 Goat 1:500 Invitrogen 
Table 2.6 Antibodies for immunofluorescence. Antibodies used in immunofluorescence throughout my thesis. 
2.6 Data handling and statistical analysis 
Data were handled and analysed using Graphpad Prisim 5 (Graphpad, CA, USA) or SPSS version 24 
(IBM, New York, USA) software. Graphs were constructed using Graphpad Prism 5 (Graphpad, CA, 
USA). For each experiment normality was assessed visually using histograms and the Kolmogorov-
Smirov, Shapiro-Wilk and D’Agosinto & Pearson normality tests available in Graphpad prism. N 
numbers (n) for each experiment are included in the figure for each experiment. 
Data analysis methodology for the clinical study was discussed with Winston Banya (Medical 
statistician, NHLI, Imperial College). Demographic data are quoted as mean ± standard deviation (SD) 
or median and interquartile range (IQR). Student’s t-tests or Mann-Whitney U tests were used to 
compare differences between 2 groups depending on the distribution of the data. When more than 2 
groups were compared one way analysis of variance (ANOVA) with Bonferroni correction for multiple 
analysis or Kruskall-Wallace with Dunn’s correction was used to determine differences between the 
groups of interest in normally and non-normally distributed data respectively. Correlations between 
different outcomes were assessed by Pearson or Spearman’s tests depending on whether the data 
suggested linear or non-linear correlation. For linear regression to determine the independent 
predictors of exercise tolerance measured by 6MWD and QOL measured by SGRQ a model was 
constructed and analysed on SPSS version 24. Variables included in the model were Age, BMI, USRFCSA, 
BNP, CRP and PAL. These variables were chosen as they were either important demographic details or 
  
106 
  
variables which measured one of muscle, cardiac function, inflammation or activity and were 
significantly correlated with the outcome of interest. All the variables were normally distributed 
except for BNP and CRP. Normally distributed variables were entered as continuous data whereas BNP 
and CRP had to be entered as dichotomous variables and cut off of 100 pmol/L and 10 mgl/L were 
chosen for BNP and CRP respectively. R2 with p values for the strength of the overall model and β-
coefficient with p values to show those variables that were independently associated with the 
outcome of interest were calculated and presented. ROC curves were constructed to determine 
whether one variable could predict an important outcome such as hospital admission, mortality or 
whether a questionnaire activity score could predict an objectively measured physical activity level. 
The outcomes for ROC curves included area under the curve as well as sensitivity and specificity 
analysis for the variable in predicting the outcome. The cut off given the highest sensitivity and 
specificity is presented. For mortality analysis Kaplein-Meier plots were constructed. Data was 
censured on the date the final patient included in mortality analysis completed 2 years of follow up. 
Transplant-free survival was defined as those patients who had not died or had a transplant at the 
time of assessment. Differences in mortality between 3 groups of patients based on FFMI of < 14, 14-
19 and >19 and 2 groups of patients based on steps per day of > or < 2500 and SGRQ of < or > 70  was 
assessed by Log-rank Mantel-Cox Test as well as for FFMI the log rank test for trend.  
For MCT, Sugen/hypoxia mouse and patient data presented in Chapter 4, similar techniques to those 
described above were employed to assess differences between groups, correlations and ROC curves. 
For mRNA data outcome genes of interest were normalised to the geomean of RPLPO and GAPDH 
using the ΔΔCT method, normalised to control values for the same gene in the same experiment and 
then logged to increase the normality of distribution of the data. The results from 2 rat experiments 
with the same conditions were pooled. In order to reduce variation between experiments and 
processing involving mRNA data, mRNA expression in individual animals were normalised only to the 
mean mRNA expression of control animals analysed at the same time. mRNA expression was analysed 
  
107 
  
in the TA of the Sugen/hypoxia and control mouse but not in the hypoxia mouse as circulating GDF-15 
was not raised in the hypoxia alone treated group. 
For cell experiments between 1 and 8 repeated experiments in singlicate to quadruplicate were 
included for analysis. The n’s used in each experiment are included in the appropriate figure in the 
results section. Student’s t-test, Mann Whitney U test, one way or repeated measures ANOVA with 
Bonferroni or Kruskall-Wallace with Dunn’s correction were used. Where none of the above analyses 
were possible due to lack of variability in the control samples a one sample t-test or a Wilcoxon signed 
rank test was used. mRNA data was analysed similarly to that described above with the data from 
each experiment normalised to mean control data from that experiment and then log transformed to  
increase the normality of the data set.  Luciferase data for each individual condition was normalised 
to control samples for that condition in individual experiments. Western blot data was determined by 
normalising results of protein of interest to β-actin in cells or GAPDH in animals or the total amount 
of the protein of interest. Relative activity or amount of protein was compared to control value in the 
same experiment and repeats were analysed.  Myotube diameter data is presented as raw data and 
relative change in diameter across individual experiments. 
For MCT TAK1 experiments ANOVA with Bonferroni or Kruskall Wallace with Dunn’s was used. Rats 
who continued to grow were defined as those who reached their maximum weight on the last day of 
treatment without plateauing. Fisher’s exact test was used to compare the proportion of rats still 
growing in the MCT and MCT TAK1i groups. Differences in TA atrogin-1 mRNA expression and 
circulating GDF-15 levels between those growing and not growing in the group overall and in the MCT 
and MCT TAK1i groups were analysed by Student’s t test and Mann-Whitney U test. Correlations and 
ROC curves were performed and constructed as detailed above and mRNA and protein data analysis 
was handled as above. In the MCT TAK1 experiments fibre diameter was assessed as an average across 
each group and as a curve showing proportions of cells below cumulative 5 micron cut-offs, which 
were then assessed using ANOVA (410). 
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Chapter 3 Clinical outcomes pertaining to muscle wasting and physical activity in PAH 
3.1 Background 
Skeletal muscle dysfunction is emerging as an important complication in patients with PAH. 
Respiratory (154, 159) and peripheral muscle dysfunction (160, 161, 412) have been described in these 
patients, both of which have been associated with markers of prognosis, the 6MWD, and the cardio-
pulmonary exercise test measured maximal oxygen uptake (159-161). Interestingly there was no 
direct association between muscle strength or size and haemodynamic parameters, in this group (160, 
161).  
Further indirect evidence of the importance of a peripheral muscle myopathy in PAH comes from 
studies looking at the effects of pulmonary rehabilitation. A number of studies have now shown that, 
contrary to previous thinking, rehabilitation was safe and effective in patients with PAH (164, 167, 
172). Various forms of exercise programs have been able to improve QOL, functional status, peak 
oxygen consumption, muscle strength, size and oxidative capacity and 6MWD by between 0 and 
110m, without changing haemodynamic parameters (164, 167, 172). 
Physical inactivity in chronic cardio-respiratory disease is conceptually both a cause and effect of 
muscle wasting and contributes to the vicious cycle of disease progression (75). Physical activity has 
been infrequently measured in PAH but is emerging as both a target for intervention and an outcome 
measure in this group of patients. The latest European Society of Cardiology (ESC) / European 
Respiratory Society (ERS) guidelines have suggested that patients with PAH should be encouraged to 
remain as active as possible within symptom limits and that supervised rehabilitation is beneficial in 
terms of both exercise capacity and QOL (16).  A small number of studies have shown that physical 
activity is reduced in patients with PAH when compared to healthy controls (173, 174, 176, 413). 
Furthermore, physical activity has been correlated with important prognostic markers, the 6MWD 
(173, 414) and WHO functional class (174, 415), as well as with QOL (413).  
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The association of muscle strength and physical activity have not been investigated together in a 
population of patients with PAH, and the effects of muscle strength and physical activity on outcomes 
like hospitalisation and mortality have not been directly measured. Furthermore the optimal way to 
practically measure physical activity in patients with PAH has not been investigated.  
There are a number of ways in which physical activity can be quantified, each having its own 
advantages and disadvantages (177). The gold standards are calorimetry or double-labelled water, 
which are highly accurate but are time consuming, expensive and somewhat invasive (416). 
Accelerometers are considered accurate at measuring physical activity on an individual basis. They are 
able to pick up different modes of movement, not just walking, but they are expensive and must be 
worn over a number of days to collect accurate information, which may decrease patient compliance 
(417). One widely used accelerometer is the SWA. Its ability to measure physical activity has been 
validated in healthy individuals (376), in arthritis  (418) and in COPD (419). It has been previously used 
to study physical activity in patients with PAH (173).   Lastly physical activity questionnaires are quick 
to administer, cheap and non-invasive but they can be inaccurate, with over or under-estimation being 
reported (420). Indeed, we have previously noted the inaccuracy of a number of self-reported activity 
questionnaires when compared to objective activity monitors in patients with COPD (383).  
Disease specific and general QOL questionnaires have been utilised to investigate interventions in PAH 
(387, 389, 413). Two of these questionnaires, the CAMPHOR, and the SGRQ, as well as generating data 
on overall QOL, allow investigators to calculate activity scores (385, 389). These activity scores have 
not been compared to objectively measured values of physical activity in patients with PAH.  
3.2 Aims 
To measure the associations of muscle strength and size and physical activity in a well characterised 
group of patients with PAH.  
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To determine the effects of muscle strength and size and physical activity on outcomes such as 
hospitalisation and mortality in patients with PAH 
To investigate the association of physical outcome measures from QOL questionnaires with objectively 
measured physical activity. 
3.3 Hypotheses 
Muscle function and size and physical activity will correlate with prognostic markers, but not 
haemodynamic parameters and with outcomes such as mortality and hospitalisation in patients with 
PAH.   
Physical activity scores will correlate only modestly, if at all, with objectively measured physical activity 
in patients with PAH.  
3.4 Methods 
For a full explanation of the methods please see Chapter 2 of this thesis 
3.4.1 Participants 
Thirty-three eligible patients over 16 years old with WHO class I-III PAH from the pulmonary 
hypertension clinic at the Royal Brompton hospital, were included in the study. Patients were excluded 
if they had other significant cardio-respiratory disease, a metabolic disorder or neurological condition, 
which would significantly affect their physical activity.  The study was approved by the NRES ethics 
committee and all patients provided written informed consent. 
3.4.2 Baseline measurements 
All baseline measurements were undertaken at a single visit. Participants had their height, weight and 
BMI measured. They had their WHO functional status assessed, as well as undergoing a 6MWD (397), 
echocardiogram, C-reactive protein and BNP measurement. FFMI (370), QMVC (374) and USRFCSA were 
measured (28). Patients filled in the SGRQ (385)  and CAMPHOR (389) questionnaires to document 
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QOL and activity scores. They were then provided with the SWA and wore it over the triceps of their 
right arm for 7 days after which it was delivered back to the researcher (376). At the time of the 
assessment the researcher and participant was blinded to the activity score of the QOL questionnaires, 
which was only calculated later. 
3.4.3 Physical activity outcomes 
The SWA was worn at all times for 7 days except when there was a risk of getting the armband wet. 
Analysis of the physical activity data was performed as previously described (378). Outputs from the 
SWA included in the analysis were: the physical activity level (PAL) (total energy expenditure per 
minute / basal metabolic rate), which gives a global assessment of physical activity (379); time spent 
in at least moderate physical activity defined as 3 metabolic equivalents (3.0 METs) (383) and steps 
per day. Data for physical activity level (PAL), time spent in greater than 3.0 metabolic equivalents and 
active energy expenditure was excluded from analysis if the SWA was worn for less than an average 
of 22.5 hours per day for 5 days including at least one weekend day as described by Watz et al. (378). 
Steps per day were excluded if the patient wore the armband for fewer than 8 hours for 4 days as has 
been previously described (380). For assessment of activity, low activity was defined as a PAL < 1.4 
which has previously used to define extremely inactive individuals (382, 383). Active individuals were 
defined as those achieving 30 minutes of at least moderate activity (> 3.0 METs) as per current 
recommendations (384). The SGRQ and CAMPHOR total QOL and activity scores are expressed as 
arbitrary units with higher scores indicating lower QOL and lower levels of physical activity (385, 389).    
3.4.4 Follow up period and measurements 
Patients were followed up for at least 2 years after their initial assessment. They had their 
demographics, 6MWD, echocardiogram, BNP, functional status and QOL measured. QOL was 
measured by the Emphasis 10 questionnaire (391) at approximately 6 monthly intervals after their 
initial assessment. Average QOL score between 1 and 2.5 years was calculated. Transplant-free 
survival and overnight hospital admissions throughout the follow up period were documented.  
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3.4.5 Data Analysis 
Statistics were performed using Graphpad prism version 5 (Graphpad, CA, USA) or SPSS version 24 
(IBM, Portsmouth, UK). Demographic data is expressed as mean and standard deviation or median 
and inter-quartile range depending on whether the data was normally distributed; normal distribution 
was assessed using the Kolmogorov-Smirnov test and visually using histograms. Student’s t-test or 
Mann Whitney U tests were used to compare experiments with 2 groups and ANOVA with Bonferroni 
correction or Kruskall-Wallace with Dunn’s correction used to compare more than 2 groups. Pearson’s 
or Spearman’s test was used to assess correlations between scores. Survival curves were constructed 
to analyse the effect of muscle parameters and physical activity measures on transplant free survival 
and differences were analysed using the log-rank Mantel-Cox test. Data was censured on the day the 
final participant completed 2 years of follow up.  Linear regression was used to determine the 
independent associations of various measured parameters with outcomes 6MWD and QOL.  Receiver 
operator characteristic (ROC) curves and area under the curves (AUC) were used to assess the ability 
of the measured variables to predict outcomes including mortality, hospital admission and SWA 
measured physical activity.  
3.5 Results 
3.5.1 Demographics and compliance 
The demographics with n numbers for the patients recruited to the study are shown in table 3.1. 
Measures of muscle function, size, physical activity and QOL and number of data points are included 
in Table 3.2. Follow up data is detailed in table 3.3.  
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Age 46.6 ± 13.6 years n = 33 
Sex  n = 33 
Male 10  
Female 23  
Cause  n = 33 
IPAH 25  
CHD 8  
BMI 25.2 (21.7 - 29.2) kg/m2 n = 33 
WHO  n =33 
I 3  
II 20  
III 10  
6MWD 367.8 ± 131.4 m n = 32 
BNP 134.0 (53.5 - 278.0) pmol/L n = 33 
Echo   
RVSP 86.3 ± 26.9 mmHg n = 26 
TR velocity 409.6 ± 80.5 cm/s n = 25 
PAcT 83.8 ± 26.5 msec n = 27 
TAPSE 1.9 (1.5 - 2.1) cm n = 32 
CRP 3 (1 - 6) mg/L n = 31 
Table 3.1. Demographics. Demographic details of 33 eligible patients with pulmonary arterial hypertension 
enrolled in the study. Idiopathic pulmonary arterial hypertension (IPAH), Congential heart disease (CHD), World 
health organisation functional status (WHO), Right ventricular systolic pressure (RVSP) measured by 
echocardiogram (echo), tricuspid anterior posterior systolic excursion (TAPSE), tricuspid regurgitant (TR) 
velocity, pulmonary artery acceleration time (PAcT), Six minute walk distance (6MWD), plasma brain natriuretic 
peptide (BNP). 
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FFMI 17.1 ± 2.8 kg/m2 n = 30 
QMVC/BMI 1.30 ± 0.36 n = 30 
USRFCSA 481 ± 133 mm2 n = 30 
SWA   
Steps per day 5616 ± 3286 n = 30 
AEE 243.5 (84.5 - 444.0) kcal n = 26 
Time in > 3.0 METs 49.0 (18.8 - 88.5) mins n = 26 
PAL 1.42  ± 0.19 n = 26 
SGRQ   
Activity 63.8 ± 24.6 n = 31 
Total 44.8 ± 19.6 n = 31 
CAMPHOR   
Activity 9.62 ± 5.70 n = 29 
Total 27.71 ± 13.72 n = 28 
Table 3.2. Muscle bulk, physical activity and quality of life.  Muscle bulk strength and size, physical activity and 
quality of life patients with pulmonary arterial hypertension Fat free mass index (FFMI) Quadriceps maximal 
volitional capacity / Body mass index (QMVC/BMI) Rectus femoris cross sectional area measured by ultrasound 
(USRFCSA) Sensewear armband (SWA) Active energy expenditure (AEE). Metabolic equivalents (METs) St George’s 
respiratory questionnaire (SGRQ). 
Follow up  n = 31 
Alive  no transplant 25  
Alive with transplant 1  
Dead 5  
Dead after transplant 2  
Admission  n =31 
Yes 16  
No 15  
Follow up QOL   
Emphasis 10 24.0 (16.8 - 35.0) n = 29 
Table 3.3.  Follow up data. Follow up data in 31 patients with pulmonary arterial hypertension studied.  
 
3.5.2 Muscle mass, strength and size and physical activity across WHO functional groups in patients 
with PAH 
FFMI was not different between WHO functional classes, however quadriceps strength and size was 
significantly lower in patients in WHO class III than in class I or II (Figure 3.1 A, B and C). All 
measurements of physical activity including: steps per day; active energy expenditure; time spent in > 
3.0 metabolic equivalents; and physical activity level were lower in patients in WHO functional class 
III than in class I / II (Figure 3.2 A-D).  
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Figure 3.1 Muscle measurements across functional class. A. Fat free mass index (FFMI) across WHO functional 
class in patients with PAH (ANOVA p = 0.719) (WHO I n = 3, WHO II n = 18, WHO III n = 9). B. Quadriceps maximal 
volitional capacity normalised to Body mass index (QMVC/BMI) across WHO functional class in patients with 
PAH (ANOVA p = 0.002. (WHO I n = 3, WHO II n = 18, WHO III n = 9) C. Ultrasound measured rectus femoris cross 
sectional area (RFCSA) across WHO functional class in patients with PAH (ANOVA p = 0.001) (WHO I n = 3, WHO II 
n = 18, WHO III n = 9).  
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Figure 3.2 Physical activity across functional class. A. Steps per day across WHO functional class in patients with 
PAH (Mann Whitney U test p < 0.001, WHO class I/II n = 21, WHO class III n = 9). B. Active energy expenditure 
(AEE) across WHO functional class in patients with PAH (Mann Whitney U test p = 0.023, WHO class I/II n = 17, 
WHO class III n = 9). C. Time spent in activity of greater than 3.0 metabolic equivalents (METs) across WHO 
functional class in patients with PAH (Mann Whitney U test p = 0.015, WHO class I/II n = 17, WHO class III n = 9). 
D. Physical activity level (PAL) across WHO functional class in patients with PAH (Mann Whitney U test p = 0.001, 
WHO class I/II n = 17, WHO class III n = 9). 
 
3.5.3 Correlations of muscle strength and size and physical activity in patients with PAH 
In the cohort of PAH patients studied, 6MWD was associated with QMVC/BMI, USRFCSA, PAL and BNP 
(Figure 3.3 A-D). No echocardiographic marker measured correlated significantly with 6MWD, 
however CRP did correlate non-linearly with 6MWD (Figure 3.3 E). A linear regression model using 
age, BMI, RFCSA, PAL, BNP (< 100) and CRP (<10) had an adjusted R2  value of 0.37 in predicting 6MWD 
in patients with PAH with a p value of 0.031, suggesting that 37 percent of the variance in 6MWD was 
  
117 
  
explained by the model. The only independent variable making a significant unique contribution to 
the 6MWD was USRFCSA, which had a β co-efficient of 0.72 (p = 0.003).  
QOL measured by the SGRQ also correlated significantly with QMVC/BMI, USRFCSA, PAL, and CRP 
(Figure 3.4 A-D) but failed to associate with any echocardiographic marker of disease severity or with 
BNP. Using the same inputs in a linear regression model, as above, the adjusted R2 was 0.59 (p = 0.002) 
meaning 59% of the variance in SGRQ score was accounted for by the model. The only independent 
association of the SGRQ was again USRFCSA with a β co-efficient -0.82 and p value < 0.001.  
QOL measured by the CAMPHOR also correlated significantly with Quads CSA, PAL and CRP but not 
with muscle strength, BNP or echocardiographic parameters (Figure 3.5 A-C).  
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Figure 3.3 Correlations of six minute walk distance (6MWD). A. Quadriceps maximal volitional capacity / Body 
mass index (QMVC/BMI) plotted against 6MWD in patients with PAH (n=30). B. Ultrasound measured rectus 
femoris cross sectional area (RFCSA) plotted against 6MWD in patients with PAH (n=30). C. Physical activity level 
(PAL) plotted against 6MWD in patients with PAH (n=26). D. Brain natriuretic peptide (BNP) plotted against 
6MWD in patients with PAH (n=32). E. C-reactive protein plotted against 6MWD in patients with PAH (n=30). 
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Figure 3.4 Correlations of St. George’s respiratory questionnaire (SGRQ) quality of life. A. Quadriceps maximal 
volitional capacity / Body mass index (QMVC/BMI) plotted against total St. George’s Respiratory questionnaire 
(SGRQ) score.in patients with PAH (n = 28). B. Ultrasound measured rectus femoris cross sectional area (RFCSA) 
plotted against total SGRQ in patients with PAH (n = 28). C. Physical activity level (PAL) plotted against total SGRQ 
score in patients with PAH (n = 24). D. C-reactive protein (CRP) plotted against total SGRQ score in patients with 
PAH (n = 30). 
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Figure 3.5 Correlations of CAMPHOR quality of life. A. Ultrasound measured rectus femoris cross sectional area 
(RFCSA) plotted against total CAMPHOR score in patients with PAH (n=25). B. Physical activity level (PAL) plotted 
against total CAMPHOR score in patients with PAH (n=22). C. C-reactive protein (CRP) plotted against total 
CAMPHOR score in patients with PAH (n=27). 
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3.5.4 Association of muscle size, strength and cardiovascular markers with physical activity in PAH 
Time spent in greater than 3.0 METs correlated with QMVC/BMI and RFCSA (Figure 3.6 A and B), whilst 
PAL correlated only with RFCSA (Figure 3.6 C). None of the measures of physical activity correlated with 
BNP or echocardiographic parameters. 
 
Figure 3.6 Correlations of physical activity and muscle parameters. A. QMVC/BMI plotted against SWA 
measured time in > 3.0 metabolic equivalents (METs)) (n = 25).  B. Ultrasound measured rectus femoris cross 
sectional area (RFCSA) plotted against SWA measured time in > 3.0 METs (n=25). C. RFCSA plotted against SWA 
measured physical activity level in patients with PAH (n=25). 
 
3.5.5 Muscle bulk and physical activity predict mortality in patients with PAH 
Transplant-free survival curves for those patients with PAH for whom we had at least two year follow 
up data are shown in Figure 3.7. Comparing survival in patients with a FFMI < 14, 14-19 and > 19 
  
122 
  
demonstrated a Log-rank Mantel-Cox Test Chi squared of 6.40 (p = 0.041), whilst the log rank test for 
trend showed a Chi squared of 5.47 (p = 0.019) (Figure 3.7A). We also compared mortality between 
those patients taking < 2500 or > 2500 steps per day. In this case the Log-rank Mantel-Cox Test 
demonstrated a Chi squared of 11.0 (p < 0.001) (Figure 3.7B).  
Figure 3.7 Survival in PAH by muscle bulk and activity. A. Kaplan-Meier plot showing survival in patients with 
pulmonary arterial hypertension and a fat free mass index (FFMI) in kg/m2 of < 14 (n = 4), 14-19 (n = 17) and > 
19 (n = 9). Log-rank Mantel-Cox Test Chi squared of 6.40 (p = 0.041). Log rank test for trend showed a Chi squared 
of 5.47 (p = 0.019). B. Kaplan-Meier plot showing survival in patients with pulmonary arterial hypertension and 
taking greater than (n = 22) or less than (n = 4) 2500 steps per day fat. Log-rank Mantel-Cox Test Chi squared of 
11.0 (p < 0.001). 
 
3.5.6 Muscle bulk and strength identify those patients with PAH at risk of hospital admission 
 As well as mortality, factors associated with overnight admission to hospital within 2 years of 
enrolment was examined. Age was significantly higher (p < 0.001), whilst FFMI and QMVC/BMI was 
significantly lower in those patients admitted to hospital in the follow up period compared to those 
not admitted (Figures 3.8 A and B). There was no difference in BNP, echocardiographic or physical 
activity parameters in those admitted and those not admitted.  ROC curves were constructed for FFMI 
and QMVC/BMI in predicting admission over the follow up period. These are shown in Figure 3.8 C 
and D. Numerically, QMVC/BMI had a greater AUC compared to FFMI. The best sensitivity and 
specificity cut offs for each variable in predicting admission are shown in the Figures 3.8 C and D. 
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Figure 3.8 Muscle parameters predict hospitalisation in PAH A. Fat free mass index (FFMI) in those admitted (n 
= 15) and not admitted (n = 14) to hospital at 2 year follow up (Mann Whitney U test p = 0.037).  B. Quadriceps 
maximal volitional capacity normalised to Body mass index (QMVC/BMI)) in those admitted (n = 14) and not 
admitted (n = 14) to hospital at 2 year follow up (Mann Whitney U test p = 0.006). C. Receiver operator 
characteristic (ROC) curve of FFMI in predicting those admitted to hospital at 2 years follow up. D. ROC curve of 
the QMVC/BMI in predicting those admitted to hospital at 2 years follow up.  
 
3.5.7 Muscle strength and physical activity are correlated with future levels of quality of life in 
patients with PAH 
Mean Emphasis 10 score on follow up was associated with QMVC/BMI, PAL and 6MWD and non-
linearly with CRP (Figure 3.9 A - D) Neither BNP nor any echocardiographic measure correlated 
significantly with follow up QOL measured by EMPHASIS 10. A linear regression model including 
QMVC/BMI, PAL, 6MWD and CRP revealed an adjusted R2 of 0.276, with a p of 0.042. This suggests the 
model accounted for 28 % the variance in follow up EMPHASIS 10 data. No one variable made a 
significant unique contribution to the EMPHASIS 10 score within this model. 
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Figure 3.9 Correlates of future quality of life in PAH A. Quadriceps maximal volitional capacity / Body mass 
index (QMVC/BMI) plotted against average follow up EMPHASIS 10 score in patients with PAH (n=25). B. 
Sensewear armband measured physical activity level (PAL) plotted against average follow up EMPHASIS 10 score 
in patients with PAH (n=24) C. Six minute walk distance (6MWD) plotted against average follow up EMPHASIS 
10 score in patients with PAH (n=28). D. C-reactive protein (CRP) plotted against average follow up EMPHASIS 
10 score in patients with PAH (n=28). 
 
3.5.8 Activity scores from QOL questionnaires can predict those patients with low physical activity 
in the context of PAH. 
SGRQ measured activity levels correlated negatively with SWA derived steps per day, PAL and time 
spent in activity of > 3.0 METs (Figure 3.10 A, B and C). The CAMPHOR derived activity scores also 
correlated negatively and significantly with SWA steps per day, PAL and time spent in activity of > 3.0 
METs (Figure 3.10 D, E and F).  
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ROC curves for the SGRQ activity, CAMPHOR activities and 6MWD in predicting patients who took < 
2500 steps per day, are shown in Figure 3.11 A - C. The SGRQ activity score ROC curve AUC of 0.95, 
was numerically but not statistically better than the CAMPHOR and 6MWD in predicting those with a 
step count that I have shown to be associated with increased mortality.   
Similar curves were generated for the SGRQ activity, CAMPHOR activities and 6MWD in predicting low 
physical activity, defined as a PAL < 1.4. These ROC curves and are shown in Figure 3.12 A - C. Again 
the SGRQ activity score performed best in predicting those with a PAL < 1.4 with an AUC of 0.78 (p = 
0.019) when compared numerically to the CAMPHOR activities score and 6MWD.  
ROC curves were also generated for the SGRQ activity, CAMPHOR activities and 6MWD in predicting 
those patients achieving the recommended amount of physical activity per week (30 minutes per day 
at > 3.0 METs). These ROC curves are shown in Figure 3.13 A - C.  In this case neither SGRQ nor 
CAMPHOR activity scores, which had AUCs of 0.68 (p = 0.116) and 0.74 (p = 0.062) respectively, were 
numerically or statistically better than the 6MWD in predicting active individuals which had an AUC of 
0.74 (p = 0.040). 
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Figure 3.10. SGRQ and CAMPHOR activity scores correlate with objectively measured physical 
activity. Correlations of SGRQ activity score with: A. SWA measured steps per day (n = 28); B. SWA physical 
activity level (PAL – total daily energy expenditure / Basal metabolic rate) (n = 24); C. SWA measured time spent 
in greater than 3.0 metabolic equivalents (METs) (n = 24). Correlations of CAMPHOR activities score with: D. 
SWA measured steps per day (n = 27); E. SWA physical activity level (n = 23); F. SWA measured time spent in 
greater than 3.0 metabolic equivalents (METs) (n = 23).  
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Figure 3.11 ROC curves of activity scores from the SGRQ, CAMPHOR and 6MWD in predicting low step count. 
A. Receiver operator characteristic (ROC) curve of the St. George’s respiratory questionnaire (SGRQ) activity 
score in predicting those with low physical activity defined as <2500 steps per day (n = 28). B. ROC curve of the 
CAMPHOR questionnaire activity score in predicting those with low physical activity defined as <2500 steps per 
day (n = 27) C. ROC curve of the six minute walk distance (6MWD) in predicting those with low levels of physical 
activity defined as <2500 steps per day (n = 30). 
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Figure 3.12 ROC curves of activity scores from the SGRQ, CAMPHOR and 6MWD in predicting low PAL A. ROC 
curve of the St. George’s respiratory questionnaire (SGRQ) activity score in predicting those with low physical 
activity defined as a physical activity level (PAL) < 1.4 (n = 24).  B. ROC curve of the CAMPHOR questionnaire 
activity score in predicting those with low physical activity defined as a physical activity level (PAL) < 1.4 (n = 23).   
C. ROC curve of the six minute walk distance (6MWD) in predicting those with low levels of physical activity 
defined as a physical activity level (PAL) < 1.4 (n = 26).  
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Figure 3.13 ROC curve of activity scores from the SGRQ, CAMPHOR and 6MWD in predicting active individuals 
A. ROC curve of the St. George’s respiratory questionnaire (SGRQ) activity score in predicting those achieving 
the recommended amount of physical activity defined as those spending at least 30 minutes in greater than 3.0 
metabolic equivalents (METs) (n = 24). B. ROC curve of the CAMPHOR questionnaire activity score in predicting 
those achieving the recommended amount of physical activity defined as those spending at least 30 minutes in 
greater than 3.0 METs (n  = 23). C. ROC curve of the six minute walk distance (6MWD) in predicting those 
achieving the recommended amount of physical activity defined as those spending at least 30 minutes in greater 
than 3.0 METs ( n = 26).  
 
Finally we have also shown that SGRQ activity score of > 70 can predict mortality in patients with PAH. 
The log-rank Mantel-Cox test chi squared was 5.60 (p = 0.018) (Figure 3.14 A). Furthermore a SGRQ 
activity score of > 69.5 was able to predict 2 year mortality / transplant with a sensitivity of 88% and 
a specificity of 63%   (Figure 3.14 B).  
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Figure 3.14 Kaplan-Meier and ROC curve predicting survival in patients based on SGRQ activity scores. A. 
measured by the SGRQ. Kaplan-Meier plot showing survival in patients with pulmonary arterial hypertension 
and a St George’s respiratory questionnaire activity score of < (n = 16) or > (n = 14) 70. Log-rank Mantel-Cox Test 
Chi squared of 5.15 (p = 0.023 (n =30). B. Receiver operator characteristic (ROC) curve of the St. George’s 
respiratory questionnaire (SGRQ) activity score in predicting 2 year mortality on patients with PAH (n = 30).  
 
3.6 Discussion 
The results documented above highlight the importance of both skeletal muscle and physical activity 
in patients with PAH.  Skeletal muscle and physical activity parameters are associated with known 
markers of prognosis, the 6MWD and WHO functional status, current and future QOL; hospital 
admission; and mortality. The data also shows that the SGRQ activity score is a reasonable surrogate 
of more objectively measured physical activity, and is associated with mortality at 2 years.  
We have shown that muscle strength and size and physical activity is lower in PAH patients with worse 
functional status. Objectively measured physical activity also was significantly lower in patients at 
higher WHO functional class. This is in keeping with the work from Mainguy et al. who demonstrated 
similar findings using the same activity monitor (173).  The data also demonstrates that one of the 
most important markers of prognosis in patients with PAH, the 6MWD (421), is associated with muscle 
strength and size and with physical activity. This is in keeping with data published by other groups 
(160, 173). There was also an association of 6MWD and CRP and BNP, but no association with 
echocardiographic parameters, confirming the findings of other studies (160, 161). Using a linear 
regression analysis the only independent association with 6MWD in this group was the USRFCSA. This 
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suggests that muscle size rather than the other variables included in this analysis, including age, BMI, 
PAL, CRP and BNP might influence 6MWD independently. QOL has been associated with physical 
activity (422) but not directly with muscle strength in patients with PAH. I found that lower QOL was 
associated with muscle strength, muscle size, CRP and PAL but not with markers of cardiovascular 
function as measured by BNP or echocardiographic parameters. Using the same inputs for linear 
regression, again, only the USRFCSA was independently associated with SGRQ measured QOL. Taken 
together this suggests that muscle size is an important factor that might influence outcomes in 
patients with PAH. This data is supported by studies showing that rehabilitation improves 6MWT, 
quadriceps function but not cardiovascular parameters in patients with PAH (164, 171, 172).  
Muscle wasting and low physical activity have been linked to mortality in COPD (34, 423-425) and 
heart disease (425-427), but not previously in PAH. For the first time, as far as I am aware, I have 
shown that patients with PAH with lower FFMI and step counts have an increased mortality at 2 years. 
The cut offs of FFMI and steps per day predicting higher mortality in this cohort were very low. 
Epidemiological studies have suggested that the 5th to 95th percentile of FFMI was 16.8 -21.1 in young 
men and 13.8-17.6 in young women (370). This suggests that an FFMI of < 14, which has been 
identified as predicting the highest mortality, is well below average.  Tudor-Locke suggested that 
people taking less than 5000 steps per day lived a sedentary lifestyle, whilst 2500 steps represented 
basal activity (428). In our cohort it was in those patients taking less than this basal activity who 
exhibited higher levels of mortality at 2 years.  
In our cohort only one patient who underwent transplant for PAH survived. One of the major 
determinants of outcomes in transplant is pre-conditioning. If these patients had higher muscle 
strength and physical activity prior to assessment the outcomes may have improved (429).   
Hospitalisation has been identified (430) and used as an important outcome measure in patients with 
PAH (431). The current cost of a hospital bed in the NHS in the UK is £400 per day (432). In a recent 
study in PAH patients in the USA the average length of stay for a hospital admission was 15 days, 
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compared to an average of 11 days for other diagnoses, with higher daily costs in the PAH population. 
Furthermore most of those re-admitted after their initial visit for PAH had at least one other admission 
in the follow up period (433). This suggests that the economic cost of admission for PAH is higher than 
the general population and avoiding admission might deliver higher economic benefits. Furthermore 
it has been shown that in a large unselected cohort of patients that hospitalisation was associated 
with deterioration in QOL (434) ; this is also likely to be true for patients with PAH. The data presented 
here suggests that patients with lower muscle strength and bulk are more likely to be admitted to 
hospital for an overnight stay for any reason within 2 years. Both FFMI and QMVC/BMI were able to 
predict those admitted to hospital within 2 years with reasonable AUC of their ROC curves. A 
QMVC/BMI of < 1.1 was particularly specific in defining those admitted over the 2 year follow up 
period. We have also shown that muscle strength and physical activity, as well as 6MWD and CRP 
correlated significantly with average follow up QOL using the PH specific EMPHASIS 10 questionnaire. 
As mentioned above, studies of rehabilitation have generally shown an improvement in 6MWD, a 
predictor of prognosis (421), through an improvement in muscle strength and without a change in 
cardiovascular function (18). This suggests that interventions aimed at altering muscle strength, size 
or bulk and physical activity may result in improved mortality, reduced hospital admission and 
improved QOL in patients with PAH. 
Rehabilitation already has a theoretical if not an established practical role in the treatment of patients 
with PAH (18, 164, 171, 172). There is some emerging evidence of the mortality benefits of 
rehabilitation in a wide range of conditions as well as in a geriatric population (98, 435-438), and this 
is also likely to be true in PAH, especially given the data presented in this Chapter. This gives a rationale 
to support a more major role for rehabilitation in the management of pulmonary hypertension. The 
ideal method of rehabilitation in PAH, or for that matter in any chronic cardio-respiratory disease, has 
yet to be established and the method by which to transfer gains in exercise capacity into physical 
activity is as yet unknown, and these should be the focus of future research in this area (439).  
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There are a number of barriers to rehabilitation. Both low levels of baseline physical activity (440) and 
cachexia (441) have been associated with decrease uptake and or efficacy of rehabilitation in some 
studies. The data presented above suggests that it this group, who may respond less well to 
rehabilitation, and also have the worse prognosis, may benefit most from agents aimed at blocking 
muscle atrophy and promoting muscle gain. This may allow them to take part in rehabilitation and 
may alter their prognosis.  At present international guidelines do not recommend the use of anabolic 
agents as adjuncts to rehabilitation (439) and there are currently no pharmacological agents aimed at 
improving muscle strength in chronic disease in established clinical use (442). Part of this may be due 
to a lack of clinical biomarkers of cachexia allowing the easy identification of patients at risk of muscle 
wasting. The authors of a recent review identify a number of biomarkers including GDF-15 as having 
potential to identify those with muscle loss (443). The issues of biomarkers and pharmacological 
treatment of muscle wasting in PAH are addressed in subsequent chapters of this thesis. 
Our data suggests that objectively measured low physical activity is associated with increased 
mortality in patients with PAH.  Assessment of physical activity is difficult. Screening tests which can 
be done quickly and cheaply are helpful in identifying those patients with low physical activity who 
may need more detailed assessment with expensive and time consuming activity monitors. 
Questionnaire based assessment is an attractive method to screen large populations for low physical 
activity levels (416). Our data suggests that a SGRQ physical activity score and, to a lesser extent a 
CAMPHOR physical activity score, can be used to determine those patients with PAH who are inactive. 
In addition, our data suggests that the SGRQ activity score outperforms the 6MWD in predicting 
inactive patients with PAH. In contrast to the above, we have found that these questionnaire 
generated activity scores were not as good at predicting those patients who achieved the 
recommended amount of moderate physical activity per day.  
This study is the first to compare questionnaire-based assessment of physical activity against an 
objective measure in patients with PAH. Questionnaire based assessment of physical activity can be 
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unreliable with many researchers finding over and under-estimation. This bias may be due to patient 
factors including age, cultural differences and social desirability of physical activity, and questionnaire 
factors including length, complexity and whether it is self-report or interviewer led (444). The activity 
scores examined in our study were part of a wider assessment of QOL. The framing of a recall based 
activity assessment can have a significant influence over the results (444). Taking this into account, it 
may be that embedding an activity assessment in a general QOL questionnaire removes some of the 
bias, particularly that which relates to the social desirability of physical activity, conferring an 
advantage to both the SGRQ and CAMPHOR in assessing physical activity.  
The SGRQ was superior to the CAMPHOR and 6MWD in predicting those patients with low physical 
activity based both on steps per day and PAL measured by the SWA. The SGRQ is a QOL questionnaire 
designed for use in in COPD although it has been used in other conditions including asthma (445). The 
activity component consists of 16 questions to which the subject answers yes or no (385) . Although 
not validated against any objective measure of activity, the activity score of the SGRQ has been shown 
to correlate with other questionnaire based assessments of physical activity (446) and to  predict 
exacerbation frequency in COPD (447). The questionnaire has also been used to assess QOL in PAH 
(387). The CAMPHOR is a well-validated disease specific QOL questionnaire designed for use in 
patients with PAH (389). Its activity score is based on 15 questions in a single section. In the recent 
article by Matura et al. physical activity scores from the CAMPHOR correlated with accelerometer 
measured variability in physical activity but not with physical activity counts themselves, possibly due 
to the lower number of patients studied (413). Our data suggests that screening patients for low 
physical activity would be best done using the SGRQ.  
Neither questionnaire’s activity score was as good as the 6MWD in predicting those patients achieving 
their recommended amount of physical activity per day, defined as greater than 30 minutes and 
greater than 3.0 METs (384). This may be because these questionnaires ask patients what they can’t 
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do rather than what they are doing and may be insensitive to light and moderate activity performed 
by the participant (448). 
Importantly an SGRQ activity score of > 70 was able to define those patients at higher risk of mortality 
in the subsequent 2 years with reasonable sensitivity and specificity. This further supports the use of 
the SGRQ activity score to monitor patients’ physical activity. Prospective studies should concentrate 
on whether improving activity scores are associated with improved long-term outcomes. 
3.7 Limitations 
One of the main limitations of this study is the small number of patients involved. It is difficult to make 
generalisations about the associations seen in our small cohort to a wider range of patients in other 
centres. I have undertaken multiple comparisons using the same data set and have not carried out 
Bonferroni corrections for multiple analysis. This is because the numbers needed to study would be 
higher than feasibly possible given the time and resources available and the rarity of the condition. 
This does leave us open to type 1 error but reduces the amount of type 2 error. As long as this is 
understood by the reader then this seems to be a reasonable approach and is supported in the wider 
literature when dealing with small sample sizes (449). The use of linear regression models in these 
small numbers to demonstrate independent associations of muscle, physical activity and other factors 
must be interpreted with caution. The data does however comply with the requirements of Austin et 
al. who suggested that only 2 subjects per variable were required for this analysis to be valid (450). 
This methodology was also discussed with a statistician.  It should also be noted that PAH is a rare 
condition and the associations demonstrated in these small number are reasonably strong. A lager 
cohort might have demonstrated a statistical as well as numerical difference in area under the ROC 
curve analysis between the various measures, adding more weight to our arguments.  
Another weakness of the study relates to missing data. This is particularly true with adequate SWA 
and questionnaire data. We have adopted the strategy of using all the valid data available to increase 
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the sample size. This was particularly important given the small sample size to begin with and is 
consistent with the approach taken by Dziura et al. (451)  
The mortality and admission assessments undertaken were all cause and not PH specific. It would be 
interesting to split the admissions into those, which were for PH and those for other reasons. The 
numbers, again, were too small to attempt this assessment in our cohort. 
Although we have addressed the subject of validity of questionnaires in our study we have not 
assessed the reliability or reproducibility of these questionnaires in PAH patients both of which need 
to be assessed prior to making firm conclusions on the effectiveness of the questionnaires as screening 
tools for low physical activity. Furthermore, although the SWA has been validated in other chronic 
diseases such as COPD (419), it has not been validated in PAH and we have not compared the SWA 
outputs to the gold standard calorimetry or DLW in this cohort.  
Finally this study does not address whether the primary deficit accounting for the association of poor 
outcomes is low physical activity due to breathlessness leading to muscle loss or whether cachexia 
due to muscle loss from inflammation and hypoxia is a primary driver of low physical activity. Only 
longitudinal observational and multi-armed interventional studies with adequate follow would be able 
to address this issue. Whichever is true, breaking the vicious cycle of breathlessness, low activity and 
muscle loss at any point is likely to have positive effects on outcomes in these patients (75).   
3.8 Conclusions 
The main findings of this study were that muscle strength and size and physical activity were 
associated with functional status, exercise capacity, and QOL both at time of measurement and at 
follow-up in patients with PAH. Quadriceps muscle size was independently associated with both 
6MWD and QOL in this cohort.  
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The data demonstrates for the first time that extremely low FFMI and physical activity was associated 
with increased mortality in patients with PAH, whilst low FFMI and muscle strength was associated 
with increased risk of hospital admission.  
In this study we have demonstrated for the first time a moderately strong association between the 
activity scores generated by two commonly used QOL questionnaires and physical activity measured 
objectively by the SWA in a fully characterised group of patients with PAH. The questionnaires may be 
effective screening tests for low physical activity for use in larger population studies, to guide 
intervention or for enrolment in clinical trials. 
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Chapter 4 TGFβ signalling in muscle wasting in pulmonary hypertension 
4.1 Background 
TGFβ signalling has been implicated in both the development of muscle wasting (182) and PH (402). 
The MCT rat has been used for many years as a model of PH associated cachexia (133, 136). The role 
of TGFβ signalling in the development of PH in the MCT rat model has been studied extensively (402). 
However the part that the TGFβ super-family plays in muscle wasting in this model is poorly 
understood, being limited to one study showing raised circulating levels of GDF-8 associated with 
muscle loss (153).  Another animal model of PH, the Sugen/hypoxia mouse (452), has been shown to 
have similar fibre type changes in the diaphragm as the MCT rat (162) but has not been examined for 
peripheral muscle wasting.  
The TGFβ super-family protein, GDF-15, which is a marker of prognosis in PAH (207), has been 
implicated in the development of muscle wasting in ICU acquired weakness (218, 265), COPD (266), 
cancer (269) and in a healthy elderly population (263). Originally, it was thought that GDF-15 caused 
muscle loss exclusively through appetite suppression (260), but our group has shown, both in vitro 
and in vivo, that GDF-15 treatment or over-expression can cause direct myotube and myofibre atrophy 
(265, 453). In ICU patients and in those with COPD, both local and circulating GDF-15 levels were 
associated with levels of muscle wasting (265, 453). Other groups have shown that the source of GDF-
15 in patients with PAH was the pulmonary endothelial cells and plexiform lesions (283). It is known 
that GDF-8 can cause muscle wasting in both a paracrine and endocrine manner (182) and that GDF-
15 producing tumours can cause a reduction in weight (269) but it is not clear whether local or 
systemic GDF-15 is most important in influencing muscle wasting.  
4.2 Aims 
To define the association of GDF-15 with muscle function and size in animal models and in patients 
with PAH. 
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To identify the source of GDF-15 in animal models of PAH 
4.3 Hypotheses  
Circulating GDF-15 is associated with muscle strength and size in animal models and in patients with 
PAH. 
The source of circulating GDF-15 is the pulmonary vasculature and not the skeletal muscle 
4.4 Methods 
For a full explanation of the methods please see Chapter 2 of this thesis 
4.4.1 Animal models 
Thirty male Sprague-Dawley rats were treated with 40mg/kg MCT (16) or PBS (14) to induce PH (401).  
Some animals underwent MRI of the hind limb and the heart at the outset of the experiment and then 
4 weeks later (405).   At this time all animals were humanely killed by exsanguination, at which time 
blood was collected, after cardiac catheterisation. The heart was dissected for RV / LV+S weight. Half 
the lung was agarose inflated and placed into formalin and the other half was flash frozen (402). The 
TA and soleus muscles from one leg were snap frozen, whilst those from the other leg were embedded 
in OCT and frozen in isopentane, cooled in liquid nitrogen.  
10 Male C57BL/6J mice were injected subcutaneously with the VEGF antagonist, SU5416 (Sugen), or 
vehicle control at a dose of 20mg/kg per dose on a weekly basis. Mice were exposed to either room 
air or chronic normobaric hypoxia for 3 weeks. After this, the mice underwent cardiac catheterisation, 
and were humanely killed by exsanguination, at which time blood was taken. The heart, lung, TA and 
soleus were processed as described above, except the muscle was fixed in formalin and embedded in 
wax ready to be cut into slides (403) 
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4.4.2 Tissue processing and analysis  
Lung and muscle tissue was homogenised for mRNA and protein using methods described in full in 
Chapter 2. Blood was spun down for serum and/or plasma. Lung and muscle tissue was sectioned and 
mounted on slides. Muscle tissue was stained with haematoxylin and eosin and fibre diameter was 
assessed as previously described. Lung tissue was stained for GDF-15 and α smooth muscle actin. 
Blood samples and lung tissue protein were analysed for GDF-15 by ELISA as per manufacturer’s 
instructions. Lung and muscle tissue was analysed by qPCR using primers listed in Chapter 2 as 
previously described and fully explained in Chapter 2 (265). 
4.4.3 Clinical study 
Thirty patients with PAH, recruited from PH clinics at the Royal Brompton Hospital were included in 
this portion of the study. They underwent 6MWD according to American Thoracic Society guidelines 
(397) and had their QMVC measured (374) which was expressed as a function of  BMI (34). These 
patients also had their USRFCSA measured using the ultrasound technique described by Seymour et al. 
(67). All patients initially enrolled also underwent physical activity monitoring for 7 days with the SWA 
(376). Twenty-six had adequate data defined as wearing the armband for 22.5 hours for at least 5 days 
including both Saturday and Sunday (378). The primary output from the SWA we examined against 
GDF-15 was the PAL (378). All patients also underwent echocardiographic assessment (394). Blood 
was taken and plasma was extracted for analysis of GDF-15 levels, which were measured by ELISA 
(R&D systems, Abingdon, UK). This study was approved by the REC and the Royal Brompton hospital. 
The REC study number was 13/LO/0481. All patients gave full written informed consent for 
participation in this study. 
4.4.4 Statistics 
Differences between control and PH groups or those with high and low muscle strength were assessed 
using Student’s t-test or Mann-Whitney U test depending on the distribution of the data. Normality 
was assessed using the Kolmogorov-Smirov, D’Agostino and Pearson test and the Shapiro-Wilk test as 
  
141 
  
well as visually using histograms. Correlations were assessed using Pearson or Spearman analysis 
depending on the linearity of the association of the data sets. ROC curve analysis was used to define 
the ability of GDF-15 to predict patients with preserved muscle strength defined by a QMVC/BMI > 
1.5.   
4.5 Results  
4.5.1 The MCT rat is a model of PH and muscle loss 
Four weeks after a single injection of MCT, all the treated rats had developed PH. MCT rats had a 
higher RV/LV+S weight ratio when compared to controls (Figure 4.1 A) and, in those that had cardiac 
catheter data available , right ventricular systolic pressure was also raised (Figure 4.1 B). MRI revealed 
a number of abnormalities in the MCT group when compared to controls (n=3). These changes include 
right ventricular hypertrophy and dilation as well as bowing of the septum in systole (Figure 4.1 C). At 
4 weeks the MCT rats weighed less, (Figure 4.2 A) had grown less (Figure 4.2 B) and, on average, had 
eaten less (Figure 4.2 C) than their control counterparts. Both TA (predominantly fast twitch) and 
soleus (predominantly slow twitch) muscle weight was lower in MCT compared to control treated rats 
(Figure 4.2 D and E). MRI of the hind limb of the animals (n=3) showed a general reduction in muscle 
bulk in the MCT animals compared to controls (Figure 4.3). In view of evidence from previous studies 
suggesting that the atrophy in the skeletal muscle of the MCT rat is type II fibre specific, the fibre 
diameter of the type II fibre rich TA was analysed. The mean fibre diameter of the TA was lower in the 
MCT rat when compared to controls (Figure 4.4 A and B).  
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Figure 4.1 The monocrotaline (MCT) rat is a model of pulmonary hypertension. A. Right Ventricular / Left 
Ventricular + Septal (RV/LV+S) weight in control (n=14) and MCT (n=16) rats (student’s t-test p < 0.001). B. Right 
ventricular systolic pressure in mmHg in control (n=14) and MCT (n=12) rats (Mann Whitney U test p = 0.009).  
C. Representative four chamber and sagittal magnetic resonance image views of control (n=3) and MCT (n=3) 
rat heart in systole demonstrating a thickened and dilated right ventricle and bowing of the interventricular 
septum. 
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Figure 4.2 Growth, body weight, muscle weight and food intake in the monocrotaline (MCT) rat. A. Final weight 
in grams (g) in control (n=14) or MCT (n=16) rats (student’s t-test p < 0.001). B. Change in weight in grams (g) in 
control (n=14) or MCT (n=16) rats (student’s t-test p < 0.001). C. Average food intake per animal in control (n=13) 
or MCT (n=15) rats (Mann Whitney U test p < 0.001). D. Tibialis anterior (TA) muscle (predominantly fast twitch) 
weight in grams (g) in control (n=14) or MCT (n=16) rats (student’s t-test p < 0.001). E. Soleus muscle 
(predominantly slow twitch) weight in grams (g) in control (n=13) or MCT (n=15) (Mann Whitney U test p < 
0.001).  
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Figure 4.3 MRI imaging of the hind limb of the monocrotaline (MCT) rat. Representative  cross sectional  MRI 
showing the muscle bulk of the hind limb  of control and MCT rats taken through the femur before and after 
control or MCT injection (n=3).    
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 Figure 4.4 Tibialis fibre diameter in the monocrotaline (MCT) rat.  A. TA fibre diameter in micrometres (μm) in 
control (n=12) or MCT (n=11) rats (student’s t-test p < 0.001). B. Representative bright-field image of rat muscle 
tissue stained with haematoxylin and eosin from which average fibre diameter was determined by Image J.  
 
4.5.2 TGFβ super-family member expression in the muscle and blood in the MCT rat 
mRNA expression of a number of TGFβ ligands was analysed in the TA of the MCT rat. There was 
no difference in the expression levels of TGFβ1 (Figure 4.5 A) or GDF-15 (Figure 4.5 B) between 
MCT and control treated animals. There was, however, a significant increase in GDF-8 expression 
within the TA of the MCT rat compared to controls (Figure 4.5 C). Next, serum levels of GDF-15 
were analysed. GDF-15 levels were raised in the serum of MCT rats when compared to controls 
(Figure 4.6 A). GDF-15 protein levels were undetectable in the TA of the MCT rat, by this same 
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ELISA (data not shown). Across both MCT and control rats, circulating GDF-15 levels were 
negatively correlated with final animal weight TA weight and TA fibre diameter (Figure 4.6 B, C 
and D). 
 
Figure 4.5 TGFβ super-family member mRNA expression in the muscle of the monocrotaline (MCT) rat. A. 
log TGFβ1 mRNA expression in the TA of control (n=14) and MCT (n=16) treated rats (Mann Whitney U test 
p = 0.190). B. log GDF-15 mRNA expression in the TA of control (n=14) and MCT (n=16) treated rats (Mann 
Whitney U test p = 0.575). C. log GDF-8 mRNA expression in the TA of control (n=14) and MCT (n=16) treated 
rats (Mann Whitney U test p = 0.026). 
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Figure 4.6 Circulating GDF-15 and muscle loss in the monocrotaline (MCT) rat A. GDF-15 levels in the serum 
of control (n=13) and MCT (n=14) treated rats (Student’s t-test p = 0.008). B. Serum GDF-15 levels plotted 
against final animal weight in control (n=13) and MCT (n=14) treated rats. C. Serum GDF-15 levels plotted 
against tibialis anterior (TA) weight in control (n=13) and MCT (n=14) treated rats. D. Serum GDF-15 levels 
plotted against TA fibre diameter in control (n=11) and MCT (n=11) treated rats. 
 
4.5.3 The pulmonary vasculature is a source of circulating GDF-15 in the MCT rat 
qPCR revealed a significant increase in expression of GDF-15 mRNA in the lungs of the MCT rat 
compared to control (Figure 4.7 A). GDF-15 mRNA levels correlated with serum levels of the 
protein suggesting that the lung is an important source of GDF-15 production in this model (Figure 
4.7 B).  ELISA also showed an increase in GDF-15 protein expression in lung homogenates from 
MCT rats when compared to controls (Figure 4.7 C). Immunohistochemistry revealed that GDF-15 
production was localised in the pulmonary vasculature and particularly in the endothelial and to 
a lesser extent the smooth muscle cell layer of the vessels (Figure 4.8).  
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Figure 4.7 GDF-15 mRNA and protein in the lung of the MCT rat. A. GDF-15 mRNA expression in the lung of 
control (n=14) and MCT (n=16) treated rats (Student’s t-test p = 0.017) B. Serum GDF-15 levels plotted against 
GDF-15 mRNA expression in the lung of control (n=13) and MCT (n=14) treated rats. C. GDF-15 protein 
expression normalised to loading 100 μg of protein in the lung of control (n=5) and MCT (n=5) treated rats 
(Mann-Whitney U test p = 0.032). 
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Figure 4.8. GDF-15 in the pulmonary vasculature of the monocrotaline (MCT) rat. GDF-15 produced in the 
pulmonary vasculature Representative immunohistochemistry of lung sections showing large and small 
pulmonary arteries stained for GDF-15 or Smooth muscle actin (SMA) in  control (n=5) and MCT treated rats 
(n=5). 
 
4.5.4 Sugen/hypoxia mice develop PAH and associated muscle loss 
Sugen/hypoxia treated animals had a median RVSP of 38 (36, 42) mmHg and RV/LV+S weight of 0.36 
(0.38, 0.43), whilst hypoxia treated animals had a median RVSP of 36 (30, 42) and a median RV/LV+S 
weight of 0.43 (0.27, 0.53). The Sugen/hypoxia treated mouse TA weighed less than that of control 
animals (Figure 4.9 A). The Sugen/hypoxia mice also had significantly smaller TA fibre diameters than 
the normoxic mice (Figures 4.9 B and C). Hypoxic mice had intermediate TA weights and TA fibre 
diameters that did not differ statistical from either the normoxic of Sugen/hypoxia mouse groups 
(Figures 4.9 A-C). 
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Figure 4.9. Tibialis anterior (TA) weight and fibre diameter in Normoxic, Hypoxic and Sugen/hypoxia mouse. 
A. TA weight in grams (g) in normoxic (n=5), hypoxic (n=5) or Sugen/hypoxia (n=5) mice (Kruskall-Wallace with 
Dunn’s correction p = 0.017) B. TA fibre diameter in micrometres (μm) in normoxic (n=5), hypoxic (n=5) or 
Sugen/hypoxia (n=5) mice (Kruskall-Wallace with Dunn’s correction p = 0.023). C. Representative bright-field 
image of rat muscle tissue stained with haematoxylin and eosin from which average fibre diameter was 
determined by Image J.  
 
4.5.5 GDF-15 and other TGFβ super-family members in the muscle and circulation of the 
Sugen/hypoxia mouse 
GDF-15 levels were significantly raised in the plasma of the Sugen/hypoxia mice when compared to 
both normoxic controls and to hypoxic mice (Figure 4.10 A). Plasma GDF-15 levels correlated 
significantly with TA weight and non-linearly with TA fibre diameter in this model (Figures 4.10 B and 
C). Further analysis of the muscle was limited to the Sugen/hypoxia and normoxia mice as a model of 
GDF-15 induced wasting. There was no difference in TA mRNA expression of TGβ1, GDF-15 or GDF-8 
between normoxic and Sugen/hypoxia treated animals (Figures 4.11 A – C).  
  
151 
  
 
Figure 4.10 Circulating GDF-15 and muscle loss in the Sugen/hypoxia mouse. A. Plasma GDF-15 levels were 
higher in the Sugen/hypoxia mouse than in mice held in normoxic or hypoxic conditions (Kruskall-Wallace with 
Dunn’s correction p = 0.009, control (n=5), hypoxic (n=5) and Sugen/hypoxia (n=5)). B. Plasma GDF-15 levels 
plotted against TA weight in grams (g) in control (n=5), hypoxic (n=5) and Sugen/hypoxia (n=5) treated mice. C. 
Plasma GDF-15 levels plotted against TA fibre diameter in control (n=5), hypoxic (n=5) and Sugen/hypoxia (n=5) 
treated mice.  
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Figure 4.11 TGFβ super-family member mRNA expression in the muscle of the Sugen/hypoxia mouse A. log 
TGFβ1 mRNA expression in the TA of normoxic (n=5) and Sugen/hypoxia (n=5) treated mice (Mann Whitney U 
test p = 0.691). B. log GDF-15 mRNA expression in the TA of normoxic (n=5) and Sugen/hypoxia (n=5) treated 
mice (Mann Whitney U test p = 0.547). C. log GDF-8 mRNA expression in the TA of control (n=4) and MCT (n=5) 
treated rats (Mann Whitney U test p = 0.905). 
 
4.5.7 The Sugen/hypoxia mouse also over-expresses GDF-15 in the lung 
Analysis of lung tissue by qPCR revealed an increase in mRNA expression of GDF-15 in the 
Sugen/hypoxia model of PH compared to normoxic controls. Again there was intermediate expression 
of GDF-15 in the lung of the hypoxia treated mice that did not differ from either other group (Figure 
4.12A). Lung GDF-15 mRNA expression correlated significantly, but non-linearly with plasma GDF-15 
levels in this model (Figure 4.12B).   
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Figure 4.12 GDF-15 mRNA expression in the lung of the Sugen/hypoxia mouse. A. log GDF-15 mRNA expression 
in the lung of control (n=5), hypoxia (n=5) and Sugen/hypoxia (n=5) (Kruskall-Wallace with Dunn’s correction p 
= 0.042) B. Serum GDF-15 levels plotted against GDF-15 mRNA expression in the lung of control (n=5), hypoxia 
(n=5) and Sugen/hypoxia (n=5) mice. 
 
4.5.8 Circulating GDF-15 is negatively correlated with physical activity, muscle strength and size in 
patients with PAH 
The demographics of thirty patients with concurrently measured muscle size, strength, physical 
activity, echocardiogram, BNP and GDF-15 are shown in Table 4.1. In this group of patients, at 
various points in their treatment course, median plasma GDF-15 was 862 (459, 1635) pg/ml. 
Plasma GDF-15 correlated with general markers of severity in PAH including 6MWD (Pearson r = 
-0.45, p = 0.013) and plasma BNP levels (Pearson r = 0.52, p = 0.003). GDF-15 also correlated 
linearly with USRFCSA and PAL and non-linearly with QMVC/BMI Figure (4.13 A-C). GDF-15 plasma 
levels were significantly lower in those patients with preserved muscle strength defined as a 
QMVC/BMI of > 1.5 (Figure 4.13 D). This cut off was associated with a lower risk of admission to 
hospital (see Chapter 3). A ROC curve for GDF-15 plasma levels predicting those with preserved 
muscle mass had an AUC of 0.74 (p = 0.035). The most useful cut-off was a GDF-15 concentration 
of < 564 pg/ml and had an 80 (44 - 97) % sensitivity and 84 (62 - 97) % specificity in identifying 
those patients with preserved muscle strength (Figure 4.13 E). 
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Demographics n = 30 
Age 46.8 (± 13.9) years 
Female 20 
Height 167 (± 8) cm 
Weight 67.3 (58.8 - 77.7) kg 
Diagnosis 
 
IPAH 23 
Congenital heart disease 7 
Echocardiogram 
 
RVSP 88.5 (± 26.8) mmHg 
TAPSE 1.9 (1.5, 2.1) mm 
TR velocity 408 (± 84) cm/sec 
PAcT 83.8 (± 26.5) msec 
Exercise, WHO, BNP 
 
6MWD 373 (± 126) m 
WHO I : II : III 3 : 19 : 8 
BNP 131 (44, 271) pmol/L 
Table 4.1 Demographics. Demographic details of 30 patients with pulmonary arterial hypertension investigated 
for circulating growth and differentiation factor 15 (GDF-15) levels and muscle loss. World health organisation 
functional status (WHO), Idiopathic pulmonary arterial hypertension (IPAH), Right ventricular systolic pressure 
(RVSP) measured by echocardiogram (echo),  tricuspid anterior posterior systolic excursion (TAPSE), tricuspid 
regurgitant (TR) velocity, pulmonary artery acceleration time (PAcT), Six minute walk distance (6MWD), plasma 
brain natriuretic peptide (BNP). 
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Figure 4.13 Circulating GDF-15, muscle wasting and physical activity in patients with PAH. A. Quadriceps 
maximal volitional capacity (QMVC) / Body mass index (BMI) plotted against plasma GDF-15 levels in 30 patients 
with PAH. B. Ultrasound measured rectus femoris cross sectional area (USRFCSA) plotted against plasma GDF-15 
levels in 30 patients with PAH C. SWA measured physical activity level (PAL) plotted against plasma GDF-15 levels 
in 25 patients with PAH. D. GDF-15 levels in patients with high and low muscle strength defined by a QMVC/BMI 
of < or > 1.5 (Mann-Whitney U test p = 0.037). E. ROC curve of GDF-15’s ability to predict those with a QMVC < 
1.5 or > 1.5 (AUC 0.74, p = 0.036). 
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4.6 Discussion 
In these experiments I have shown that circulating GDF-15 levels are associated with muscle loss in 2 
animal models of PH and that in patients with PAH, GDF-15 is negatively associated with lower limb 
muscle function and size.  These data suggest that GDF-15 could be used as a biomarker of muscle loss 
in PAH. Consistent with this suggestion, we have shown that GDF-15 levels less than 564 pg/ml are 
indicative of a clinically significant preservation of proportional strength. My data also suggests that 
the pulmonary vasculature is a major source of circulating GDF-15 in animal models of PH, thereby 
linking the primary disease to the muscle wasting. Other novel findings include: that the addition of 
Sugen to hypoxia was required to stimulate a rise in circulating GDF-15 levels in the mouse models of 
PH and that TA GDF-8 mRNA production is raised in the MCT treated rat compared to controls and 
may therefore contribute to muscle wasting in this model. 
MCT treatment of rats is a well-established model for studying skeletal muscle atrophy in 
association with heart failure and PH.  The observation of reduced TA and soleus weight in 
association with increased pulmonary artery pressures is consistent with these earlier studies 
(132).  Previous studies have also shown that after 3 weeks Sugen/hypoxia treated mice exhibited 
weight loss (452) and similar diaphragm changes to those seen in the MCT rat model (162). Here 
we show for the first time a loss of TA muscle weight and fibre diameter in this model of PH, which 
mimics the changes seen in the MCT rat.  
Circulating GDF-15 has been shown to be raised in patients with PAH when compared to controls. 
It is also a recognised marker of prognosis (207). This is the first work to show GDF-15 levels are 
raised in the serum or plasma of the both the MCT rat and Sugen/hypoxia mouse.  Circulating 
GDF-15 has been identified as a biomarker and potential regulator of muscle wasting in a number 
of conditions including in COPD (453) as well as in elderly women, where circulating GDF-15 was 
significantly negatively correlated with handgrip strength (263). The results presented here 
confirm this association in patients with PAH. They also show that GDF-15 levels are reduced in 
patients with preserved QMVC/BMI of > 1.5, which has been associated with a lower risk of 
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hospitalisation (see Chapter 3). Furthermore I have demonstrated that physical activity level, 
measured by the SWA, were associated with circulating GDF-15 levels. Physical activity has rarely 
been studied alongside GDF-15 levels. Transgenic and knockout mice data have yielded conflicting 
results (260, 270, 271, 273), whilst a study in patients with ischaemic heart disease showed that 
6 months of rehabilitation after coronary artery stenting had no effect on GDF-15 levels (257).  
Further data is needed to establish the usefulness of GDF-15 as a clinical or research biomarker of 
muscle loss. Future work should therefore focus on demonstrating how GDF-15 responds to a 
variety of treatments aimed both at the primary disease as well as muscle wasting itself.  
Studies in ICU acquired weakness have shown an increase in GDF-15 expression in the quadriceps, 
raising the possibility of an autocrine or paracrine effect of the protein on muscle mass (265). 
Recently it has been demonstrated that GDF-8 can exert its negative effect on muscle mass 
through autocrine, paracrine and endocrine mechanisms (182).  In this study there was no change 
in GDF-15 expression in the TA of the MCT rat or Sugen/hypoxia mouse indicating that elevated 
circulating GDF-15 was derived from another tissue. Previous studies have shown that GDF-15 is 
expressed in the vascular endothelium and plexiform lesions in the lung of patients with PAH 
(283).  We found that GDF-15 was over-expressed in the lung of MCT treated rats. GDF-15 was 
predominantly associated with the vascular endothelium but also to a lesser extent with the 
pulmonary artery smooth muscle cells in this MCT model of PH.  Furthermore mRNA expression 
of GDF-15 was strongly correlated with circulating GDF-15 protein levels suggesting that the lung 
is a major source of GDF-15 in this animal model. Whether there is a local increase in GDF-15 
expression in the skeletal muscle of patients with PAH remains to be determined, but the 
association of muscle mass with circulating GDF-15 in both the animal models and in patients 
strongly implies that the protein can act in an endocrine fashion. Our hypothesis is supported by 
recent work showing GDF-15 secreting tumours can cause muscle loss that is antagonised by a 
GDF-15 neutralising antibody (269).  
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Our data has implications outside PAH. GDF-15 has been identified as a marker of all-cause 
mortality in a wide range of different conditions including cardiovascular disease, cancer, renal 
failure and even a healthy elderly population (454). Sarcopaenia and cachexia are also almost 
universally associated with increased risk of morbidity and mortality across all disease states (455) 
suggesting that our data showing an association of GDF-15 and muscle may be more generalizable 
to all chronic diseases. 
GDF-15 is known to be a stress response protein produced by a number of different stimuli including 
but not limited to inflammation, UV light and hypoxia (227). This study also demonstrated that after 
3 weeks of hypoxia there was no significant increase in GDF-15 in the mouse model of pulmonary 
hypertension. This was in contrast to the Sugen/hypoxia mouse, which did exhibit raised circulating 
levels of GDF-15. It can therefore be concluded that SU5416 is required to stimulate GDF-15 secretion 
into the circulation in this model. Whether SU5416 alone is enough to stimulate GDF-15 production 
has not been tested. Whether hypoxic mice get an initial rise in circulating GDF-15 that then falls back 
to normal has, again, not been addressed by this work. SU5416 is a vascular endothelial growth factor 
antagonist, which causes greater increases in PH in mice over hypoxia alone (452). The interaction of 
VEGF and GDF-15 has been examined in a small number of studies. GDF-15 was shown to be important 
for increasing VEGF expression by HIF1α in HUVEC cells (284) and is responsible for a VEGF type neo-
vascularisation response in malignant melanoma tumours (456). GDF-15 is known to prevent 
apoptosis in HPMECs (283) and VEGF inhibition in hypoxic rats leads to general endothelial cell 
apoptosis but also to emergence of a pool of apoptosis resistant endothelial cells (457). It may be that 
GDF-15 is produced in response to hypoxia in both hypoxia and Sugen/hypoxia mouse endothelium 
but is downregulated when its target, VEGF, is elevated in the hypoxic mouse, due to the adaptive 
effects of neo-vascularisation. The lack of VEGF response in SU5416 treated mice and subsequent 
unchecked GDF-15 in this model may contribute to the excess pulmonary hypertension seen in this 
model.  
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GDF-8 has been identified as a major negative regulator of muscle mass. It is known to activate both 
SMAD and non-SMAD pathways (458). Circulating levels of the protein have been shown to be raised 
i11n the MCT rat (153).  We have shown that GDF-8 expression is raised in the TA of the MCT rat. 
Being a TGFβ super-family member means that GDF-8 is likely to activate some of the same pathways 
as GDF-15. This highlights the potential difficulty in attempting to antagonise only one molecule in a 
system with so much redundancy and is one of the reasons why GDF-8 antagonists may failed to have 
significant clinical effects in large studies (459). It is therefore important to identify common 
downstream points that are activated by a number of different pathways. These can then be targeted 
to improve clinical outcomes. 
4.7 Limitations 
The main limitation of these studies is the small sample size. This is especially true for the mouse 
model of PH. Despite this, GDF-15 levels in the circulation were consistently associated with muscle 
wasting in these models. We have limited biopsy data in patients with PAH and therefore it is not clear 
whether the models we used accurately represent what is going on in the muscle and pulmonary 
circulation of patients. GDF-15 has been linked to muscle wasting directly (453) through pro-atrophic 
processes and through appetite suppression (260). The MCT rat did eat less than its control 
counterparts meaning we cannot exclude nutrition as a contributing cause of loss of muscle mass in 
this model. Finally, although we found an excess of GDF-15 in the pulmonary vascular endothelium of 
the MCT rat, other tissues as a source of significant GDF-15 production in these models cannot be 
ruled out. 
4.8 Conclusions 
Circulating GDF-15, a major source of which is likely to be the pulmonary vascular endothelium, is 
associated with muscle wasting in 2 animal models and in patients with PAH.  Low GDF-15 levels may 
be used as a biomarker of preserved muscle mass in this population. 
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Chapter 5 GDF-15 causes muscle atrophy in vitro through actions on TAK1 
5.1 Background 
GDF-15 is secreted as a 25kda protein. It is considered to be the first and only member of a sub-group 
of TGFβ super-family of cytokines due to its lack of structural homology to any other family members. 
GDF-15 has generally low expression levels during periods without cellular stress, but on stimulation 
by hypoxia, inflammation, short wavelength light exposure, tissue injury and cancer progression levels 
can substantially increase (227). The role of GDF-15 in health and disease remains to be fully 
elucidated. GDF-15 has been found to be expressed in high levels: in the placenta suggesting it may 
have a role in pregnancy and embryonic development (220); in seminal fluid, suggesting it has a role 
in fertility (231); and in macrophages where it  exerts anti-inflammatory effects (219).  Studies defining 
the role of GDF-15 in neurological, cardiac, and cancerous tissue both in vitro and in vivo have 
produced varied and contrasting results (237-239, 258). 
 Our group has previously shown that addition of GDF-15 to differentiated myotubes causes atrophy 
(218), possibly through an increase in expression of ubiquitin ligases atrogin-1 and MuRF-1 (265).We 
have also demonstrated that over-expression of GDF-15 in the TA of mice through electroporation 
causes muscle fibre atrophy (460). 
Generally, TGFβ super-family member proteins are secreted and stored in the extracellular matrix as 
inactive pro-peptides which are cleaved by proteases to adopt their active form, which then bind to 
their target receptors (183). The receptors are classed as type 1 and 2 (184). The ligand binds to its 
receptor which forms a hetero-tetrameric complex consisting of 2 type 1 and 2 type 2 receptors (185). 
The type 2 receptor is a constitutively active serine threonine kinase which is able to phosphorylate 
the type 1 receptor (184), which, in turn, phosphorylates intracellular SMAD molecules (186). The 
TGFβ / activin ligands tend to activate SMAD 2 and 3, whilst BMPs activate SMAD 1, 5, 8 but there is 
significant overlap within the system (187). These SMADs combine with the co-SMAD, SMAD 4, which 
translocates them to the nucleus to stimulate gene transcription (188). All SMADs recognise the 
binding site CAGAC whilst SMADs 1 and 5 have higher affinity for GC rich areas of DNA (179).  Despite 
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nearly 40 TGFβ ligands being identified, there are only 5 type 2 receptors and 7 type 1 receptors 
meaning that most ligands can bind to different combinations of receptors with different affinities, 
altering the consequences for downstream signalling (178). As well as classical SMAD signalling, it has 
been established that TGFβ super-family members can interact directly and indirectly with a number 
of other pathways.  Particularly important pathways include the TAK, Iκκ-β, NFκB axis (190) p38 MAPK 
(191), ERK 1 and 2 (192), JNK (193) and PI3 kinase - AKT(194). These non-canonical pathways are often 
involved in antagonising or augmenting the effects of classical SMAD signalling, suggesting that, by 
activation of a number of competing pathways, the TGFβ super-family can fine tune its effects in a 
cell, time and environment dependent manner (178, 179).     
The signalling pathways activated by GDF-15 are still under investigation. The receptor through which 
GDF-15 acts is unclear. In neural tissue, very recently, it has been established that GDF-15 acts through 
the GFRAL to regulate appetite (292-294, 296). This receptor is not present in skeletal muscle (295).  
Some data shows that in some cells, at least, the TGFBR2 and ALK-5 receptors are required for GDF-
15 activity (288, 301), whilst others have shown that GDF-15’s activity is independent of TGFBR2 (243, 
260) and ALK-5 (243, 289, 460). Other TGFβ receptors implicated in GDF-15 response include ALK1, 
(291) ALK4, 6 or 7 (290). GDF-8, the archetypal TGFβ super-family member involved in muscle wasting, 
acts through the ACVR2B (73). The affinity of GDF-15 for this receptor has not been investigated. 
Some authors have shown that stimulation with GDF-15 can result in the activation of SMAD 2, 3 (235, 
290, 297), whilst others have shown that SMAD 1, 5, 8 (238, 291, 300) are involved, both through 
western blot and luciferase assay. Others still have shown no SMAD activation in response to GDF-15 
(260, 299), with some finding that GDF-15 actually caused a reduction in a TGFβ1 mediated SMAD 
response (298).  
Similar findings of a cell type, context and dose dependant response to GDF-15 are applicable to non-
canonical pathways. Most researchers have shown that GDF-15 increases the phosphorylation of ERK 
and AKT in a number of different cell lines (238, 243, 245, 294, 304, 308, 315). However this is not a 
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universal phenomenon (313). Data regarding P38-MAPK phosphorylation is less clear with some 
showing an upregulation (303, 304, 314, 315) and other showing a downregulation in the signal (312, 
317). The effect of GDF-15 on the TAK1, IKK, NFκB axis has also yielded conflicting results. In HCT-8 
intestinal epithelial cells, infection with enteropathic E-coli caused an up-regulation of GDF-15.  
Recombinant GDF-15 was also able to directly stimulate TAK1 phosphorylation in these cells. 
Furthermore enteropathic E-coli effects on TAK1 were shown to be GDF-15 dependant, whilst 
enteropathic E-coli effects on NFκB were inhibited in the presence of the TAK1i 5(Z)-7-oxozeaenol 
(318). Similar results were generated in HCT-116 colorectal cancer cells where enteropathic E-coli 
infection caused GDF-15 dependent TAK1 activation and TAK1 dependent increases in RhoA protein 
levels with an increase in cell detachment and possible migration (319). In contrast in human umbilical 
vein endothelial cells GDF-15 knockout seemed to have an enhancing effect on glucose mediated NFκB 
activation (316).   
5.2 Aims   
To define the pathway through which GDF-15 might cause muscle wasting in vitro with a view to 
antagonising its effects.  
 5.3 Hypotheses 
GDF-15 acts through the TGFBR2 and a non-canonical pathway in C2C12 cells. Antagonising this 
pathway will prevent GDF-15 mediated myotube atrophy in vitro. 
5.4 Methods 
For a full explanation of the methods please see Chapter 2 of this thesis 
5.4.1 C2C12 cells 
C2C12 myoblast DMEM with 10% foetal calf serum were seeded in 96, 24, 12 or 6 well plates. Some 
cells were transfected with various receptors, luciferase reporters and or pCAGGs-EGFP. Some cells 
for western blot, qPCR and myotube diameter studies were differentiated into myotubes for 10 days. 
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This was achieved by incubating myoblasts in DMEM supplemented with 2% horse serum. Cells were 
then treated at various concentrations of: GDF-15, TAK1i (5Z)-7-oxozeaenol and or the ALK-5 inhibitor 
SB431542 (408).  For some experiments cells were co-treated with GDF-15 and TGFβ1 or pre-treated 
with GDF-15 for 48 hours and then co-treated with GDF-15 and TGFβ1 and / or BMP-4. TGFβ1, GDF-8, 
BMP-4 and TNFα were used as positive controls. 
5.4.2 Animal experiments 
The details of experiments for the MCT rat and Sugen/hypoxia mouse are documented in Chapter 2 
and 4.  
5.4.3 Human Samples 
A small subset of PAH patients from the clinical study detailed in Chapter 3 underwent muscle biopsy 
by the Bergstrom technique detailed in Chapter 2. (265).   
5.4.4 Cloning  
5.4.4.1 Truncated TGFBR2 (TTGFBR2)  
A TTGFBR2 was constructed with an active extracellular domain but only a short intracellular tail 
lacking the kinase domain meaning it was capable of binding TGFβ super-family members but not able 
to partake in intracellular signal transduction. The extracellular and trans-membrane portion of the 
TGFBR2 was identified. Primers were designed to isolate this portion, PCR, and cloning techniques 
were then used to drop the TTGFBR2 sequence into the pCDNA3 expression vector. 
5.4.4.2 BMP responsive element BRE  
A SMAD 1, 5 BRE binding element was cloned into pGL4luc vector using the technique described by 
Korchynskyi et al.(409). 
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5.4.4.3 pRL-TK without BRE 
A BMP responsive element in the promoter region of the pRL-TK vector was removed using restriction 
digests, T4 DNA polymerase and relegation of blunt ends. 
5.4.5 Luciferase experiments 
5.4.5.1 Transfection 
Cells were transfected with a SMAD 2, 3 dependent (CAGA12) luciferase reporter or a SMAD 1, 5 
dependent (BRE) luciferase reporter and pRL-TK or pR-LTK without BRE luciferase reporter. In 
experiments involving the interaction between TGFβ super-family members and receptors, cells were 
also transfected with a combination pCDNA3 with or without TGFBR2, ACVR2B, BMPR2 or a TTGFBR2 
vector. Cells were treated with GDF-15, TGF-1, GDF-8 or BMP4. 
5.4.5.2 Luciferase Activity  
Luciferase activity was determined using a dual luciferase reporting system (Promega, Wisconsin, USA) 
and Luminark plate reader according to manufacturer’s instructions. CAGA12 or BRE dependent 
luminescence was divided by pRLTK luminescence.  
5.4.6 Myotube Diameter 
Cells were seeded in 6 well plates. The next day they were transfected as above with pCAGGS-EGFP 
with or without pCDNA3 or TTGBFR2. The next day cells were differentiated as above. After 10 days 
cells were treated with GDF-15 with or without 5(Z)-7-oxozeaenol or control. At 48 hours myotubes 
were visualized using a Fluorescent microscope at 10x magnification. Twenty representative images 
were taken at random from each of the 6 wells and myotubes identified by identifying multinucleated 
cells. Only myotubes transfected with pCAGGS-EGFP were included. Using Image J the average of 5 
discreet measurements were taken across the length of the myotube to estimate its diameter (218).      
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5.4.7 Western blotting  
Transfected and un-transfected myoblasts and myotubes were treated with GDF-15, TGFβ1 or TNFα 
at a number of different doses, with or without 5(Z)-7-oxozeaenol. Cells for phospho-protein analysis 
were serum starved overnight prior to treatment.  Cells, animal TA muscle and PAH patient and control 
muscle biopsies were lysed with CLB and PMSF. Protein content was analysed using Bradford reagent 
against a known set of standards. Samples were analysed a described in Chapter 2 and membranes 
were cut at 55KDa so that they could be interrogated for 2 different proteins on the same blot.  
Membranes were then incubated with primary antibody in BSA or milk overnight at 4oC. Blots were 
then washed with 0.05% TBS-T and incubated with secondary antibody conjugated with horseradish 
peroxidase for 1 hour at room temperature. They were washed again and exposed to Pierce enhanced 
chemiluminecence (ECL) detection reagent and imaged on an Ettan dige-imager (EDI) or with 
radiographic film using a photo-developer. Blots were then analysed by densitometry using Image J 
software.  
5.4.8 Quantitative real time polymerase chain reaction (qPCR) 
qPCR was carried out as previously described using primers detailed in Chapter 2 (265). Samples from 
myoblasts and myotubes treated with GDF-15,   5(Z)-7-oxozeaenol, SB431542 or vehicle control and 
TA samples from animal experiments were analysed using primers listed below. All mRNA levels were 
normalised to levels of housekeeping genes RPLPO and GAPDH within the samples. 
5.4.9 Immunofluorescence 
Myoblasts were serum starved overnight and then treated with GDF-15, TNFα or vehicle control or 
transfected with TGFBR2 or ACVR2B. Cells were then fixed in 4% PFA and lysed with 1% triton. Cells 
were then blocked for in 5% milk before being incubated in PBS-T with 5% milk containing with 
antibodies listed in Chapter 2 overnight at 4oC.  Cells were again washed in PBS-T and then incubated 
in secondary antibody and then in DAPI. Cells were washed and stored in PBS and were then imaged 
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on a widefield fluorescent microscope at 10x magnification, using filters set at to pick up green, red 
and blue light. Images were analysed using Image J software to calculate relative nuclear fluorescence.      
5.4.10 Statistics 
Results were expressed as mean and standard error of the mean or median and range dependant on 
the distribution of the data, which was assessed by Kolmogorov-Smirov, D’Agostino and Pearson test 
and the Shapiro-Wilk test normality tests as well as visually using histograms. Student’s t-test with or 
without Welch’s correction or Mann-Whitney U test were used to compare differences between 2 
groups.  When more than one group was to be compared a one way or repeated measures ANOVA 
with Bonferroni correction or Kruskall-Wallace with Dunn’s correction was used. Repeated measures 
ANOVA was specifically employed for the analysis of time course experiments where a single passage 
of cells was treated with the same dose of GDF-15 for differing times on the same day. Where the 
above analyses were not possible due to lack of variability in the control samples a one sample t-test 
or a Wilcoxon signed rank test was used. 
5.5 Results 
5.5.1 In myoblasts GDF-15 does not stimulate SMAD 2, 3 and decreases SMAD 1, 5 response 
GDF-15 caused no change in SMAD 2, 3 dependent luciferase activity at high or low dose when 
compared to control. In fact at 5 ng/ml there was a trend to a decrease in SMAD 2, 3 dependent 
luciferase activity (Figures 5.1 A and B).  As a positive control TGFβ1 caused a significant increase in 
SMAD 2, 3 dependent luciferase activity at very low dose, down to 0.1 ng/ml (Figure 5.1C). GDF-15 
also caused no significant change in SMAD 1, 5 dependent luciferase activity in myoblasts treated with 
5 or at 50 ng/ml of GDF-15 for 24 hours. BMP-4 at 10 ng/ml acted as a positive control (Figure 5.2 A, 
B and C). 
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Figure 5.1 SMAD 2, 3 dependent luciferase activity in C2C12 myoblasts treated with growth and differentiation 
15 (GDF-15). A. GDF-15 at 5ng/ml for 6 hours (n = 7) (One sample t test p = 0.118). B. GDF-15 at 50ng/ml for 6 
hours (n = 7) (One sample t test p = 0.416). C. Transforming growth factor β 1 (TGFβ1) at a number of different 
doses for 6 hours (n=3) (One way ANOVA p = 0.018). 
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Figure 5.2. SMAD 1, 5 dependent luciferase activity in C2C12 myoblasts treated with growth and 
differentiation 15 (GDF-15). A. Growth and differentiation factor (GDF-15) at 5ng/ml for 24 hours (n = 4) 
(Wilcoxon signed rank test p = 0.875). B. GDF-15 at 50ng/ml for 24 hours (n = 14) (Wilcoxon signed rank test p = 
0.950).C. Bone morphogenetic protein 4 (BMP) at 10ng/ml for 24 hours as a positive control caused a significant 
increase in SMAD 1, 5 dependent luciferase response (n = 4) (One sample t-test p = 0.010). 
 
5.5.2 GDF-15 causes a significant increase in significant increase in SMAD 2, 3 dependent response 
in TGFBR2 over-expressing cells.  
Over-expression of the TGFBR2, the ACVR2B and the BMPR2  receptors was demonstrated using 
western blot (Figure 5.3 A - C) Over-expression of the TGFBR2 and ACVR2B was also shown using 
immunofluorescence (Figure 5.4 A  and B) (Negative controls are shown in appendix 5.1). 
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Figure 5.3. Western blot showing over-expression of receptors in C2C12 cells. A. pCDNA3 or the Transforming 
growth factor β receptor 2 (TGFBR2) probed with anti-TGFBR2 antibody with accompanying Ponceau S of the 
blot (n = 1); B. pCDNA3 or the Activin receptor 2B (ACVR2B) probed with anti-ACVR2B antibody with 
accompanying Ponceau S of the blot (n = 1); C. pCDNA3 or the Bone morphogenetic protein receptor 2 (BMPR2) 
probed with anti-BMPR2 antibody with accompanying Ponceau S of the blot (n = 1).   
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Figure 5.4. Immunofluorescence showing over-expression of receptors in C2C12 cells A. Immunofluorescence 
of cells over-expressing pCDNA3 or the Transforming growth factor β receptor 2 (TGFBR2) probed with anti-
TGFBR2 antibody and Alexa-Fluor 568 and DAPI (n = 1). B. Immunofluorescence of cells over-expressing pCNDA3 
or the Activin receptor 2B (ACVR2B) probed with anti-ACVR2B antibody and Alexa-Fluor 488 and DAPI (n = 1). 
 
Over-expression of the TGFBR2 caused a significant upregulation in SMAD 2, 3 and a significant 
reduction in SMAD 1, 5 dependent luciferase responses (Figure 5.5 A). Over-expression of the ACVR2B 
caused a significant reduction in SMAD 2, 3 response but a significant increase in SMAD 1, 5 luciferase 
response, whilst over-expression of the BMPR2 caused a significant increase in SMAD 1, 5 responses 
(Figures 5.5 A and B). Because SMAD 2, 3 responses to over-expression of the ACVR2B showed a 
downregulation in signal I attempted to prove that the ACVR2B that we overexpressed was functional 
by stimulating the cells with their natural ligand and known upstream mediator of SMAD 2,3 signalling, 
GDF-8. At 50ng/ml no  SMAD 2, 3 dependent luciferase activity was seen in pCDNA3 transfected cells 
but there was a significant increase in SMAD 2, 3 dependent luciferase activity in response to GDF-8 
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stimulation in the presence of the ACVR2B at this dose. At higher doses GDF-8 could stimulate SMAD 
2, 3 dependent luciferase activity in pCDNA3 transfected cells (Figure 5.5 C).   
 
Figure 5.5 Effect of receptor over-expression on SMAD 2, 3 and SMAD 1, 5 dependent luciferase activity in 
C2C12 cells. Difference in SMAD 2, 3 dependent luciferase activity in: A. pCDNA3 and TGFBR2 over-expressing 
C2C12 myoblasts (n = 9) (Wilcoxon signed rank test p = 0.008); B. pCDNA3 and ACVR2B over-expressing C2C12 
myoblasts (n = 4) (One sample t test p = 0.003) Difference in SMAD 1, 5 dependent luciferase activity in: C. 
pCDNA3 and TGFBR2 over-expressing C2C12 myoblasts (n = 4) (One sample t test p = 0.004); D. pCDNA3 and 
ACVR2B over-expressing C2C12 myoblasts (n = 4) (One sample t test p = 0.016); E. pCNDA3 and BMPR2 over-
expressing C2C12 myoblasts (n = 4) (One sample t test p = 0.015). F. SMAD 2, 3 dependent luciferase responses 
to GDF-8 treatment for 6 hours at 50 ng/ml and at 100 ng/ml in C2C12 myoblasts in pCDNA3 and ACVR2B 
transfected cells (n = 1).  
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GDF-15 at 50ng/ml caused no significant increase in SMAD 2, 3 dependent luciferase activity in 
pCDNA3 transfected cells. However, in cells over-expressing the TGFBR2, GDF-15 at 50ng/ml caused a 
significant increase in SMAD 2, 3 dependent luciferase activity (Figure 5.6 A). No similar change was 
seen in cells over-expressing the ACVR2B (Figures 5.6 B). When cells over-expressing the TGFBR2 were 
treated with low dose GDF-15 (5ng/ml) this effect on SMAD 2, 3 dependent luciferase activity was not 
seen (Figures 5.7). Over-expression of the TGFBR2, ACVR2B or BMPR2 and treatment with GDF-15 at 
50ng/ml resulted in a small but significant increase in SMAD 1, 5 dependent luciferase activity over 
that seen in pCDNA3 transfected GDF-15 treated cells (Figure 5.8 B). 
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Figure 5.6. SMAD 2, 3 dependent luciferase activity in C2C12 myoblasts over-expressing pCDNA3, TGFBR2, or 
ACVR2B treated with vehicle control or GDF-15 at 50 ng/ml for 6 hours. Results were normalised to luciferase 
activity of control treatment for each individual receptor. TGFβ1 at 2.5 ng/ml was used as a positive control A. 
GDF-15 resulted in a significant up-regulation in SMAD 2, 3 dependent luciferase dependent activity in TGFBR2 
over-expressing cells (n = 12) (One way ANOVA p < 0.001) B. GDF-15 caused no significant change in SMAD 2, 3 
dependent luciferase activity in cells transfected with the ACVR2B (n = 8) (Kruskall-Wallace p = 0.032, but no 
difference between the groups). 
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Figure 5.7. SMAD 2, 3 dependent luciferase activity in C2C12 myoblasts over-expressing pCDNA3 or TGFBR2 
with vehicle control or GDF-15 at 5 ng/ml for 6 hours. Results were normalised to luciferase activity of control 
treatment for each individual receptor. TGFβ1 at 2.5 ng/ml was used as a positive control. GDF-15 caused no 
significant change in SMAD 2, 3 dependent luciferase activity in TGFBR2 over-expressing cells when compared 
to GDF-15’s effects in pCDNA3 transfected cells (n = 3) (One way ANOVA p = 0.007, but no difference between 
PCDNA3 GDF-15 and TGFBR2 GDF-15).  
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Figure 5.8. SMAD 1, 5 dependent luciferase activity in C2C12 myoblasts over-expressing pCDNA3, TGFBR2, 
ACVR2B or BMPR2 treated with vehicle control or GDF-15 at 50 ng/ml for 24 hours. Results were then 
normalised to control treatment for each individual receptor. BMP4 at 10 ng/ml was used as a positive control 
A. GDF-15 caused a significant increase in SMAD 1, 5 dependent luciferase activity in TGFBR2 over-expressing 
cells (n = 3) (One way ANOVA p = 0.034). B. GDF-15 caused a significant increase in SMAD 1, 5 dependent 
luciferase activity in ACVR2B over-expressing cells (n = 3) (One way ANOVA p = 0.038). C. GDF-15 caused a 
significant increase in SMAD 1, 5 dependent luciferase activity in BMPR2 over-expressing cells (n = 3) (One way 
ANOVA p = 0.030). 
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5.5.3 In myoblasts longer term treatment with GDF-15 failed to alter TGFβ1 or BMP-4 dose 
responses 
We have previously shown that GDF-15 may augment TGFβ1 activity through actions on miR-181 
(265). The effects of GDF-15 on SMAD 2, 3 dependent luciferase activity in TGFβ1 treated cells and 
SMAD 1, 5 dependent luciferase activity in BMP-4 treated cells were therefore examined.  There was 
no difference in SMAD 2, 3 dependent luciferase responses to TGFβ1 in the presence or absence of 
co-treatment with GDF-15 (Figure 5.9 A and B). Cells were then pre-treated with GDF-15 (50ng/ml) for 
48 hours and then incubated for 6 hours with fresh GDF-15 with or without TGFβ1 or BMP4 at a 
number of doses. At the 54 hour time point mean SMAD 2, 3 dependent luciferase activity  was higher 
in response to GDF-15 alone but this difference did not reach statistical significance (Figure 5.9 C). 
There was no difference in the subsequent dose response curve to TGFβ1 in these pre-treated cells 
(Figure 5.9 D).  Similarly mean SMAD 1, 5 dependent luciferase activity was higher at 54 hours in GDF-
15 pre-treated cells (Figure 5.9 E) but did not reach statistical significance and no difference in SMAD 
1, 5 dependent responses to BMP-4  was observed with GDF-15 pre-treatment at any dose used 
(Figure 5.9 F). 
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Figure 5.9. SMAD 2, 3 and SMAD 1, 5 dependent luciferase activity in cells co-treated with GDF-15 and TGFβ1 
/ BMP-4. A. SMAD 2, 3 dependent luciferase activity in C2C12 myoblasts treated for 6 hours with various doses 
of TGFβ1 in the presence or absence of GDF-15 at 50 ng/ml. There was no difference in response between GDF-
15 and control treated cells (n = 3) (Two way ANOVA p = 0.515). B.  SMAD 2, 3 dependent luciferase activity in 
cells treated with GDF-15 at a number of doses for 6 hours in the presence of TGFβ1 at 2.5 ng/ml. There was 
no+ difference in response with GDF-15 at any dose (n = 4) (One way ANOVA p = 0.987). C. SMAD 2, 3 dependent 
luciferase activity in C2C12 myoblasts treated with GDF-15 at 50 ng/ml for 54 hours (n = 3) (One sample t test p 
= 0.285). D. SMAD 2, 3 dependent luciferase activity in cells pre-treated with GDF-15 at 50 ng/ml for 48 hours 
then co-treated with TGFβ1 at various doses and GDF-15 at 50 ng/ml for 6 hours, There was no difference in 
response between GDF-15 and control pre-treated cells (n = 3) (Two way ANOVA p = 0.485).  E. SMAD 1, 5 
dependent luciferase response in C2C12 myoblasts treated with GDF-15 at 50 ng/ml for 54 hours (n = 3) (One 
sample t test p = 0.079). F. SMAD 1, 5 dependent luciferase activity in cells pre-treated with GDF-15 at 50 ng/ml 
for 48 hours then co-treated with BMP4 at various doses and GDF-15 at 50 ng/ml for 6 hours, There was no 
difference in response between GDF-15 and control pre-treated cells (n = 3) (Two way ANOVA p = 0.431). 
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 5.5.4 A truncated TGFBR2 (TTGBFR2) failed to prevent GDF-15 mediated atrophy in myotubes. 
A truncated TGFBR2 expression vector was then cloned, which lacked part of the intra-cellular portion 
of the protein essential for signal propagation but still allowing ligand binding. When over-expressed* 
the TTGFBR2 reduced SMAD 2, 3 dependent luciferase activity when compared to pCDNA3 transfected 
cells (Figure 5.10 A). When examining the effects of the TTGFBR2 on the response to GDF-15, there 
was a significant increase in SMAD 2, 3 dependent luciferase responses to GDF-15 at 5ng/ml in 
TTGFBR2 over-expressing cells when compared to responses in pCDNA3 transfected cells (Figures 5.10 
B). There was no such change in cells over-expressing TTGFBR2 and treated with GDF-15 at 50ng/ml 
(Figure 5.10 C). GDF-15 (50 ng/ml) is known to cause a reduction in myotube diameter in 10 day 
differentiated myotubes (218). In pCAGGS-EGFP pCDNA3 transfected C2C12 cells, GDF-15 at high dose 
mean and relative myotube diameter was lower than in control treated cells, but this reduction did 
not meet statistical significance. This reduction in diameter was unaltered by over-expression of the 
TTGFBR2 (Figures 5.11 A - C).  
 
 
 
 
 
  
179 
  
 
Figure 5.10 SMAD 2, 3 dependent luciferase responses in TTGFBR2 over-expressing cells A. SMAD 2, 3 
dependent luciferase activity in pCDNA3 or TTGFBR2 transfected cells. TTGFBR2 caused a significant reduction 
in SMAD 2, 3 dependent luciferase activity when compared to pCDNA3 transfection in control treated cells (n = 
8) (One sample t test p < 0.001). B. SMAD 2, 3 dependent luciferase activity in pCDNA3 and TTGFBR2 over-
expressing cells treated with GDF-15 at 5 ng/ml for 6 hours. There was no a significant increase in GDF-15 
responses in TTGFBR2 over-expressing cells when compared to those over-expressing pCDNA3 (n = 3) (One way 
ANOVA p < 0.001). C. SMAD 2, 3 dependent luciferase activity in pCDNA3 and TTGFBR2 over-expressing cells 
treated with GDF-15 at 50 ng/ml for 6 hours. There was no difference in GDF-15 responses in pCDNA3 and 
TTGFBR2 over-expressing cells (n = 3) (One way ANOVA test p = 0.044, but no difference between the groups). 
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Figure 5.11 Myotube diameter in TTGFBR2 over-expressing GDF-15 treated cells. A. Representative GFP images 
of pCAGGS-EGFP expressing cells transfected with pCDNA3 or TTGFBR2 and treated with GDF-15 (50ng/ml) or 
vehicle control from which myotube diameters were measured. B. Myotube diameter in pCDNA3 or TTGFBR2 
over-expressing cells treated with GDF-15 (50ng/ml) or vehicle control (n=3) (One way ANOVA p = 0.981). C. Fold 
change in myotube diameter in pCDNA3 or TTGFBR2 over-expressing cells treated with GDF-15 (50ng/ml) or 
vehicle control normalised to control myotube diameter (n=3) (One way ANOVA p = 0.035, No difference 
between groups). 
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5.5.5 GDF-15 may act through non-canonical TGFβ pathways, which is best studied in myotubes 
The above results suggest that any SMAD response to GDF-15 in myoblasts is at most small.  GDF-15’s 
effects on non-canonical signalling in C2C12 myoblasts was studied next. Of particular interest was 
GDF-15’s effects on the NFκB p65 pathway. GDF-15 (50ng/ml) caused an increase in nuclear 
localisation of NFκB p65 at 60 minutes post treatment (Figures 5.12A and B) (Negative controls are 
shown in appendix 5.1). GDF-15 treatment, also, caused a significant up-regulation in mRNA 
production of NFκB p65 in myoblasts after 48 hours (Figure 5.13 A). In order to see if TAK1 was an 
important intermediate in GDF-15’s ability to increase mRNA production of NFκB p65 I treated C2C12 
myoblasts with GDF-15 in the presence and absence of the TAK1 inhibitor 5(Z)-7-oxozeaenol 
(1000nM). There was a significant reduction in NFκB p65 mRNA expression in GDF-15 and TAK1i co-
treated cells when compared to those treated with GDF-15 alone (Figure 5.13B). 
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Figure 5.12 Nuclear localisation of NFκB p65 in response to GDF-15 treatment. A. Representative 
immunofluorescent images of C2C12 cells treated with control, GDF-15 50ng/ml or TNFα 10ng/ml for 1 hour and 
stained with anti-NFκB p65 and Alexa-Fluor 488 and DAPI. Images showing nuclear DAPI staining. NFκB p65 
staining and a merged image are shown. B. Difference in relative immunofluorescent nuclear signal compared 
to total cell fluorescent signal in cells treated with control or GDF-15 50 ng/ml (n = 3) (Student’s t test p = 0.003). 
TNF α acted as a positive control. 
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Figure 5.13. mRNA expression of NFκB p65 in response to GDF-15 and TAK inhibition A. log NFκB p65 mRNA 
expression in C2C12 myoblasts treated with control or GDF-15 50 ng/ml for 48 hours (n = 6) (Wilcoxon signed 
rank test p =  0.031). B. Differences in relative log NFκB p65 mRNA expression in C2C12 myoblast treated with 
GDF-15  in the presence or absence TAK1 inhibitor 5(Z)-7-oxozeaeol at 1000 nM  (TAK1i) (n = 3) (One way ANOVA 
p = 0.001).   
 
The effects of GDF-15 on phosphorylation of TAK1 in myoblasts was next examined by western 
blotting. TAK1 was shown to be constitutively active in myoblasts (Figure 5.14 A). When protein lysates 
from myoblasts were compared to those from myotubes a decrease in phospho-TAK1 and phospho- 
NFκB p65 activity was seen (figure 5.14 B). Furthermore, during serum starvation NFκB p65 was shown 
to be located in the nucleus of day 2 C2C12 myoblasts (Figure 5.14 C). This is in keeping with data from 
Bhatnagar et al. (361).  The role of TAK1 and NFκB in propagating the effects of GDF-15 was therefore 
examined in myotubes rather than in myoblasts and was the focus of further investigations. 
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Figure 5.14 Non-canonical GDF-15 signalling in myoblasts versus myotubes. A. Western blot of Phospho-TGFβ 
activated kinase 1 (P-TAK1) and B-actin in myoblasts treated for 0, 10, 30 and 60 minutes with GDF-15 50 ng/ml 
(n = 1). B. Western blot of P-TAK1, phospho-nuclear factor Kappa B p65 (P-NFκB p65), and β-actin levels in 
myoblasts and myotubes (n = 1).  C.  Representative images of serum starved day 2 myoblasts stained with anti-
NFκB p65, Alexa-Fluor 488 goat anti-rabbit secondary and DAPI imaged and merged to show nuclear localisation 
(n = 3).  
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5.5.6 GDF-15 activated TAK1 and NFκB p65 at high and low dose in C2C12 myotubes 
In 10 day C2C12 myotubes GDF-15 at high dose (50ng/ml) caused phosphorylation of TAK1 which 
peaked at 60 minutes. GDF-15 treatment also caused phosphorylation of NFκB p65 which peaked at 
120 minutes after treatment and caused a reduction in phosphorylation of p38MAPK which reached 
its nadir at 60 minutes (Figures 5.15 A-F). As a positive control TGFβ1 (0.5ng/ml) also caused a rapid 
phosphorylation of TAK1 (Figure 5.15 G and H). Having established the effects of GDF-15 at high dose, 
a dose response was performed. The maximum TAK1 phosphorylation effect was seen at 5ng/ml 
(Figure 5.16 A and B). NFκB p65 phosphorylation was also increased by 5ng/ml GDF-15 at 60 minutes 
(5.16 C and D). Although there was a trend to increase in P-p38 MAPK levels at this lower dose of 
5ng/ml it did not meet statistical significance (Figure 5.16 E and F). 
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Figure 5.15. Western blots of day 10 myotubes treated for 0, 10, 30, 60 and 120 minutes with 50 ng/ml of GDF-
15. The time at which GDF-15 caused its maximal response for each phosphorylated protein was used for 
statistical comparison. A. Phosphorylated TAK1 (P-TAK1) activity and β actin levels in GDF-15 treated myotubes 
(Representative blot n = 4). B. Relative intensity of P-TAK1 activity normalised to β-actin (Repeated measures 
ANOVA p = 0.020). C. Phosphorylated p65 NFκB (P-NFκB) activity and total NFκB levels in GDF-15 treated 
myotubes (Representative blot n = 4). D. Relative intensity of P-NFκB activity normalised to total NFκB (Repeated 
measured ANOVA p = 0.046). E. Phosphorylated p38 MAP kinase activity in GDF-15 treated myotubes (P-p38 
MAPK) and total p38 MAPK levels inGDF-15 treated myotubes (Representative blot n = 4).  F. Relative intensity 
of P-p38 MAPK activity normalised to total p38 MAPK (Repeated measures ANOVA p < 0.001).  H. P-TAK1 activity 
and β-actin levels in TGFβ1 treated myotubes for 60 minutes (Representative blot n = 3). H. Relative intensity of 
P-TAK1 activity normalised to β-actin (Student’s t-test p = 0.047). 
  
187 
  
 
Figure 5.16. Western blot of day 10 myotubes treated for 60 minutes with 0, 1, 5 or 10 ng/ml of GDF-15. The 
western of the dose response is presented but only the treatment with 5 ng/ml was repeated 3 times for 
statistical analysis. A.  Phosphorylated TAK1 (P-TAK1) activity and β actin levels in GDF-15 treated cells (n = 3). 
B. Relative intensity of P-TAK1 activity normalised to β-actin in cells treated with vehicle control and GDF-15 (5 
ng/ml) (Student’s t-test p = 0.045). C. Phosphorylated p65 NFκB (P-NFκB) activity and total NFκB levels in GDF-
15 treated cells (n = 3). D. Relative intensity of P-NFκB activity normalised to total NFκB in cells treated with 
vehicle control and GDF-15 (5 ng/ml) (Student’s t-test p = 0.011). E. Phosphorylated p38 MAP kinase activity in 
GDF-15 treated cells (P-p38 MAPK) and total p38 MAPK levels inGDF-15 treated cells (n = 3).  F. Relative intensity 
of P-p38 MAPK activity normalised to total p38 MAPK in cells treated with vehicle control and GDF-15 (5 ng/ml) 
(Student’s t-test p = 0.378).   
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5.5.7 GDF-15 mediated myotube atrophy can be antagonised by the TAK1 inhibitor 5(Z)-7-
oxozeaenol 
Our group has previously shown that GDF-15 (50ng/ml) can cause the up-regulation of atrogin-1 and 
MuRF-1 mRNA (265) and cause a reduction in myotube diameter in vitro (218). The data above suggest 
that GDF-15 can activate TAK1, therefore the effects of the TAK1 inhibitor, 5(Z)-7-oxozeaenol, on GDF-
15 mediated atrophy was investigated. In vitro 5(Z)-7-oxozeaenol at 1000nM prevented TNFα 
mediated increases in NFκB p65 activity (Appendix 5.2), acting as a positive control. TAK1 inhibition 
with 5(Z)-7-oxozeaenol was able to partially prevent the GDF-15 mediated reduction in myotube 
diameter seen at 48 hours at low dose (100 nM) and completely block GDF-15’s effects at high dose 
(1000nM) (Figure 5.17 B and C). Furthermore myotubes treated with GDF-15 (50ng/ml) for 96 hours 
showed an increase in atrogin-1 mRNA expression. The increase in atrogin-1 mRNA expression was 
inhibited by co-treatment with 5(Z)-7-oxozeaenol at both 100nM and 1000nM (Figure 5.18 A). There 
was no significant change in MuRF-1 mRNA in TAK1i treated cells with high dose GDF-15 (Figure 5.18 
B). 
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Figure 5.17 Myotube diameter in high dose GDF-15 / 5(Z)-7-oxozeaenol treated cells A. Representative Green 
fluorescent images of pCAGGS-EGFP expressing cells treated with GDF-15 (50ng/ml) or vehicle control with or 
without TAK1i at 100 or 1000 nM. B. Comparison of myotube diameter in cells treated for 48 hours with GDF-
15 (50ng/ml) or vehicle control with or without the TAK1 inhibitor 5(Z)-7-oxozeaenol (TAK1i) at 100 or 1000 nM 
(n = 3) (One way ANOVA p = 0.068). C. Fold change in myotube diameter compared to baseline in cells treated 
for 48 hours with GDF-15 (50ng/ml) or vehicle control with or without the TAK1 inhibitor 5(Z)-7-oxozeaenol 
(TAK1i) at 100 or 1000 nM. TAK1i rescued GDF-15 mediated atrophy partially at 100 nM and completely at 1000 
nM (n =3) (One way ANOVA p = 0.003).  
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Figure 5.18 Ubiquitin ligase expression high dose GDF-15 / 5(Z)-7-oxozeaenol treated cells. C2C12 myotubes 
were treated with control or GDF-15 50 ng/ml with or without 5Z-7-oxozeaenol (TAK1i) at 100 or 1000nm for 96 
hours after which RNA was extracted for qPCR. A. GDF-15 caused a small but significant increase in mRNA 
expression of atrogin-1. TAK1i co-treatment at 100 nM and 1000 nM reduced GDF-15 induced increases in 
atrogin-1 levels (n = 5) (One way ANOVA p = 0.001). B. Neither GDF-15 nor TAK1i in this experiment had an effect 
on MuRF-1 mRNA levels (n = 5) (Kruskall-Wallace p = 0.011).   
 
Low dose GDF-15 (5ng/ml) had similar effects on myotube diameter as high dose. Again 5(Z)-7-
oxozeaenol was able to inhibit GDF-15 mediated myotube atrophy (Figure 5.19 A and B). Low dose 
GDF-15 (5ng/ml) mediated atrogin-1 and MuRF-1 mRNA expression was inhibited by 1000nM but not 
100nM doses of 5(Z)-7-oxozeaenol (Figured 5.20 A and B).  
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Figure 5.19 Myotube diameter in low dose GDF-15 / 5(Z)-7-oxozeaenol treated cells A. Representative Green 
fluorescent images of pCAGGS-EGFP expressing myotubes treated with GDF-15 (5ng/ml) or vehicle control with 
or without TAK1i at 100 nM for 48 hours. B. Myotube diameter in cells treated with GDF-15 (5g/ml) or vehicle 
control with or without TAK1i at 100 nM (n = 3) (One way ANOVA p = 0.033, No difference between the groups). 
C. Fold change in myotube diameter compared to baseline in cells treated for 48 hours with GDF-15 (5ng/ml) or 
vehicle control with or without the TAK1 inhibitor 5(Z)-7-oxozeaenol (TAK1i) at 100. TAK1i rescued GDF-15 
mediated atrophy (n = 3) (One way ANOVA p = 0.005). 
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Figure 5.20 Ubiquitin ligase expression in low dose GDF-15 / 5(Z)-7-oxozeaenol treated cells. C2C12 myotubes 
were treated with control or GDF-15 5 ng/ml with or without 5Z-7-oxozeaenol (TAK1i) at 100 or 1000nm for 96 
hours after which RNA was extracted for qPCR. A. TAK1i (1000nM) treatment caused a reduction in GDF-15 
induced Atrogin-1 mRNA expression (n = 5) (Kruskall-Wallace with Dunn’s correction p = 0.001) B. TAK1i 
(1000nM) treatment also caused a reduction in GDF-15 induced MuRF-1 mRNA expression (n = 5) (One way 
ANOVA p = 0.039).    
 
It has been reported that GDF-15 may act through the ALK-5 type 1 TGFβ receptor (243). Myotubes 
treated with GDF-15 (50ng/ml) were co-treated for 96 hours with the ALK5 inhibitor SB-431542 (10 
μM) (461). ALK-5 inhibition prevented the rises in atrogin-1 mRNA expression induced by GDF-15.  
(Figure 5.21 A and B).  
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Figure 5.21. Atrogin-1 mRNA expression in high dose GDF-15/ ALK5 inhibitor treated cells. C2C12 myotubes 
were treated with control or GDF-15 50 ng/ml with or without SB-431542 (ALK5i) at 10μM for 96 hours after 
which RNA was extracted for qPCR. A. Representative brightfield images of myoblasts treated with control, GDF-
15 and GDF-15 / ALK5i. B. ALK5i prevented GDF-15 mediated increases in atrogin-1 mRNA expression (n = 3) 
(One way ANOVA p = 0.014).  
 
5.5.8 Downstream mediators of GDF-15 are up-regulated in the muscle of the MCT rat  
In the MCT rat TA at 4 weeks post treatment there was no significant increase in MuRF-1 mRNA 
expression (Figure 5.22A). There was a trend to increase in atrogin-1 mRNA expression that did not 
reach statistical significance (p = 0.08) (Figure 5.22B). However in the MCT rat TA atrogin-1 mRNA 
expression correlated with both animal growth (Figure 5.22C) and TA weight (Figure 5.22D). In the 
Sugen/hypoxia mouse there was no significant increase in MuRF-1 or atrogin-1 mRNA expression 
within the TA (Figures 5.23 A and B). In the MCT model, TAK1, NFκB p65 and p38 MAPK mRNA levels 
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remained stable between control and MCT treated animals (Figures 5.24 A-C). However, we did find 
at the earlier time point used in the MCT TAK1 inhibitor study that phospho-TAK1 was upregulated in 
the MCT rat TA compared to the control treated animals (Figure 25 A and B). Furthermore there was 
a suggestion, from the limited data available, that phospho-TAK1 was also increased in skeletal muscle 
biopsies of patients with PAH compared to controls (Figure 5.25 C) 
 
Figure 5.22. Ubiquitin ligase mRNA expression in the TA of the MCT rat. A. log MuRF-1 expression in the TA of 
control and MCT and control treated rats (control n = 14, MCT n = 16, Student’s t-test p = 0.298). B. log Atrogin-
1 mRNA expression in the TA of control and MCT treated rats (control n = 14, MCT n = 16, Student’s t-test p = 
0.077). C. log TA atrogin-1 mRNA expression plotted against change in weight in control and MCT treated rats 
(control n = 14, MCT n = 16). D. log TA atrogin-1 mRNA expression plotted against TA weight in MCT and control 
treated rats (control n = 14, MCT n = 16).  
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Figure 5.23. Ubiquitin ligase mRNA expression in the TA of the Sugen/hypoxia mouse.  A. log MuRF-1 mRNA 
expression in the TA of the control and Sugen/hypoxia treated mice (control n = 4, MCT n = 5, Mann Whitney U 
test p = 1.00). B. log Atrogin-1 mRNA expression in the TA of control and Sugen/hypoxia treated mice (control n 
= 5, MCT n = 5, Mann Whitney U test p = 1.00). 
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Figure 5.24. mRNA expression of TAK1, NFκB p65 and p38 MAPK in the TA of the MCT rat. A. log TGFβ activated 
kinase 1 (TAK1) mRNA expression in the TA of control and MCT treated rats (control n = 14, MCT n = 16, Student’s 
t-test p = 0.699). B. log NFκB p65 mRNA expression in the TA of control and MCT treated rats (control n = 14, 
MCT n = 16, Mann Whitney U test p = 0.643). C. log p38MAPK mRNA expression in the TA of control and MCT 
treated rats (control n = 9, MCT n = 10, Student’s t-test p = 0.419). 
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Figure 5.25. Phospho-TAK1 in the TA of the MCT rat and in the rectus femoris of patients with PAH. A. 
Representative western blot of P-TAK1 and GAPDH in homogenates from the TA of control and MCT treated 
rats. B. Relative intensity of P-TAK1 activity normalised to GAPDH in TA homogenates from control and 
monocrotaline (MCT) treated rats (control n = 5, MCT n = 5, Mann Whitney U test p = 0.008). B. Western blot of 
P-TAK1 and GAPDH in quadriceps homogenates from control volunteers and patients with PAH. 
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5.6 Discussion 
The above results show that GDF-15 can interact with both the TGFBR2 and ALK5 receptors. GDF-15 
treatment did not seem to have any effect on SMAD 1, 5 or SMAD 2, 3 dependent luciferase activity 
at either high or low dose. The clinical significance and relevance of this interaction between GDF-15 
and TGFBR2 in both myoblasts and mature muscle cells is difficult to interpret. The TTGFBR2 changed 
GDF-15 induced SMAD 2, 3 dependent luciferase activity but had no effect on GDF-15 induced 
myotube atrophy. Larger changes are seen in the effects of GDF-15 on non-canonical pathways, 
particularly the up-regulation in TAK1 and NFκB p65 activity. The main findings of this chapter suggest 
that GDF-15 activates TAK1 and that TAK1 inhibition can prevent GDF-15 mediated myotube atrophy 
possibly by preventing up-regulation in pro-atrophic ubiquitin ligases atrogin-1 and MuRF-1. Finally 
the results demonstrate that these non-canonical pathways are potentially important in the 
development of muscle wasting in the MCT rat model of PH induced muscle loss, and may therefore 
be targets for future therapeutic intervention. 
GDF-15 caused no significant change in SMAD 2, 3 dependent luciferase activity at any dose used at 6 
hours, although there was a trend at lower doses (5 ng/ml) to inhibition of SMAD signalling. This is in 
keeping with data presented by Johnen et al. who could see no evidence of SMAD 2, 3 signalling in 
response to GDF-15 in mouse hypothalamus (260), but is in contrast to data showing an increase in 
SMAD 2, 3 dependent luciferase activity in conditioned media from GDF-15 over-expressing cells 
(235). The latter is not direct evidence of the positive effect of GDF-15 on SMAD 2, 3 activity as an 
alternative protein in the conditioned media may have caused this effect and the 3TP promoter that 
they used in their luciferase may have mis-identified a TAK1 effect through 3TP-Luc binding. GDF-15 
also had no effect on SMAD 1, 5 dependent luciferase activity in myoblasts. 
The purity of recombinant human GDF-15 has been called into question (Email from S. Breit Appendix 
5.3) and concerns have been raised about contamination of GDF-15 with TGFβ1. My experiments have 
shown that the batch of GDF-15 we used was not significantly contaminated with TGFβ1. There was 
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an up-regulation in SMAD2, 3 dependent luciferase activity with as little as 0.1 ng/ml of TGFβ1. The 
maximum dose of GDF-15 used was 50 ng/ml. Even at this high dose there was no SMAD 2, 3 
dependent luciferase effect. We can therefore conclude that if contamination of GDF-15 with TGFβ1 
was present then it was in the order of less than 0.2%. Furthermore GDF-15 at 5 ng/ml caused a similar 
upregulation in P-TAK1 activity to TGFβ1 at 0.5 ng/ml meaning that contamination with TGFβ1 would 
have to reach 10% if this was solely responsible for the changes seen with GDF-15, ruling out this 
possibility.   
Recent data suggests that GDF-15 acts in the central nervous system through the GFRAL receptor 
(294). This receptor is not present in skeletal muscle (295).  A number of other groups have shown 
that GDF-15’s effects are mediated by the TGFBR2 and ALK5 (288, 301).  In TGFBR2 over-expressing 
cells GDF-15 (50ng/ml) caused a small but significant increase in SMAD 2, 3 activity above baseline. 
This change was not seen at lower doses of GDF-15 (5 ng/ml). It seems therefore that in the presence 
of excess receptor and high dose ligand, GDF-15 can be forced to bind to the TGFBR2 to stimulate 
SMAD 2, 3 responses, but the physiological relevance of this in vivo and in patients is yet to be 
elucidated.  GDF-15 at 50 ng/ml could also be shown to stimulate small increases in relative SMAD 1, 
5 responses above that seen in pCDNA3 transfected cells, in the presence of excess TGFBR2, ACVR2B 
or BMPR2. The fold change of this up-regulation was again small. This demonstrates that GDF-15 has 
some affinity to bind to all these receptors. However the small fold change means the results 
presented here must be interpreted with caution. The ALK-5 inhibitor SB-431542 was able to prevent 
GDF-15 mediated increases in atrogin-1 expression, suggesting that the ALK-5 is involved in GDF-15 
signalling. However, SB-431542, as well as ALK-5 has some activity against ALK-4 and ALK-7, meaning 
GDF-15 may act through these receptors as well. (462).  Interestingly, in the presence of ALK5 
inhibition, GDF-15 actually caused a decrease in atrogin-1 expression compared to ALK-5 alone. This 
suggests that, as we have seen with the type II receptors, GDF-15 can act with a number of type I 
activin receptor like kinase receptors with contrasting effects on gene expression. This serves to 
further highlight the high levels of receptor promiscuity within TGFβ signalling pathways (178).  
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GDF-15 had no significant effect on the dose response curves of TGFβ1 or BMP-4 on their relevant 
SMAD luciferase assay, suggesting that the ligand does not act as a competitive antagonist to these 
ligands by binding out their receptors but not contributing to downstream signalling.  
In view of the fact that the TGFBR2 has previously been identified as a potential receptor through 
which GDF-15 might signal (260) and the findings that there was some interaction between the 
TGFBR2 and GDF-15, a TTGFBR2 was cloned. This was effective in reducing baseline SMAD 2, 3 
luciferase activity (178).  TTGFBR2 over-expression was also able to influence SMAD 2, 3 responses to 
GDF-15 at 5 but not 50ng/ml. TTGFB2 over-expression had no effect on GDF-15 mediated myotube 
atrophy. This is in contrast to data showing TGFBR2 antagonism with a truncated receptor was able to 
prevent the formation of a dystrophic phenotype in δ-sacroglycan-null mice and reduced 
inflammation and increased regeneration in a mouse model of muscle injury (463). The results 
presented here should be treated with caution as the effects of the TTGFBR2 are not necessarily GDF-
15 specific and in fact may be mediated through antagonism of a number of different potential ligands 
resulting in no net change in the balance between protein synthesis and degradation. 
There was no evidence that GDF-15 caused any change in SMAD responses in C2C12 myoblasts. GDF-
15 did however cause an increase nuclear localisation of NFκB p65 activity measured by 
immunofluorescence. GDF-15 treatment also increased mRNA expression of NFκB p65 in C2C12 
myoblasts, a phenomenon inhibited by co-treatment with the TAK1 inhibitor 5(Z)-7-oxozeaenol. This 
provided some evidence that GDF-15 may signal through the TAK1 - NFκB p65 axis in muscle cells. This 
pathway has already been shown to be important in mediating GDF-15 signalling in Ecoli infected 
gastric epithelial cells (318, 319). TAK1 and its downstream target NFκB p65 are constitutively active 
in C2C12 myoblasts and this activity is lost during differentiation (361, 464), meaning investigation of 
factors which upregulate this signalling pathway is difficult in these immature cells. Therefore in order 
to determine the relevance of this pathway further we concentrated on myotubes where only low 
level baseline TAK1 and NFκB activity was exhibited. This also had the advantage of being a more 
representative population of mature muscle cells seen in adults with chronic disease such as PH.  
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As we have already shown, GDF-15, like other TGFβ super-family members, acts in a dose and 
environment dependant manner (227). In myotubes GDF-15 treatment caused phosphorylation of 
TAK1 and NFκB p65 at a number of times and doses. It also caused a significant decrease in p38 MAPK 
phosphorylation which was only seen with high dose treatment. In other cells GDF-15 has been shown 
to both activate and prevent activation of TAK1, NFκB and p38 MAPK (312, 317-319), adding validity 
to our results but also providing more evidence of the context dependant nature of pathways 
activated by TGFβ proteins.  It is well established that TAK1 is upstream of NFκB and p38 MAPK, both 
of which have been associated with muscle atrophy through activation of ubiquitin ligases (465-467). 
Previous work from our group showed that GDF-15 can up-regulate atrogin-1 and MuRF-1 expression 
(265) and cause myotube atrophy (218). It is generally accepted that activation of p38 MAPK is 
associated with up-regulation of both MuRF-1 and atrogin-1, whilst NFκB has generally been 
associated with upregulation of MuRF-1 alone (467).  TAK1 inhibition with 5(Z)-7-oxozeaenol 
prevented GDF-15 mediated relative myotube atrophy and expression of atrogin-1 mRNA. It also 
prevented MuRF-1 mRNA expression caused by low but not high dose GDF-15. Taken together these 
results suggest that GDF-15 may phosphorylate TAK1, activating NFκB and up-regulating mRNA 
expression of MuRF-1. The increase in atrogin-1 demonstrated also seems to be dependent on TAK1 
but is likely to be independent of both NFκB, which is not thought to be in involved in up-regulation 
of atrogin-1 expression (467) and p38 MAPK, activation of which was, if anything, was inhibited by 
GDF-15, at high doses in these experiments.  
Downstream mediators of GDF-15 effects are elevated in the muscle of the MCT rats, a model of 
cachexia associated with raised GDF-15 levels. Although expression of neither ubiquitin ligase were 
elevated in the TA of the MCT rat in this experiment, atrogin-1 mRNA levels trended to increase with 
a p value of 0.08. Furthermore Atrogin-1 mRNA expression was associated with both a change in 
animal weight and final TA weight of the animal. Atrogin-1 mRNA and protein have both previously 
been shown to be raised in the gastrocnemius of the MCT rat (153, 468).  MuRF-1 mRNA expression 
remained unchanged at the time point studied in my experiment, but this does not rule out its 
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involvement in the muscle wasting process. Previous work has shown that as well as Atrogin-1 mRNA, 
MuRF-1 mRNA levels are also raised in the gastrocnemius of the MCT rat at 21-22 days (60, 468) a 
week prior to the time point at which the rats in our experiment were investigated. It is interesting to 
note that variation in ubiquitin ligase expression with time have also been observed in man (469) and 
that in an animal model of burns induced muscle wasting whilst atrogin-1 mRNA remained persistently 
elevated at 5 days post insult MuRF-1 mRNA levels fell to baseline after 5 days (470). This suggests 
that atrogin-1 and MuRF-1 mRNA may have peaked prior to the time at which the animals were 
humanely killed explaining why we don’t necessarily see an increase in expression at the time point 
we investigated. This may also be the reason we don’t see any change in ubiquitin ligase expression 
in the Sugen/hypoxia mouse.  
TAK1 seems to have a dual role in the balance between atrophy and hypertrophy as, whilst is seems 
to be a vital component of satellite stem cell function in regenerating muscle or in muscle 
development in immature animals (363, 364) it is also an essential requirement in allowing myostatin 
to propagate its growth inhibitory signal in muscle cells (67, 366). Its role in chronic disease in vivo has 
not been investigated and the finding of elevated levels of phosphorylated TAK1 in the TA of the MCT 
model and the preliminary data in patients with PAH confirms it as a potential future therapeutic 
target for intervention.  
5.7 Conclusion 
GDF-15 may act through ALK-5 and possibly through TGFBR2 to stimulate TAK1 and NFκB which leads 
to increased expression of ubiquitin ligases, including but not limited to Atrogin-1 and MuRF-1, 
resulting in muscle loss. This pathway seems to be active in an animal model of PAH. TAK1 inhibition 
may be a target for therapeutic intervention aimed at antagonising the muscle weakness found in 
PAH. 
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Chapter 6 The effect of 5(Z)-7-oxozeaenol on muscle wasting in the MCT rat. 
6.1 Background 
Data from previous chapters has shown that TAK1 might be involved in GDF-15 mediated muscle 
atrophy in PAH. TAK1 is a mitogen activated protein kinase kinase kinase and a serine threonine kinase, 
which is found in the cell as a hetero-tetramer bound to its adapter proteins TAB1 and TAB2/3. TAK1 
is activated by a number of different signalling factors including the IL-1 and TNFα. This activation 
results from the interaction of receptor associated factors with TAB2/3.  Other factors known to 
stimulate TAK1 activity include lipopolysaccharide and TGFβ1. Activation of TAK1 involves 
phosphorylation at Thr184/187 sites, which in turn results in phosphorylation of JNK, NFκB and p38 
MAPK resulting in a pro-inflammatory state through transcription of cytokines and an increase in 
inflammatory cell recruitment (344, 345). Recent data has suggested that for full activation of TAK1 
and propagation of down-stream signals phosphorylation at Ser412 is also required. Whether this is 
dependent or independent of Thr 184/187 phosphorylation remains to be elucidated (335, 471).   
Although essential for embryonic development, innate and adaptive immunity and homeostasis of 
essential organ function (344-346) excessive TAK1 activity has also been associated with inflammatory 
conditions, cancers (347), cardiovascular disease (348), and fibrosis (349, 350). TAK1 has become an 
exciting potential therapeutic target in a wide range of conditions and a number of compounds, aimed 
at antagonising its actions, are in development. These include: covalent cysteine binders such as 5(Z)-
7-oxozeaenol and hypothemycin, which act on the cysteine residue in the Asp-Phe-Gly / DFG 1 region 
on the N-terminal of the activation loop of the kinase; type I molecules which interact directly with 
ATP binding site of the kinase which is not dependent on the conformation of the kinase, known as 
DFG-in binders, e.g. AZ-TAK1; and type II DFG out-binders, like PF-04358168, which also bind to the 
nearby ‘allosteric’ site of the protein, only when the kinase is in inactive form, called DFG out (351, 
472). All the mechanisms by which it might be possible to inhibit TAK1 have advantages and 
  
204 
  
disadvantages with some compounds being potent but having off-target effects whilst others may be 
more specific but less effective (351).  
5(Z)-7-oxozeaenol was the first TAK1 inhibitor characterised (352) and has been the most widely used 
to inhibit TAK1 in vitro and in vivo. It is a resorcyclic acid lactone naturally produced by a fungus (352). 
It acts as an irreversible kinase inhibitor by forming a covalent bond between the cis-enone group of 
5(Z)-7-oxozeaenol and the functional thiol group of the cysteine residue of TAK1 resulting in alkylation 
of the protein and preventing the binding of TAK1 and ATP at its DFG site.  The compound is highly 
specific  for TAK1, with very few off target effects (353).  In vivo 5(Z)-7-oxozeaenol has been shown to: 
enhance chemotherapeutic effect of doxorubicin on neuroblastoma tumours in mice (354); prevent 
diabetes in a mouse model of the disease (355); reduce the severity of nephropathy in in diabetic mice 
(356); increase neuronal survival and decrease seizure duration in epileptic rats  (357); reduce the size 
of infarct after stroke (358); and prevent neo-intimal formation in wire induced vascular injury (359). 
Its effects on muscle wasting has not been investigated. 5(Z)-7-oxozeaenol has been used intra-
peritoneally at doses of between 0.5 – 5 mg/kg/day (356, 358, 359). 
The data presented in Chapter 5 suggests that in vitro GDF-15 mediated muscle loss is antagonised by 
blocking TAK1 activation, which to a certain extent prevents the upregulation of atrogin-1 and MuRF-
1. The validity of this pathway is supported by data from others showing GDF-15 can activate TAK1 
(318, 319) and that GDF-15 mediated muscle loss involves the up-regulation of the aforementioned 
ubiquitin ligases (265). In Chapter 4 and 5, muscle wasting in the MCT rat was shown to be associated 
with both an upregulation of circulating GDF-15 and local TAK1 activation. Consistent with these 
observations, muscle wasting in the MCT rat is also associated with up-regulation of atrogin-1 and 
MuRF-1 (60).  
GDF-15 is not the only upstream mediator of TAK1 signalling that is involved in the development of 
muscle wasting in the MCT rat. Both GDF-8 and TNFα can activate TAK1 (67, 345) and are over-
expressed (136, 153) in this rodent model of PAH and muscle wasting. This observation suggests that 
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TAK1 may be more effective than other inhibitors of muscle wasting in this model as it blocks a number 
of different synergistic pathways.  Furthermore, data from a cohort of patients undergoing 
rehabilitation after a fractured neck of femur has shown that TAK1 levels drop after exercise 
suggesting a protective role for TAK1 inhibition in an adult population (473), backing up the limited 
muscle biopsy data on TAK1 phosphorylation shown in Chapter 5.  
6.2 Aim  
To determine whether TAK1 inhibition prevented muscle loss in the MCT rat model of PAH 
6.3 Hypothesis 
TAK1 inhibition with 5(Z)-7-oxozeaenol will prevent muscle loss and weight loss in the MCT rat model 
of PAH by altering the mRNA levels of ubiquitin ligases.  
6.4 Methods 
For a full explanation of the methods please see Chapter 2 of this thesis 
6.4.1 Animal experiments 
Twenty rats were treated with MCT and 10 with control injections as before. After 2 weeks, 10 of the 
animals in the MCT group were treated with 5(Z)-7-oxozeaenol, 0.5mg/kg/day, (dissolved in 10% 
DMSO/90% PBS) intra-peritoneally for 9 days as previously described, after which they were humanely 
killed (358, 402). During the experiment rats were weighed regularly. One animal in the MCT TAK1i 
group was excluded from analysis as it had to be humanely killed before the treatment end point. 
Blood was collected, after cardiac catheterisation. The heart was dissected for and RV/LV+S weight 
measured. Half the lung was agarose inflated and dropped into formalin. The other half was flash 
frozen. The TA and soleus muscles from one leg were snap frozen, whilst those from the other leg 
were embedded in OCT and frozen in isopentane cooled in liquid nitrogen.  
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6.4.2 Tissue processing and analysis  
Lung and muscle tissue was homogenised for mRNA and protein as previously described (See Chapter 
2). Blood was spun down for serum. Lung and muscle tissue was sectioned and mounted on slides. 
Muscle tissue was stained with haematoxylin and eosin and fibre diameter was assessed as previously 
described. Blood samples were analysed for GDF-15 by ELISA as per manufacturer’s instructions. Lung 
and muscle tissue was analysed by qPCR and western blot using primers and antibodies fully explained 
in Chapter 2 (265). 
6.4.4 Statistics 
The 3 treatment groups were compared using ANOVA with Bonferroni correction or Kruskall-Wallace 
with Dunn’s correction depending on the distribution of the data. When only 2 groups were compared, 
Student’s t-test or Mann Whitney U test was used depending on the distribution of the data. Normality 
was assessed using the Kolmogorov-Smirov, D’Agostino and Pearson test and the Shapiro-Wilk test as 
well as visually using histograms. Rats were defined as continuing to grow if they reached their 
maximum weight on the last day of the experiment and had not plateaued. Fisher’s exact test was 
used to compare the proportions of MCT treated rats continuing to grow or not growing after 9 days 
treatment with 5(Z)-7-oxozeaenol. A ROC curve was constructed to define GDF-15’s ability to predict 
those animals growing or not growing at the end of the experiment. The number of fibres in 5 micron 
groups were determined for each animal. The cumulative number of fibres below each 5 micron 
diameter cut off was determined and expressed as a percentage of the total number of fibres counted.   
Two way ANOVA with Bonferroni correction was used to compare the proportion of fibres in the 
control, MCT and MCT TAK1 group at each diameter cut off.  
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6.5 Results  
6.5.1 TAK1 inhibition prevents weight loss in the MCT rat model of PAH 
Two weeks after MCT treatment, rats were treated with 9 days of 5(Z)-7 oxozeaenol. Both MCT control 
and MCT TAK1 inhibitor rats had similar final weights, overall growth, growth since initiation of TAK1 
inhibitor treatment, and change from maximum weight (Figure 6.1 A-D). Examining the growth curves 
of the animals completing 9 days of treatment there was a trend to stabilisation of weight in the MCT 
TAK1i group that did not meet statistical significance (Figure 6.2 A). In the MCT TAK1i rat group, 4/9 
continued to gain weight on the last day of treatment compared to 0/10 of the MCT control treated 
rats (Fisher’s exact test p = 0.033) (Figure 6.2 B). There was no difference in overall or weekly food 
intake between MCT and MCT TAK1 inhibitor rats, which ate, as expected, less on average than their 
control treated counterparts (control 477g; MCT 389g; MCT TAK1i 387g). 
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Figure 6.1 Weight in the MCT rat treated with 5(Z)-7-oxozeaenol. A. Final weight in grams (g) in control (n=10), 
MCT (n=10) and MCT TAK1i (n=9) treated rats (ANOVA p < 0.001). B. Change in weight in grams (g) in control 
(n=10), MCT (n=10) and MCT TAK1i (n=9) rats over the entire experiment (ANOVA p < 0.001). C. Change in weight 
in grams (g) after treatment with TAK1i of PBS/DMSO in control (n=10), MCT (n=10) and MCT TAK1i rats (n=9) 
(ANOVA p < 0.001). D. Change in weight in grams (g) from maximum in control (n=10), MCT (n=10) and MCT 
TAK1i rats (n=9) (ANOVA p = 0.195). 
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Figure 6.2 Growth in the MCT rat treated with 5(Z)-7-oxozeaenol. A. Growth curves showing mean and standard 
error of the mean in weight of MCT (n=10) and MCT TAK1i (n=9) treated MCT rats after initiation of PBS/DMSO 
or TAK1i. B. Number of MCT animals growing and not growing at the end of the experiment in the MCT (n=10) 
and MCT TAK1i (n=9) groups Fisher’s exact test p = 0.033). 
 
6.5.2 TAK1 inhibition may partially prevent loss of TA fibre diameter and prevents MCT induced 
increases in activated NFκB and atrogin-1 expression 
TAK1 inhibitor treated MCT rats had significantly heavier TAs than MCT control treated animals (Figure 
6.3 A). There was no difference in soleus weight between MCT control and MCT TAK1i treated animals 
(Figure 6.3B). In this model TAK1i inhibition prevented MCT induced fibre atrophy, as shown by the 
fact that MCT TAK1i rats had a lower proportion of fibres with diameters between 30 – 50 μm (Figure 
6.4 A, B and C). 
 
Figure 6.3 Muscle wasting in the MCT rat treated with 5(Z)-7-oxozeaenol. A. Tibialis Anterior (TA) weight in 
grams (g) in control (n=10), MCT (n=10) and MCT TAK1i (n=9) treated animals (ANOVA p < 0.001). B. Soleus 
weight in grams (g) in control (n=10), MCT (n=10) and MCT TAK1i (n=9) treated animals (ANOVA p = 0.007) 
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6.4 TA Fibre diameter in the MCT rat treated with 5(Z)-7-oxozeaenol A. TA fibre diameter in micrometres (μm) 
in control (n=10), MCT (n=10) and MCT TAK1i (n=9) treated animals (ANOVA p = 0.004). B. Fibre profiles of 
control (n = 10), MCT (n = 10), and MCT TAK1i (n = 9) plotted as mean and standard error of the mean of 
proportion of fibres below the indicated fibre diameter in 5 μm increments (Two way ANOVA p < 0.001 for row, 
column and interaction, * and ** represent a significant difference between MCT and MCT TAK1 proportions at 
each 5μm fibre intervals by Bonferroni). C. Representative bright-field image of rat muscle tissue stained with 
haematoxylin and eosin from which average fibre diameter was determined by Image J. 
 
5(Z)-7-oxozeaenol treatment prevented increases in phospho-NFκB p65 protein levels in the TA of the 
MCT rat (Figure 6.5). There was a trend to a reduction in atrogin-1 and MuRF-1 mRNA levels in the TA 
of the MCT rat treated with TAK1 inhibition at this time point that did not meet statistical significance. 
(Figure 6.6 A and B). TA Atrogin-1 mRNA expression was, however, lower in animals which continued 
to grow at the end of the experiment when analysed in the group as a whole (Figure 6.6 C) and when 
the MCT treated animals were analysed alone (Figure 6.6 D).  
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Figure 6.5 Phospho-NFκB p65 in the TA of the MCT rat treated with 5(Z)-7-oxozeaenol. Representative western 
blot of TA homogenates probed for phospho-NFκB p65 normalised to GAPDH in monocrotaline (MCT), MCT 5(Z)-
7-oxozeaenol (MCT TAK1i) and control treated rats (n=5 MCT and control and n = 4 MCT TAKi). 
 
Figure 6.6 Ubiquitin ligase mRNA expression in the TA of the MCT rat treated with 5(Z)-7-oxozeaenol. A. log 
atrogin-1 mRNA expression in the TA of control (n=10), MCT (n=10) and MCT TAK1i (n=9) treated rats (Kruskall-
Wallace p = 0.018). B. log MuRF-1 mRNA expression in the TA of control (n=10), MCT (n=10) and MCT TAK1i 
(n=9) treated rats (Kruskall-Wallace p = 0.177). C. log atrogin-1 mRNA expression in the TA of rats that were 
growing (n = 13) and not growing (n = 16) at the end of the experiment across the group as a whole (Student’s 
t-test p = 0.003). D. log atrogin-1 mRNA expression in the TA of rats that were growing (n = 4) and not growing 
(n = 15) at the end of the experiment across the MCT treated animals alone (Student’s t test p = 0.041). 
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6.5.3 TAK1 inhibition did not significantly change pulmonary pressure, right ventricular remodelling 
or GDF-15 levels in the MCT rat.   
TAK1 inhibition, at the concentration used, had no discernible effect on RVSP or RV/LV+S weight 
(Figure 6.7A and 6.7B). Serum levels of GDF-15 in control, MCT and MCT TAK1i treated rats are shown 
in Figure 6.8A. Treatment with the TAK1 inhibitor caused a reduction in circulating GDF-15 levels in 
some animals, a trend that did not reach statistical significance (Figure 6.8A). GDF-15 mRNA 
expression in the lung of the control, MCT and MCT TAK1 inhibitor treated rats followed a similar 
pattern to serum levels in this model (Figure 6.8B).  
 
Figure 6.7 Pulmonary hypertension in the MCT rat treated with 5(Z)-7-oxozeaenol. A. Right ventricle / Left 
ventricle plus septal weight (RV/LV+S) in control (n=10), MCT (n=10) and MCT TAK1i (n=9) treated rats (Kruskall-
Wallace p < 0.001). B. Right ventricular systolic pressure (RVSP) in mmHg in control (n=8), MCT (n=6) and MCT 
TAK1i (n=6) rats (Kruskall-Wallace p = 0.001). 
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Figure 6.8 GDF-15 in the MCT rat treated with 5(Z)-7-oxozeaenol A. Circulating GDF-15 in pg/ml in control (n=9), 
MCT (n=9) and MCT TAK1i (n=9) treated rats (Kruskall-Wallace p = 0.013). B. log GDF-15 mRNA expression in the 
lung of control (n=10), MCT (n=10) and MCT TAK1i (n=9) rats (Kruskall-Wallace p = 0.002). 
 
6.5.4 Circulating GDF-15 levels were associated with markers of muscle loss as well as continued 
growth in MCT rats treated with 5(Z)-7-oxozeaenol. 
GDF-15 levels were correlated linearly and significantly with change in weight and TA atrogin-1 mRNA 
expression in this model (Figures 6.9 A and C). GDF-15 also correlated non-linearly with TA weight 
(Figure 6.9 B). Circulating GDF-15 levels were significantly lower in those animals which continued to 
grow at the end of the experiment compared with those that didn’t. This was true across the group as 
a whole (Figure 6.10 A) and within the MCT treated group alone (Figure 6.10 B). GDF-15 had an AUC 
of 0.82 (p = 0.005) in predicting those animals which continued to grow at the end of this experiment. 
A GDF-15 cut off of < 260 pg/ml had a sensitivity of 83% and a specificity of 73% in predicting those 
animals which continued to grow (Figure 6.10 C). 
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Figure 6.9 Correlations of circulating GDF-15 levels in MCT rats treated with 5(Z)-7-oxozeaenol. A. Plasma GDF-
15 levels plotted against changed in weight in grams (g) in control (n=9) MCT (n=9) and MCT TAK1i (n=9) treated 
rats. B. Plasma GDF-15 levels plotted against TA weight in grams (g) in control (n=9) MCT (n=9) and MCT TAK1i 
(n=9) treated rats. C. Plasma GDF-15 levels plotted against log atrogin-1 mRNA expression changed in weight in 
grams (g) in control (n=9) MCT (n=9) and MCT TAK1i (n=9) treated rats.  
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Figure 6.10 GDF-15 as a biomarker of continued growth in MCT rats treated with 5(Z)-7-oxozeaenol. A. GDF-
15 levels in control (n = 10), MCT (n = 10) and MCT TAK1i (n = 9) treated animals growing and not growing at the 
end of the experiment (Student’s t-test p = 0.003). B. GDF-15 levels in MCT (n = 10) and MCT TAK1i (n = 9) treated 
animals not growing and growing at the end of the experiment (Student’s t test p = 0.002). C. ROC curve of GDF-
15’s ability to predict those still growing at the end of the experiment across all animals (n = 29) (AUC 0.82 p = 
0.005). 
 
6.6 Discussion    
Inhibiting TAK1 with 5(Z)-7-oxozeaenol partially reversed MCT induced TA muscle wasting and 
prevented weight loss in some animals potentially in part by preventing increases in atrogin-1 mRNA 
expression. Interestingly circulating GDF-15 levels were able to predict those animals still growing at 
the end of the experiment confirming its utility as a biomarker of cachexia. 
5(Z)-7-oxozeaenol treatment in the MCT rat did not change the final weight of the animals but did 
seem to prevent some of the muscle wasting seen in this model. Looking at previous work on growth 
  
216 
  
of the MCT rat weight loss does not occur until between the 3rd and 4th week, depending on the dose 
of MCT used, although growth inhibition occurs immediately after dosing (474, 475). This may go some 
way to explain why we only see the beginning of divergence in growth curves in the data presented 
and why the only difference in growth is in the proportion of animals still putting on weight at the end 
of the experiment.  
TAK1 is an important mediator of NFκB activity (476). 5(Z)-7-oxozeaenol was able to significantly 
inhibit increases in phosphorylated NFκB p65 activity in the TA of the MCT rat, suggesting that the 
compound had the desired activity in vivo. This does not, however, confirm that inhibition of NFκB 
signalling is definitively involved in reversal of wasting seen with 5(Z)-7-oxozeaenol treatment, 
especially as NFκB is not felt to be involved in increase in atrogin-1 expression (467). 
GDF-15 has previously been shown to cause muscle wasting and to elevate expression of atrogin-1 
and MuRF-1 (265). The data presented in Chapter 5 suggests that GDF-15 may mediate this effect 
through TAK1, a mechanism supported by others (318, 319). In the data shown above atrogin-1 mRNA 
there was a trend to a reduction in atrogin-1 mRNA the TA of the MCT TAK1i treated rats when 
compared to their MCT control treated counterparts, which did not meet statistical significance. These 
rats had larger TAs and on average an increase in proportion of larger TA fibre. Furthermore there was 
a significant decrease in the atrogin-1 mRNA expression in the TA of the animals treated with MCT and 
TAK1i that continued to grow at the end of the experiment compared to those that lost weight across 
the MCT group as a whole. Taken together this supports a role for GDF-15 and TAK1 in the muscle 
wasting seen in the MCT rat and suggests that 5(Z)-7-oxozeaenol in vivo may prevent GDF-15 mediated 
muscle atrophy, possibly through actions on atrogin-1. As previously mentioned, other mediators, 
such as GDF-8 and TNFα, may act through TAK1 to cause muscle loss (67, 136, 153, 345). Anti-TNF α 
treatment with a soluble receptor antagonist and pentoxyfylline, a general inhibitor of TNFα activity, 
have been shown to prevent cachexia in the MCT rat through a reduction in mRNA expression of 
atrogin-1 (136), whilst GDF-8 and GDF-15 neutralising antibodies have had some success in animal 
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models of cancer in reducing muscle wasting (269, 477). 5(Z)-7-oxozeaenol is likely to have blocked 
the effects of GDF-15, GDF-8 and TNFα signalling pathways in this model, acting synergistically to 
prevent muscle loss. 
Some researchers have shown that, rather than being solely detrimental, activity in the TAK1 pathway 
is vital for maintenance of normal muscle homeostasis through its actions on satellite stem cell 
function. Genetically modified mice lacking TAK1 expression in satellite stem cells cannot regenerate 
after acute injury and actually exhibit smaller muscle fibres and increased atrogin-1 mRNA expression 
than wild type animals(363). It has also been shown that selective TAK1 knockout in mouse skeletal 
muscle impairs growth in the first few weeks of life (364). This is not surprising given the vital role that 
TAK1 has in preventing differentiation of myoblast and therefore maintaining a population of cells 
able to allow regeneration (478).  The relevance of this action in muscle wasting in chronic disease, 
where TAK1 activity may be dysregulated is, however, unclear. The majority of muscle cells in the MCT 
rat model of PAH are mature and therefore have very low intrinsic TAK1 activity.  TAK1 inhibition at 
low dose, aiming to bring the TAK1 activity levels back to baseline, rather than abolishing it all 
together, is likely to prevent inflammatory signalling in these cells resulting in the reduction in muscle 
wasting seen with this drug. The effect of high dose 5(Z)-7-oxozeaenol treatment may be very different 
from low dose therapy and may result, as with knockout models, in complete obliteration of TAK1 
signalling causing a worsening rather than an improvement in the rate of muscle loss. Careful 
pharmacokinetic studies are needed to define the role of TAK1 inhibition in muscle wasting in patients 
with chronic disease and this should be a focus of future in vivo research. It is also not clear from the 
data whether the reason for the lack of response in some animals in the MCT TAK1i group in terms of 
prevention of weight loss is due to under or over-suppression of TAK1 activity, both of which is a 
possibility given its dual actions in myoblasts and mature cells. 
TAK1 activity has been previously linked directly to disease activity in pulmonary hypertension, with 
excess levels of the phosphorylated protein being found in the lung homogenates of the MCT rat. 
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Furthermore TAK1 inhibition with 5(Z)-7-oxozeaenol has been shown to reduce the excess pulmonary 
artery smooth muscle cell proliferation seen in BMPR2 knockout cells suggesting a central role in the 
pulmonary vascular remodelling of PAH (360). 5(Z)-7-oxozeaenol can prevent neo-intimal formation 
in a wire induced vascular injury model, supporting a potential therapeutic role for TAK1 inhibition in 
vascular remodelling (359).  The data presented above, however, shows that at low dose TAK1 
inhibition has no effect of pulmonary pressure or right ventricular hypertrophy. This may be due to 
the timing of the intervention; after 2 weeks, the observed pulmonary vascular remodelling is already 
established and cannot be reversed. It may also be due to the low dose of 5(Z)-7-oxozeaenol used in 
this study. Although 0.5mg/kg doses of 5(Z)-7-oxozeaenol have been shown to be successful in some 
studies (359), in others they have not altered outcomes, where higher doses of 5mg/kg have been 
more effective (358).  
There was no significant difference in GDF-15 levels in the circulation or in the lung homogenates of 
MCT control and MCT TAK1i treated rats. However, there was a trend to lower levels in the animals 
treated with 5(Z)-7-oxozeaenol. As in Chapter 4 circulating GDF-15 levels were associated with animal 
growth, TA weight and TA atrogin-1 mRNA expression. Furthermore GDF-15 levels in the blood were 
lower in those rats who continued to grow at the end of the experiment compared to those that didn’t 
in the group as a whole. This was also true when the MCT group were analysed alone. These results 
suggest a complex interplay between GDF-15 and TAK1 in vivo.  
We have shown that GDF-15 may act through TAK1 and that 5(Z)-7-oxozeaenol can inhibit GDF-15 
mediated atrophy adding to the work of Bloch et al. (265) and Choi et al. (319). GDF-15 mRNA 
production is known to be a p53 dependant process (479). It has recently been shown that over-
expression of TAK1 has been associated with increased expression of p53 mRNA and accumulation of 
the protein in the intracellular space (480). This may go some way to explaining why TAK1 inhibition 
with 5(Z)-7-oxozeaenol was able to inhibit production of GDF-15 in at least some animals, and could 
be confirmed by examining co-localisation of GDF-15 and p53 mRNA and protein expression in the 
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endothelial cell layer of the pulmonary vasculature of MCT rats treated with control or 5(Z)-7-
oxozeaenol.  
Finally, we have added to the body of research showing that GDF-15 is an effective biomarker of 
muscle wasting in acute and chronic disease. Our group has previously shown that GDF-15 is 
associated with muscle loss in AICU acquired weakness (218) and in COPD (266). In Chapter 4 this 
association was demonstrated in patients with PAH.  A good biomarker needs to be valid, reliable and 
responsive (481). Data presented above shows that GDF-15 levels are decreased in animals that 
continued to grow who were treated with 5(Z)-7-oxozeaenol. This suggests that GDF-15 is responsive 
to change and might have be a useful biomarker of response to treatment and could be used as a 
surrogate end-point in drug trials (482). 
6.7 Limitations 
The main limitations of the study is the number of animals investigated, which meant that it was 
difficult to show a statistically significant difference between the groups studied. Other limitations 
included the requirement to humanely kill the animals on different days. Part of this is unavoidable to 
prevent a breach of the severity limits of the Home Office license, however, some was also practical 
as it was not possible to undertake cardiac catheters on all the animals in just one day. The lack of 
pharmaco-dynamic and pharmaco-kinetic assessment of the therapy also detracts from the validity of 
our study, although the fact that local NFκB p65 activity was lower in the TA of the TAK1i treated MCT 
rats than their MCT control treated counterparts was reassuring. Only one dose of 5(Z)-7-oxozeaenol 
was used and the effect of a higher dose and a trial of its use in a preventative model of MCT induced 
disease was not investigated.  
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6.8 Conclusions 
The results presented above suggest that inhibiting TAKi with 5(Z)-7-oxozeaenol at low dose can 
prevent muscle loss, atrophy and weight loss in, at least, some animals in a MCT model of cachexia. 
This research suggests GDF-15, working with GDF-8 and TNFα, acting through TAK1 and possibly 
atrogin-1 may cause muscle wasting, a process that may be blocked by a TAK1i. Therefore, TAK1 may 
be a future target for therapeutic intervention in muscle wasting in PAH and other conditions 
associated with excess GDF-15 production.  
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Chapter 7 Discussion 
7.1 Summary 
I have shown in this thesis that: 
1. Skeletal muscle wasting and physical inactivity are associated with poor outcomes in patients 
with PAH 
2. Circulating GDF-15 levels are associated with skeletal muscle wasting both in animal models 
and in patients with PAH and thus may be a useful biomarker to identify those at risk of muscle 
loss.  
3.  GDF-15 causes myotube atrophy in vitro and also activates TAK1. 
4. TAK 1 inhibition with 5(Z)-7-oxozeaenol reduced GDF-15 mediated muscle atrophy in vitro and 
reduces muscle loss but had no effect on the PAH phenotype in MCT rat. 
7.2 My findings in context  
A number of different groups have found that peripheral muscle function is impaired in patients with 
PAH and that this is associated with functional status and 6MWD but not necessarily with 
cardiovascular parameters (160, 161). We can draw the same conclusions from my data. Muscle 
strength and size are closely correlated with 6MWD and WHO functional status but not with 
echocardiographic parameters. The data presented here goes further, since I have shown that 
quadriceps cross sectional area is an independent predictor of 6MWD, suggesting muscle size exerts 
a major influence over exercise capacity, supporting data from studies of rehabilitation (164, 171, 
172). Although associations can be inferred from studies of rehabilitation (18), to the best of my 
knowledge QOL has not been measured in the same population of PAH patients as muscle strength 
and size. The data presented in this thesis therefore sheds new light on the potential influence of 
skeletal muscle mass on QOL, demonstrating that larger quadriceps muscle size was independently 
associated with improved SGRQ scores. Furthermore muscle strength has been shown to associate 
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with average follow up QOL suggesting that changes in muscle function over time could be translated 
into long term benefits in these patients.  
Physical activity has been rarely studied in PAH. Unsurprisingly, low physical activity has been 
associated with worse functional class, decreased exercise capacity (173) and lower quality life (483) 
in PAH, all findings which are corroborated by my data set, including associations with follow up QOL. 
It is interesting that physical activity, unlike muscle size, was not independently associated with either 
6MWD or SGRQ score, suggesting that at the time of measuring current muscle size had more 
influence than current activity level on these outcomes. My results also confirm the close association 
of muscle strength, size and physical activity seen in other conditions (484) in PAH. What we cannot 
tell from this study is whether a reduction in muscle size and function, or low physical activity due to 
breathlessness is the primary driver of the ‘vicious cycle’ of breathlessness, deconditioning and 
skeletal muscle weakness seen in chronic cardio-respiratory disease (75).  
The 6MWD is one of the most important prognostic indicators in PAH (421). The findings above 
suggest that locomotor muscle function and physical activity are closely linked to 6MWD. In contrast 
to COPD and heart failure, where both outcomes have been linked to mortality, (34, 423-427) neither 
muscle strength or size nor physical activity has previously been associated with mortality in PAH. In 
this cohort, patients exhibiting both lower FFMIs and steps per day had an increased mortality. This 
suggests that improving muscle strength and/or physical activity in patients with PAH may reduce 
mortality in this group.  As mentioned in Chapter 3 the cut offs of these measures associated with 
poor prognosis were very low (370, 428). These patients might have the most to gain but are also the 
potentially the least likely to take up exercise (440, 441, 485). Whether rehabilitation is as effective in 
these patients remains to be seen and whether there is greater potential for anti-atrophic and pro-
anabolic adjuncts in this particular group should be the focus of future research.  
Hospitalisation for patients with PAH is likely to be associated with lower QOL and increases in 
healthcare costs (431, 433, 434). The data presented here suggest that patients with lower muscle 
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strength and bulk are more likely to be admitted to hospital. In fact 90% those patients with a 
QMVC/BMI of < 1.1 were admitted within 2 years of enrolment, compared to 50% in the overall 
cohort. This observation suggests that improving muscle strength might prevent admission and 
thereby improve both QOL and reduce healthcare costs. 
The findings of this study and data from studies of rehabilitation (18, 164, 171, 172) reinforce the 
virtues of exercise training in patients with PAH, which may well also deliver the benefits seen in other 
populations (98, 435-438). A number of challenges remain. Firstly, the ideal method of delivering 
rehabilitation and transferring gains in muscle strength into sustained improvements in physical 
activity is unknown (439). Secondly, the method for identifying those patients with low physical 
activity and low muscle strength without doing expensive tests and without the requirement for 
specialist equipment is not established. Clinical biomarkers of cachexia (443) and simple and effective 
screening tests for low physical activity (416) are required to identify those who might benefit most 
from interventions aimed at increasing these modifiable risk factors. Thirdly, as mentioned above, 
those patients with especially low muscle mass may benefit from anabolic agents. There is currently 
no such agent in clinical use (439) meaning novel pathways need to be identified and new drugs are 
required in this area. 
Screening tests are required to determine those patients with PAH who are at risk of low physical 
activity for targeted intervention and enrolment in clinical trials. The SGRQ and CAMPHOR are QOL 
questionnaires from which activity scores can be calculated, both of which have been used in PAH 
(387, 389). The SGRQ but not the CAMPHOR activity score has been validated against other activity 
questionnaires (446).   No previous studies have attempted to compare objectively measured physical 
activity with questionnaire based assessment in this population. I have previously shown, in patients 
with COPD, that some physical activity questionnaires outcomes are associated with objectively 
measured activity (383). My data suggests that a SGRQ and to a lesser extent a CAMPHOR physical 
activity score can be used to determine those patients with PAH who are inactive. Questionnaire based 
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assessment of physical activity can be unreliable (444) but embedding activity scores in a QOL 
questionnaire may reduce recall bias through framing (444). Interestingly, higher (i.e. worse) SGRQ 
activity scores were associated with increased mortality adding weight to the argument that the SGRQ 
might be used to screen and even monitor activity in patients with PAH.   
GDF-15 is emerging as a potential biomarker of cachexia and muscle loss, although it is not in clinical 
use at present (443), although an antibody for human use is in development. We used 2 animal models 
of PAH to determine the association of circulating GDF-15 with muscle loss. The MCT treated rat is a 
well-established model of cardiac cachexia (132), and I have shown that Sugen/hypoxia treatment in 
mice, which has previously been associated with weight loss (452) and diaphragmatic changes (162), 
also exhibited a similar pattern of skeletal muscle wasting.  
My data shows that, like in patients with PAH (207), circulating GDF-15 levels are raised in the MCT 
rat and Sugen/hypoxia mouse compared to controls. Interestingly there was no increase in GDF-15 in 
the hypoxia alone treated animals. This suggests that Sugen, a vascular endothelial growth factor 
antagonist, is required for GDF-15 production in a hypoxic mouse model of PAH. 
Circulating GDF-15 has been identified as a biomarker of skeletal muscle loss in COPD (453) in healthy 
elderly women (263), in cancer (269) and in ICU acquired weakness (218). The results presented here 
confirm the association of GDF-15 and skeletal muscle wasting in animal models and in patients with 
PAH. They also show that low GDF-15 levels can be used as a reasonable biomarker of preserved 
muscle strength in these patients. I have also shown that circulating GDF-15 levels are associated with 
objectively measured physical activity in patients with PAH, with previous work done in animal and 
rehabilitation studies yielding either conflicting or negative results (257, 260, 270, 271, 273).   
As well as being a marker of muscle loss there is emerging evidence that GDF-15 is also a cause of 
low muscle mass. Initially felt to exert its actions by suppressing appetite (260) our group has also 
shown that GDF-15 can have a direct effect on muscle size in vitro (218) and in vivo (453). TGFβ 
super-family proteins, including GDF-8, have been shown to act in an autocrine, paracrine and 
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endocrine manner (182, 486).  Studies in ICU acquired weakness have shown an increase in local 
GDF-15 expression in the quadriceps of patients who exhibit muscle wasting. This suggested that 
GDF-15’s actions may be autocrine or paracrine (265).  In my study there was no change in TA 
GDF-15 expression in either animal model examined. Like in patients with PAH I have shown that 
GDF-15 in these animals is over-expressed in the pulmonary vascular endothelium (283), 
supporting the hypothesis that GDF-15 acts in a predominantly endocrine manner. This data is 
further supported by a recent study showing GDF-15 secreting tumours can cause muscle loss that 
is antagonised by a GDF-15 neutralising antibody (269).  
GDF-15 is not the only TGFβ super-family member that I have identified as potentially being important 
in regulating muscle mass in the MCT rat. GDF-8 levels are raised in the circulation of the MCT rat 
(153). I have shown that GDF-8 is also up-regulated in the skeletal muscle of this model. Unlike GDF-
15, GDF-8 primarily acts locally (182) and is almost exclusively produced by muscle cells (487). The fact 
that there are a number of different proteins which can stimulate muscle wasting in this model 
highlights the importance of identifying common pathways which co-ordinate this process, so these 
can be targeted by effective therapeutic intervention. 
Despite identifying GFRAL receptor as the receptor for GDF-15 in the central nervous system (292) the 
downstream signalling pathway and receptors through which GDF-15 acts in muscle is as yet unknown 
(227, 295). Both canonical and non-canonical pathways have been identified as important in 
propagating GDF-15’s signals in different cells lines.  
In C2C12 skeletal muscle cells GDF-15 caused no significant upregulation in SMAD 2, 3 or SMAD 1, 5 
dependent luciferase activity at 6 hours. This finding is similar to some (260, 299) but in contrast to 
others (235, 290, 297).  
Other groups have found that GDF-15 effects are mediated through the TGFBR2 and ALK-5 receptors 
(288, 301). I found in TGFBR2 over-expressing cells, GDF-15 (50 ng/ml) caused an increase in SMAD 2, 
3 activity, suggesting a potential interaction with this receptor. This demonstrates that GDF-15 has 
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some affinity to bind to the TGFBR2, however the small fold change and the dose of both receptors 
and ligand required to elicit these changes brings the physiological relevance of these results in to 
question. The ALK-5 inhibitor SB-431542 was able to reduce GDF-15 mediated atrogin-1 mRNA 
expression, suggesting that the ALK-5 receptor may be involved in GDF-15 signalling. This result is 
complicated by the fact that SB-431542, has some activity against ALK-4 and ALK-7 (462) and that ALK5 
inhibition did not just abolish GDF-15’s actions but actually reversed its effects on atrogin-1. This 
highlights some of the difficulties investigating pathways with high levels of receptor promiscuity 
(178).  
Next I cloned a truncated version of the TGFBR2. Others have shown the beneficial effects the 
TTGFBR2 in reducing inflammation and promoting regeneration in skeletal muscle (463). In my 
experiments TTGBFR2 over-expression failed to prevent high dose GDF-15 (50ng/ml) mediated 
myotube atrophy, leaving the question as to whether the TGFBR2 is the binding receptor for GDF-15 
unanswered. 
The evidence collected by luciferase assay suggested that up-regulation of SMAD responses did not 
play a major role in GDF-15 signalling in myoblasts. This led us to investigate the non-canonical TGFβ 
signalling pathway. GDF-15 has previously been shown to signal through the TAK1 - NFκB p65 axis in 
Ecoli infected gastric epithelial cells (318, 319). In myoblasts GDF-15 caused an increase in NFκB p65 
nuclear localisation and overexpression of NFκB p65 mRNA, the latter of which was antagonised by 
co-treatment with TAK1 inhibitor 5(Z)-7-oxozeaenol. 
For the remainder of the experiments mature myoblasts with low intrinsic TAK1 and NFκB p65 activity 
(361, 464) were used. In these cells GDF-15 treatment caused phosphorylation of TAK1 and NFκB p65 
at a number of times and doses. Bloch et al. has previously shown that GDF-15 up-regulated atrogin-
1 and MuRF-1 mRNA expression (265) and caused myotube atrophy (218). I have shown that TAK1 
inhibition with 5(Z)-7-oxozeaenol (1000 nM) prevented relative GDF-15 mediated myotube atrophy 
and reduced GDF-15 mediated expression of atrogin-1. It also prevented GDF-15 mediated MuRF-1 
expression caused by low but not high dose GDF-15.This suggests that GDF-15 promotes TAK1 
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phosphorylation, thereby activating NFκB and up-regulating mRNA expression of MuRF-1. The 
increase in atrogin-1 demonstrated also seems to be dependent on TAK1 but is likely to be 
independent of NFκB p65, which is not thought to be in involved in up-regulation of atrogin-1 
expression (467). 
I next examined whether the downstream mediators of GDF-15 activity were raised in the muscle of 
the MCT rat. Previous work has shown that both atrogin-1 and MURF-1 mRNA levels are raised in the 
skeletal muscle of the MCT rat at 21-22 days (60, 468). My data showed a trend to increase in atrogin-
1 mRNA in the MCT rat TA and an association between atrogin-1 mRNA expression and the animal’s 
change in weight and TA weight at 4 weeks. MuRF-1 mRNA was not elevated in these animals. The 
differences between my data and that of others could be accounted for by the time course at which 
the levels of ubiquitin ligases were assessed, meaning the time of the peak mRNA levels were missed 
in my experiments. This hypothesis is supported by the facts that MuRF-1 has been shown to peak 
earlier than atrogin-1 in a model of burns induced muscle wasting (470), that variation in ubiquitin 
ligase expression over time has been observed in man (469) and that the rats in previous experiments 
showing increases in ubiquitin ligases were assessed at 3 and not 4 weeks (60, 468). This hypothesis 
is supported by data presented in Chapter 6 where there was a significant increase in atrogin-1 mRNA 
expression at the earlier time point studied. 
TAK1 has been found to be vital for the development and regeneration of healthy muscle through its 
actions on satellite stem cell function (363, 364). It is also an essential downstream mediator of GDF-
8, allowing it to prevent hypertrophy in muscle cells (67, 366). This suggests that TAK1 regulation must 
be carefully controlled in order to prevent an imbalance between protein synthesis and degradation. 
I have shown that TAK1 activity is increased in the skeletal muscle of the MCT rat and have presented 
some limited evidence that it also raised in the quadriceps biopsy of patients with PAH. GDF-15 
activates TAK1 in vitro and antagonising TAK1 may be a potential method by which GDF-15’s actions 
can be blocked in vivo. This may have the advantage, unlike other more specific treatment, like 
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monoclonal antibodies of GDF-15 (269), of blocking the signalling of a number of molecules involved 
in muscle wasting including but not limited to GDF-15, GDF-8 and TNFα (67, 136, 153, 345).  
5(Z)-7-oxozeaenol inhibited increases in phosphorylated NFκB p65 activity, a known downstream 
mediator of TAK1 (476) in the TA of the MCT rat, suggesting that the compound had the desired 
activity in vivo. NFκB is not felt to be involved in increases in atrogin-1 expression (467), suggesting 
that there are other downstream protein involved in TAK1 mediated muscle loss, that were not 
identified in this study. 
5(Z)-7-oxozeaenol treatment at 0.5 mg/kg/day for 9 days starting at 2 weeks after MCT treatment 
seemed to prevent muscle wasting in this animal model of PAH in at least some animals. GDF-15 has 
previously been shown to cause muscle wasting through atrogin-1 and MuRF-1 over-expression (265). 
I have presented data that suggests that GDF-15 may act through TAK1 in muscle cells similar to its 
effect in Ecoli infected gastric epithelial cells (318, 319). I demonstrated that atrogin-1 mRNA was 
reduced in the TA of the MCT TAK1i treated rats that continued to grow at the end of the experiment. 
The rats in the intervention group had larger TAs and a decrease in proportion of smaller and an 
increase proportion of larger TA fibres. 
This supports a role for TAK1 in the muscle wasting seen in the MCT rat and suggests that 5(Z)-7-
oxozeaenol may prevent GDF-15 induced muscle loss in this model of chronic muscle wasting. 
Antagonising TAK1 has the advantage of potentially targeting a number of other mediators of muscle 
loss, like GDF-8 and TNFα (67, 136, 153, 345). Both anti-GDF-8 and GDF-15 monoclonal antibodies 
have been associated with a reduction in muscle wasting in animal models of cancer cachexia  (269, 
477), whilst anti-TNF α treatment has been shown to prevent cachexia in the MCT rat through a 
reduction in mRNA expression of atrogin-1 (136), closely mimicking my work. 5(Z)-7-oxozeaenol is 
likely to have blocked the effects of GDF-15, GDF-8 and TNFα signalling pathways in this model, acting 
synergistically to prevent muscle loss. 
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As mentioned above, the TAK1 pathway is vital for maintenance of normal muscle homeostasis 
through its actions on satellite stem cell function. Therefore antagonising TAK1 must be done with 
great care. Genetically modified satellite stem cell TAK1 knockout mice cannot regenerate after acute 
injury and actually exhibit smaller muscle fibres and increased atrogin-1 mRNA expression when 
compared to wild type animals (363). It has also been shown that selective TAK1 knockout in mouse 
skeletal muscle impairs growth in the first few weeks of life (364). This is not surprising given the vital 
role that TAK1 has in preventing differentiation of myoblast and therefore maintaining a population 
of cells able to allow regeneration (478).  The relevance of TAK1’s action in muscle wasting in chronic 
disease, where there may be excess TAK1 activity has not been previously defined. The majority of 
muscle cells in the MCT rat model of PAH are mature and therefore have very low intrinsic TAK1 
activity. Despite this we have shown that phosphorylated TAK1 expression is raised in these animals.  
TAK1 inhibition at low dose, like we have used here, is aimed at reducing TAK1 activity levels back to 
baseline, rather than abolishing them completely. This strategy has proven to be effective with a 
reduction in muscle atrophy and a decreased in atrogin-1 expression in the intervention group. The 
next step would be to carry out careful pharmacokinetic studies of both low and high dose TAK1 
inhibition in the MCT rat with a careful focus both on inhibition of regeneration (363) and on off target 
effects of the drug (345).    
TAK1 activity has been previously linked directly to disease activity in PH, with excess levels of the 
phosphorylated protein being found in the lung homogenates of the MCT rat. Furthermore TAK1 
inhibition with 5(Z)-7-oxozeaenol has been shown to reduce the excess pulmonary artery smooth 
muscle cell proliferation seen in BMPR2 knockout cells suggesting a central role in the pulmonary 
vascular remodelling of PAH (360). 5(Z)-7-oxozeaenol can prevent neo-intimal formation in a wire 
induced vascular injury model, supporting a potential therapeutic role for TAK1 inhibition in vascular 
remodelling (359).  The data presented in my thesis, however, shows that at low dose TAK1 inhibition 
has no effect of pulmonary pressure or right ventricular hypertrophy. This may be due to the timing 
of the intervention; that after 2 weeks the pulmonary vascular remodelling seen is already established 
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and cannot be reversed. It may also be due to the low dose of 5(Z)-7-oxozeaenol used in this study. 
Although 0.5mg/kg doses of 5(Z)-7-oxozeaenol have been shown to be successful in some studies 
(359) in others they have not altered outcomes, where higher doses of 5mg/kg have been more 
effective (358).  
There was no significant difference in GDF-15 levels in the circulation or in the lung homogenates of 
MCT control and MCT TAK1i treated rats. However there was a trend to lower levels in the animals 
treated with 5(Z)-7-oxozeaenol. Circulating GDF-15 levels were associated with animal growth, TA 
weight and TA atrogin-1 mRNA expression. Furthermore GDF-15 levels in the blood were lower in 
those rats who continued to grow at the end of the experiment compared to those that didn’t in the 
group as a whole and when the MCT group were analysed alone. These results confirm the complex 
interaction between GDF-15 and TAK1 which seems to be both up and downstream of the ligand. 
Increased TAK1 activity may drive increased GDF-15 production, as over-expression of TAK1 has been 
shown to lead to the accumulation of p53 a known activator of the GDF-15 expression (479, 480). This 
may go some way to explaining why TAK1 inhibition with 5(Z)-7-oxozeaenol was able to inhibit 
production of GDF-15 in at least some animals. This data also further demonstrates GDF-15’s role as 
an effective biomarker of muscle wasting, which is responsive to change and might have utility as a 
surrogate end-point in drug trials (482). 
7.3 Limitations 
7.3.1 Sample size  
Small sample size was a problem for the clinical study, the Sugen/hypoxia mouse study and to a certain 
extent the TAK1 inhibitor MCT rat study. There were a number of reasons for this. PAH is a rare disease 
with a limited pool of patients from which to recruit (10). Even so, this is the largest cohort of patients 
to undergo muscle testing in this condition. The Sugen/hypoxia mouse model we used had far lower 
circulating GDF-15 levels than the MCT rat, so with limited resources was not a major focus of 
investigation. The interventional model was studied in collaboration with Cambridge University, and 
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delays and animal licensing issues in our collaborators laboratory meant that work was delayed. Due 
to these small numbers it is difficult to make generalisations about the associations seen in our 
cohorts. Only relative and not absolute change in myotube diameter was statistically different 
between GDF-15 and TAK1i treated cells. This is again likely due to the small sample numbers. Our 
group has previously published myotube diameter findings using only 2 repeats but including all the 
cell data (218). The methodology used in this thesis, showing consistent changes in average relative 
diameter across all three experiments, adds weight, rather than detracts from the validity of the data 
presented. Throughout this thesis I have undertaken multiple comparisons using the same data set 
and have not carried out Bonferroni corrections for multiple analysis. This is because the numbers 
needed to study would be higher than feasible given the time and resources available. This does leave 
us open to type 1 error but reduces the amount of type 2 error. As long as this is understood by the 
reader then this seems to be a reasonable approach and is supported in the wider literature when 
dealing with small sample sizes (449), even when using linear regression (450).  
7.3.2 Missing data 
Both animal models and the clinical study had some missing data. This particularly effected the SWA 
and questionnaire data. I adopted the strategy of using all the valid data available to increase the 
sample size. This was particularly important given the small sample size to begin with and is supported 
by the paper by Dziura et al. (451)  
7.3.3 Validity of equipment  
In the clinical study although it has been used previously (173), and been validated in COPD (419), the 
SWA has not been validated in PAH.  
7.3.4 Animal Licensing and Assessment 
In the animal experiments a number of animals had to be humanely killed to prevent them from 
reaching their severity limits. If this had not been the case longer time courses may have been possible 
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and these may have generated a stronger signal particularly in the interventional model. There was 
some requirement to humanely kill the animals on different days. Part of this is unavoidable to prevent 
a breach of the severity limits of the Home Office license, as mentioned above, however some was 
also practical as it not possible to undertake cardiac catheters on all the animals in just one day. The 
lack of a time course of assessment of the TA gene expression means we may have missed the time at 
which maximal mRNA expression of various genes peaked.  
7.3.5 The primary deficit causing muscle loss, GDF-15 production and its actions 
This study leaves a number of important unanswered questions. I have not established the primary 
problem causing low muscle mass in patients with PAH, whether this be low physical activity due to 
breathlessness or a direct myo-toxic response to increases in inflammatory mediators and hypoxia 
seen in the disease. I have not established the relative contribution that nutrition, physical inactivity 
and direct pro-atrophic signalling play in propagating GDF-15’s effects on muscle mass in PAH. 
Although I have demonstrated like others that GDF-15 is produced in the pulmonary vascular 
endothelial cells in PAH (283), I have not ruled out alternative sites of over-expression in the MCT rat. 
In vitro I have established that GDF-15 can cause muscle atrophy and activate TAK1 at a number of 
doses and time points. I have shown that TAK1 inhibition, with a selective inhibitor, can prevent these 
actions, however there is always a possibility of off target effects with a small molecule inhibitor(488). 
I have not performed experiments in TAK1 siRNA C2C12 cells and in muscle specific conditional 
knockout animals which would add weight to my arguments.  
7.4 Conclusions (Figure 7.1) 
In this thesis I aimed to: define the association between GDF-15 and muscle parameters in patients 
and in animal models of PAH; investigate the source of production of GDF-15 in animal models of PAH; 
define the pathway through which GDF-15 acts to cause muscle wasting in vitro, with a view to 
antagonising its effects in vitro and in vivo; examine GDF-15’s usefulness as a biomarker of muscle 
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loss; and assess the association of muscle loss with outcomes in PAH like QOL, hospitalisation and 
mortality. 
I have shown that circulating but not local GDF-15 levels, likely to be released from the pulmonary 
vasculature, are associated with measures of muscle function and size in 2 animal models and in 
patients with PAH. I have shown that GDF-15 levels in the circulation are a reasonable biomarker of 
muscle loss in PAH, which, along with physical activity is associated with poor outcomes in the disease. 
I demonstrated that GDF-15 may act through TAK1 activation to increase the expression of ubiquitin 
ligases atrogin-1 and MuRF-1 in the muscle of the MCT rat. This process may be partly, but is unlikely 
to be fully, dependant on NFκB activation. GDF-15’s effects are likely to result in an imbalance between 
protein synthesis and degradation leading to a reduction in muscle mass and a decrease in function. I 
have also demonstrated that other target molecules such as GDF-8 are raised in the MCT model 
suggesting that other ligands acting through TAK1 contribute to muscle wasting in vivo. Finally I have 
been able to show that TAK1 inhibition with 5(Z)-7-oxozeaenol can prevent some of the muscle 
atrophy seen in the MCT rat model of PAH. Importantly GDF-15 is raised in a wide range of conditions 
(262, 265, 489-492), and muscle loss is a ubiquitous outcome in chronic disease (21), meaning my data 
has implications both in the management of PAH associated muscle loss and in the wider context of 
cachexia in chronic disease . 
    
 
  
234 
  
 
 Figure 7.1 Diagram showing potential mechanism through which GDF-15 may cause direct muscle atrophy in 
patients with PAH and the potential sites of action of 5(Z)-7-oxozeaenol.  
 
7.5 Future Work 
A larger prospective study across a number of centres should be set up to corroborate the associations 
of muscle loss and low physical activity that I have found in this small study. A longer follow up of 5 
years may allow stronger conclusions to be drawn. Interventional studies should focus on the optimal 
method by which rehabilitation could be delivered and transferred into gains in physical activity in this 
group. One such study that I am currently pursuing is the use of a personal trainer at home to augment 
general exercise advice in this group. A particularly important group to study identified by this thesis 
is those undergoing transplant assessment. Careful attention to physical performance and muscle 
wasting in this group may identify those at especially increased risk and be a modifiable risk factor for 
post-operative complications and increased mortality.  
GDF-15 has been shown to be a biomarker of muscle wasting in PAH as well as in a number of other 
conditions (218, 263, 269, 453). My data suggests that it may be responsive to change but this has not 
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been confirmed outside my animal model (257). The next steps might be to track GDF-15’s 
associations with muscle wasting longitudinally in a large cohort of unselected patients with chronic 
diseases to examine its validity, variability and responsiveness to change. This would allow me to fully 
map GDF-15’s utility as a biomarker of muscle loss. 
I have demonstrated that physical activity scores from QOL questionnaires are a reasonable surrogate 
of objectively measured physical activity in patients with PAH. Like GDF-15, more data is required to 
show that they have low enough variability and that they are responsive enough to be used instead 
of activity monitors in this population. Large trials with assessment using both questionnaire and 
activity monitors contemporaneously are required to inform these decisions.  
I have shown that GDF-15 over-expression in the lung homogenates and particularly in the pulmonary 
vasculature is correlated with circulating levels of the protein in the MCT rat model of PAH. There was 
no increase in expression in the skeletal muscle of this animal. This suggests but does not confirm that 
the pulmonary vasculature is the major source of GDF-15 in this model. Tissue is available from other 
potential sources of GDF-15 including the liver and the heart, both of which are known to be damaged 
by exposure to MCT (474, 493). Examination of these other tissues may be useful in confirming the 
pulmonary vasculature as the main source of GDF-15 in the circulation of the MCT rat. Furthermore a 
conditional GDF-15 knockout in the pulmonary vascular endothelial cells of a transgenic mouse 
treated with Sugen/hypoxia which did not have raised circulating GDF-15 levels would support my 
hypothesis.   
The discovery of the GFRAL receptor as the mediator of appetite driven GDF-15 induced weight loss 
(292, 293, 296) has shed new light on GDF-15’s action in neural tissue. GDF-15’s role and mechanism 
of action in other tissues including, but not limited to the pulmonary vasculature and skeletal muscle 
has yet to be defined in a similar way.  Generation of conditional and conditional tissue specific 
knockout mice would shed further light on GDF-15’s role in both the development of pulmonary 
hypertension and in skeletal muscle wasting. The experiments would have to include pair fed animals 
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as well as an insult to induce muscle wasting that was associated under normal circumstances with a 
significant rise in GDF-15 production. 
I have confirmed the work of Bloch et al. (265) showing that GDF-15 can cause over-expression of the 
mRNA of ubiquitin ligases atrogin-1 and MuRF-1 in vitro. I have shown that GDF-15 levels correlate 
with TA atrogin-1 mRNA levels in the MCT rat. This is unlikely to be the complete story as the changes 
in atrogin-1 levels are small and are not likely to be explained by my other finding of raised NFκB p65 
phosphorylation (467) in response to GDF-15. Important future steps would be to perform a time 
course of circulating levels of GDF-15 and TA ubiquitin ligase expression in the MCT rat model to give 
a better understanding of the dynamic shift in mRNA expression of ubiquitin ligases over time. Tissue 
is available for assessment of protein levels of both ubiquitin ligases in the TA of the MCT rat. This 
would add weight to my argument that these pro-atrophic factors are involved in the muscle wasting 
seen in this model. Importantly changes in atrogin-1 and MuRF-1 proteins have been described 
previously in MCT rat muscle (468).  
The receptor through which GDF-15 acts in skeletal muscle is still not clear. I have produced some 
evidence that GDF-15 can interact through the TGFBR2.  I have also shown that GDF-15 can interact 
with the ALK-5. The main body of evidence in the wider literature suggests that GDF-15’s effects are 
mediated through the GFRAL (296) TGFBR2 and ALK-5 (288, 301). In the first instance I would attempt 
to use siRNA to inhibit each TGF-beta type 1 and each type 2 receptor in turn to identify those which 
is most likely to propagate GDF-15’s downstream signal. I would also investigate the role of the GFRAL 
in propagating GDF-15’s signals in skeletal muscle, despite previous authors showing that it wasn’t 
present in this tissue (295).    
My results suggest that inhibiting TAK1 with 5(Z)-7-oxozeaenol both in vitro an in vivo can prevent 
muscle loss and atrophy signalling. A prevention study in the MCT may yield more consistent results, 
proving the concept that TAK1 inhibition may be beneficial in preventing muscle atrophy. Alternatively 
it could be detrimental in downregulating the rats’ population of pluripotent satellite stem cells from 
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the outset preventing regeneration. Pharmaco-dynamic and pharmaco-kinetic assessment of 5(Z)-7-
oxozeaenol at  number of doses and time points is required to assess in detail the drug’s mechanism 
of actions and its downstream on and off target effects and is vital to continuing  this research. A 
number of drug companies have compounds in development targeting TAK1. A commercial 
collaboration may yield very helpful results as some of these other compounds are potentially 
translatable to human studies (356). Careful assessment of muscle strength and size in any future 
human studies of a TAK1 inhibitor should be undertaken. This is most likely to be relevant, in the first 
instance, in studies using TAK1 inhibitors as adjuncts to chemotherapy in patients with cancer.   
The complex interplay between GDF-15 and TAK1 deserves further attention. Hypoxia and sheer stress 
have both been identified as potentially important in stimulating GDF-15 production from human 
microvascular pulmonary endothelial cells (283). The exact mechanism and the physiological effects 
of this on the pulmonary vasculature has yet to be defined. 
Through this thesis I have identified both GDF-15 and TAK1 as potential therapeutic targets for muscle 
wasting in PAH an unmet but important need in this population. Much work needs to be done to 
translate these preliminary findings from bench to bedside but this data could be the start of a process 
of drug development aimed at improving exercise tolerance, QOL and even mortality in patients with 
PAH as well as in other conditions.  
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Appendix 2.3  
pCDNA3 hum TTGFBR2 100% homology 
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Appendix 2.4 
PRLTK has a BMP response element in the HSV promoter region 240-247 
 
AGATCTAAATGAGTCTTCGGACCTCGCGGGGGCCGCTTAAGCGGTGGTTA 
GGGTTTGTCTGACGCGGGGGGAGGGGGAAGGAACGAAACACTCTCATTCG 
GAGGCGGCTCGGGGTTTGGTCTTGGTGGCCACGGGCACGCAGAAGAGCGC 
CGCGATCCTCTTAAGCACCCCCCCGCCCTCCGTGGAGGCGGGGGTTTGGT 
CGGCGGGTGGTAACTGGCGGGCCGCTGACTCGGGCGGGTCGCGCGCCCCA 
GAGTGTGACCTTTTCGGTCTGCTCGCAGACCCCCGGGCGGCGCCGCCGCG 
GCGGCGACGGGCTCGCTGGGTCCTAGGCTCCATGGGGACCGTATACGTGG 
ACAGGCTCTGGAGCATCCGCACGACTGCGGTGATATTACCGGAGACCTTC 
TGCGGGACGAGCCGGGTCACGCGGCTGACGCGGAGCGTCCGTTGGGCGAC 
AAACACCAGGACGGGGCACAGGTACACTATCTTGTCACCCGGAGGCGCGA 
GGGACTGCAGGAGCTTCAGGGAGTGGCGCAGCTGCTTCATCCCCGTGGCC 
CGTTGCTCGCGTTTGCTGGCGGTGTCCCCGGAAGAAATATATTTGCATGT 
CTTTAGTTCTATGATGACACAAACCCCGCCCAGCGTCTTGTCATTGGCGA 
ATTCGAACACGCAGATGCAGTCGGGGCGGCGCGGTCCCAGGTCCACTTCG 
CATATTAAGGTGACGCGTGTGGCCTCGAACACCGAGCGACCCTGCAGCGA 
CCCGCTTAAAAGCTTGATTCTTCTGACACAACAGTCTCGAACTTAAGCTG 
CAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGAC 
AGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAGACTC 
TTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTT 
TCTCTCCACAGGTGTCCACTCCCAGTTCAATTACAGCTCTTAAGGCTAGA 
GTACTTAATACGACTCACTATAGGCTAGCCACCATGACTTCGAAAGTTTA 
TGATCCAGAACAAAGGAAACGGATGATAACTGGTCCGCAGTGGTGGGCCA 
GATGTAAACAAATGAATGTTCTTGATTCATTTATTAATTATTATGATTCA 
GAAAAACATGCAGAAAATGCTGTTATTTTTTTACATGGTAACGCGGCCTC 
TTCTTATTTATGGCGACATGTTGTGCCACATATTGAGCCAGTAGCGCGGT 
GTATTATACCAGACCTTATTGGTATGGGCAAATCAGGCAAATCTGGTAAT 
GGTTCTTATAGGTTACTTGATCATTACAAATATCTTACTGCATGGTTTGA 
ACTTCTTAATTTACCAAAGAAGATCATTTTTGTCGGCCATGATTGGGGTG 
CTTGTTTGGCATTTCATTATAGCTATGAGCATCAAGATAAGATCAAAGCA 
ATAGTTCACGCTGAAAGTGTAGTAGATGTGATTGAATCATGGGATGAATG 
GCCTGATATTGAAGAAGATATTGCGTTGATCAAATCTGAAGAAGGAGAAA 
AAATGGTTTTGGAGAATAACTTCTTCGTGGAAACCATGTTGCCATCAAAA 
ATCATGAGAAAGTTAGAACCAGAAGAATTTGCAGCATATCTTGAACCATT 
CAAAGAGAAAGGTGAAGTTCGTCGTCCAACATTATCATGGCCTCGTGAAA 
TCCCGTTAGTAAAAGGTGGTAAACCTGACGTTGTACAAATTGTTAGGAAT 
TATAATGCTTATCTACGTGCAAGTGATGATTTACCAAAAATGTTTATTGA 
ATCGGACCCAGGATTCTTTTCCAATGCTATTGTTGAAGGTGCCAAGAAGT 
TTCCTAATACTGAATTTGTCAAAGTAAAAGGTCTTCATTTTTCGCAAGAA 
GATGCACCTGATGAAATGGGAAAATATATCAAATCGTTCGTTGAGCGAGT 
TCTCAAAAATGAACAATAATTCTAGAGCGGCCGCTTCGAGCAGACATGAT 
AAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAA 
AATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATT 
ATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTT 
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TCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCT 
ACAAATGTGGTAAAATCGATAAGGATCCAGGTGGCACTTTTCGGGGAAAT 
GTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTA 
TCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAA 
GGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTT 
GCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGT 
AAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGG 
ATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTT 
CCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCG 
TATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGA 
ATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGC 
ATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACAC 
TGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCG 
CTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAA 
CCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCC 
TGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA 
CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTT 
GCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGA 
TAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGG 
GGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGT 
CAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTC 
ACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTT 
AGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATC 
CTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCA 
CTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTT 
TTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCA 
GCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGT 
AACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGC 
CGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTC 
GCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTG 
TCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGT 
CGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACC 
TACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCT 
TCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAA 
CAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTAT 
AGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATG 
CTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTT 
TACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGGCTCGACCGG CGCC 
 
GC G CGCC 
 
CG A CGCC 
 
GC A CGCC 
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Appendix 4.1  
 
 
Negative controls for immunohistochemitry. Figure showing negative controls for 
immunohistochemistry for GDF-15, Smooth muscle actin and secondaries anti-rabbit and anti-mouse. 
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Appendix 5.1 
 
Negative controls for immunofluorescence. Figure showing negative controls for 
immunofluorescence for NFκB p65, TGFBR2, ACVR2B and Alexa-Fluor 488 and 568 secondary. 
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Appendix 5.2  
 
 
Positive control showing activity of 5(Z)-7-oxozeaenol in C2C12 myotubes. Western blot of 
Phospho NFκB p65 activity and β-actin levels in control, TNF-α (10 ng/ml) and TNF-α and 5(Z)-7-
oxozeanol (TAK1i) (1000 nM) cells 
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Appendix 5.3 
‘lastly, it is opportune for me to warn you about issues associated with commercially 
available MIC-1/GDF15, available from R&D, but which is quite likely to effect other 
commercial suppliers of this protein 
One of my pharamaceutical industry colleagues has been comparing MIC-1/GDF15 from 
R&D and their own in house material. They found that MIC-1/GDF15 from R&D induces 
smad phosphorylation but their in house material does not. They have traced the source of 
this disparity to a 2-3% contamination of MIC-1/GDF15 with TGF-b. They can block the 
smad phosphorylation of MIC-1/GDF15 with antibodies to TGF-b but not by antibodies to 
MIC-1/GDF15. The bioassay that R&D have on their web site seems to be based on TGF-b 
contamination of their purified MIC-1/GDF15. 
The data seems very solid and there is not much doubt that this is why at least some people 
using cytokine from R&D (and perhaps from other suppliers) report smad phosphorylation 
and other changes that we cannot reproduce… Its pretty clear that it has created enormous 
confusion in the literature and that any data using R&D MIC-1/GDF15 (and perhaps from 
other suppliers) must be suspect. 
 
They have approached R&D about this issue but the outcome is not clear at present. 
 
I believe this issue has arisen because most cell lines make lots of endogenous TGF-b. The 
physico-chemical properties of MIC-1/GDF15 and TGF-b are very similar and hence they 
tend to co-purify and probably run together on a gel. It might also be that commercial 
sources, where MIC-1/GDF15 has been expressed in mammalian cells, may be 
contaminated with other TGF-b superfamily cytokines. Fortunately the MIC-1/GDF15 we 
make and purify in house is expressed in yeast where this type of contamination cannot 
occur.If relevant, you need to consider the possibility that some of your findings may be due 
to this problem’ 
 
 
 
